Title:
ANTIGEN BINDING MOLECULES TARGETING PROGRAMMED CELL DEATH PROTEIN 1 (PD-1)
Document Type and Number:
WIPO Patent Application WO/2024/050421
Kind Code:
A2
Abstract:
The disclosure provides, in various embodiments, polypeptides (e.g., antibodies and antigen binding fragments thereof) that specifically bind to programmed cell death protein 1 (PD-1). The disclosure also provides, in various embodiments, fusion proteins comprising a polypeptide disclosed herein, polynucleotides encoding a polypeptide disclosed herein, vectors and host cells suitable for expressing polypeptides disclosed herein, and methods for treating a disease or condition (e.g., cancer) using polypeptides disclosed herein.
Inventors:
LIU YUE (US)
GRIGORYAN GEVORG (US)
RAMOS ALEXIS HIRAM (US)
TABTIENG TATE (US)
ROOT ADAM REID (US)
LEUNG CHEUK LUN (US)
GRIGORYAN GEVORG (US)
RAMOS ALEXIS HIRAM (US)
TABTIENG TATE (US)
ROOT ADAM REID (US)
LEUNG CHEUK LUN (US)
Application Number:
PCT/US2023/073172
Publication Date:
March 07, 2024
Filing Date:
August 30, 2023
Export Citation:
Assignee:
FLAGSHIP PIONEERING INNOVATIONS VI LLC (US)
International Classes:
A61K39/395; C07K16/28
Domestic Patent References:
| WO2002060919A2 | 2002-08-08 |
Other References:
SMITHWATERMAN, ADV. APPL. MATH, vol. 2, 1981, pages 482
NEEDLEMANWUNSCH, J. MOL. BIOL., vol. 48, 1970, pages 443
PEARSONLIPMAN, PROC. NAT'L. ACAD. SCI. USA, vol. 85, 1988, pages 2444
AUSUBEL ET AL., CURRENT PROTOCOLS IN MOLECULAR BIOLOGY
VERED KUNIK ET AL., NUCLEIC ACIDS RESEARCH, vol. 40, 1 July 2012 (2012-07-01), pages W521 - W524
KABAT, E.A ET AL.: "Sequences of Proteins of Immunological Interest", 1991, U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES
CHOTHIA ET AL., NATURE, vol. 342, 1989, pages 877
CHOTHIA, C. ET AL., J. MOL. BIOL., vol. 196, 1987, pages 901 - 917
AL-LAZIKANI ET AL., J. MOLEC. BIOL, vol. 273, 1997, pages 927 - 948
ALMAGRO, J. MOL. RECOGNIT, vol. 17, 2004, pages 132 - 143
DUMET ET AL.: "Insights into the IgG heavy chain engineering patent landscape as applied to IgG4 antibody development", MABS, vol. 11, no. 8, 2019, pages 1341 - 50, XP055732501, DOI: 10.1080/19420862.2019.1664365
YANG, DSINGH, AWU, HKROE-BARRETT, R: "Comparison of biosensor platforms in the evaluation of high affinity antibody-antigen binding kinetics", ANALYTICAL BIOCHEMISTRY, vol. 508, 2016, pages 78 - 96, XP029642360, DOI: 10.1016/j.ab.2016.06.024
AUSUBEL ET AL.: "Current Protocols in Molecular Biology", 1992, JOHN WILEY & SONS
SAMBROOK ET AL.: "Molecular Cloning: a Laboratory Manual", 1989, COLD SPRING HARBOR LABORATORY PRESS
"Remington's Pharmaceutical Sciences", 1980
FRANCISCO ET AL.: "The PD-1 pathway in tolerance and autoimmunity", IMMUNOL REV, vol. 236, 2010, pages 219 - 42, XP002616816, DOI: 10.1111/j.1600-065X.2010.00923.x
QIN ET AL.: "The Diverse Function of PD-1/PD-L Pathway Beyond Cancer", FRONT IMMUNOL, vol. 10, 2019, pages 2298, XP055670804, DOI: 10.3389/fimmu.2019.02298
GREBINOSKIVIGNALI: "Inhibitory receptor agonists: the future of autoimmune disease therapeutics?", CURR OPIN IMMUNOL, vol. 67, 2020, pages 1 - 9, XP086407348, DOI: 10.1016/j.coi.2020.06.001
NISHIMURA ET AL.: "Development of lupus-like autoimmune diseases by disruption of the PD-1 gene encoding an ITIMmotif-carrying immunoreceptor", IMMUNITY, vol. 11, no. 2, 1999, pages 141 - 51, XP000971788, DOI: 10.1016/S1074-7613(00)80089-8
NEEDLEMANWUNSCH, J. MOL. BIOL., vol. 48, 1970, pages 443
PEARSONLIPMAN, PROC. NAT'L. ACAD. SCI. USA, vol. 85, 1988, pages 2444
AUSUBEL ET AL., CURRENT PROTOCOLS IN MOLECULAR BIOLOGY
VERED KUNIK ET AL., NUCLEIC ACIDS RESEARCH, vol. 40, 1 July 2012 (2012-07-01), pages W521 - W524
KABAT, E.A ET AL.: "Sequences of Proteins of Immunological Interest", 1991, U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES
CHOTHIA ET AL., NATURE, vol. 342, 1989, pages 877
CHOTHIA, C. ET AL., J. MOL. BIOL., vol. 196, 1987, pages 901 - 917
AL-LAZIKANI ET AL., J. MOLEC. BIOL, vol. 273, 1997, pages 927 - 948
ALMAGRO, J. MOL. RECOGNIT, vol. 17, 2004, pages 132 - 143
DUMET ET AL.: "Insights into the IgG heavy chain engineering patent landscape as applied to IgG4 antibody development", MABS, vol. 11, no. 8, 2019, pages 1341 - 50, XP055732501, DOI: 10.1080/19420862.2019.1664365
YANG, DSINGH, AWU, HKROE-BARRETT, R: "Comparison of biosensor platforms in the evaluation of high affinity antibody-antigen binding kinetics", ANALYTICAL BIOCHEMISTRY, vol. 508, 2016, pages 78 - 96, XP029642360, DOI: 10.1016/j.ab.2016.06.024
AUSUBEL ET AL.: "Current Protocols in Molecular Biology", 1992, JOHN WILEY & SONS
SAMBROOK ET AL.: "Molecular Cloning: a Laboratory Manual", 1989, COLD SPRING HARBOR LABORATORY PRESS
"Remington's Pharmaceutical Sciences", 1980
FRANCISCO ET AL.: "The PD-1 pathway in tolerance and autoimmunity", IMMUNOL REV, vol. 236, 2010, pages 219 - 42, XP002616816, DOI: 10.1111/j.1600-065X.2010.00923.x
QIN ET AL.: "The Diverse Function of PD-1/PD-L Pathway Beyond Cancer", FRONT IMMUNOL, vol. 10, 2019, pages 2298, XP055670804, DOI: 10.3389/fimmu.2019.02298
GREBINOSKIVIGNALI: "Inhibitory receptor agonists: the future of autoimmune disease therapeutics?", CURR OPIN IMMUNOL, vol. 67, 2020, pages 1 - 9, XP086407348, DOI: 10.1016/j.coi.2020.06.001
NISHIMURA ET AL.: "Development of lupus-like autoimmune diseases by disruption of the PD-1 gene encoding an ITIMmotif-carrying immunoreceptor", IMMUNITY, vol. 11, no. 2, 1999, pages 141 - 51, XP000971788, DOI: 10.1016/S1074-7613(00)80089-8
Attorney, Agent or Firm:
BALICKY, Eric M. et al. (US)
Download PDF:
Claims:
| 5708.1067001 CLAIMS What is claimed is: 1. A polypeptide comprising: an HCDR1 comprising the amino acid sequence of SEQ ID NO:118, an HCDR2 comprising the amino acid sequence of SEQ ID NO:147, an HCDR3 comprising the amino acid sequence of SEQ ID NO:227, an LCDR 1 comprising the amino acid sequence of SEQ ID NO:229, an LCDR2 comprising the amino acid sequence of SEQ ID NO:183, and an LCDR3 comprising the amino acid sequence of SEQ ID NO:200 (AB-65); an HCDR1 comprising the amino acid sequence of SEQ ID NO:118, an HCDR2 comprising the amino acid sequence of SEQ ID NO:148, an HCDR3 comprising the amino acid sequence of SEQ ID NO:228, an LCDR 1 comprising the amino acid sequence of SEQ ID NO:177, an LCDR2 comprising the amino acid sequence of SEQ ID NO:183, and an LCDR3 comprising the amino acid sequence of SEQ ID NO:200 (AB-75); an HCDR1 comprising the amino acid sequence of SEQ ID NO:118, an HCDR2 comprising the amino acid sequence of SEQ ID NO:139, an HCDR3 comprising the amino acid sequence of SEQ ID NO:170, an LCDR 1 comprising the amino acid sequence of SEQ ID NO:178, an LCDR2 comprising the amino acid sequence of SEQ ID NO:183, and an LCDR3 comprising the amino acid sequence of SEQ ID NO:194 (AB-74); an HCDR1 comprising the amino acid sequence of SEQ ID NO:107, an HCDR2 comprising the amino acid sequence of SEQ ID NO:127, an HCDR3 comprising the amino acid sequence of SEQ ID NO:151, an LCDR 1 comprising the amino acid sequence of SEQ ID NO:172, an LCDR2 comprising the amino acid sequence of SEQ ID NO:179, and an LCDR3 comprising the amino acid sequence of SEQ ID NO:184 (AB-1); an HCDR1 comprising the amino acid sequence of SEQ ID NO:107, an HCDR2 comprising the amino acid sequence of SEQ ID NO:127, an HCDR3 comprising the amino acid sequence of SEQ ID NO:152, an LCDR 1 comprising the amino acid sequence of SEQ ID NO:172, an LCDR2 comprising the amino acid sequence of SEQ ID NO:179, and an LCDR3 comprising the amino acid sequence of SEQ ID NO:185 (AB-2); an HCDR1 comprising the amino acid sequence of SEQ ID NO:108, an HCDR2 comprising the amino acid sequence of SEQ ID NO:128, an HCDR3 comprising the amino acid sequence of SEQ ID NO:153, an LCDR 1 comprising the amino acid sequence of SEQ - 121 - 3820371.v1 5708.1067001 ID NO:172, an LCDR2 comprising the amino acid sequence of SEQ ID NO:179, and an LCDR3 comprising the amino acid sequence of SEQ ID NO:186 (AB-3); an HCDR1 comprising the amino acid sequence of SEQ ID NO:107, an HCDR2 comprising the amino acid sequence of SEQ ID NO:127, an HCDR3 comprising the amino acid sequence of SEQ ID NO:151, an LCDR 1 comprising the amino acid sequence of SEQ ID NO:172, an LCDR2 comprising the amino acid sequence of SEQ ID NO:179, and an LCDR3 comprising the amino acid sequence of SEQ ID NO:187 (AB-4); an HCDR1 comprising the amino acid sequence of SEQ ID NO:109, an HCDR2 comprising the amino acid sequence of SEQ ID NO:129, an HCDR3 comprising the amino acid sequence of SEQ ID NO:151, an LCDR 1 comprising the amino acid sequence of SEQ ID NO:172, an LCDR2 comprising the amino acid sequence of SEQ ID NO:179, and an LCDR3 comprising the amino acid sequence of SEQ ID NO:188 (AB-5); an HCDR1 comprising the amino acid sequence of SEQ ID NO:110, an HCDR2 comprising the amino acid sequence of SEQ ID NO:130, an HCDR3 comprising the amino acid sequence of SEQ ID NO:154, an LCDR 1 comprising the amino acid sequence of SEQ ID NO:172, an LCDR2 comprising the amino acid sequence of SEQ ID NO:179, and an LCDR3 comprising the amino acid sequence of SEQ ID NO:189 (AB-6); an HCDR1 comprising the amino acid sequence of SEQ ID NO:109, an HCDR2 comprising the amino acid sequence of SEQ ID NO:131, an HCDR3 comprising the amino acid sequence of SEQ ID NO:151, an LCDR 1 comprising the amino acid sequence of SEQ ID NO:172, an LCDR2 comprising the amino acid sequence of SEQ ID NO:179, and an LCDR3 comprising the amino acid sequence of SEQ ID NO:190 (AB-7); an HCDR1 comprising the amino acid sequence of SEQ ID NO:111, an HCDR2 comprising the amino acid sequence of SEQ ID NO:132, an HCDR3 comprising the amino acid sequence of SEQ ID NO:155, an LCDR 1 comprising the amino acid sequence of SEQ ID NO:172, an LCDR2 comprising the amino acid sequence of SEQ ID NO:179, and an LCDR3 comprising the amino acid sequence of SEQ ID NO:184 (AB-8); an HCDR1 comprising the amino acid sequence of SEQ ID NO:111, an HCDR2 comprising the amino acid sequence of SEQ ID NO:133, an HCDR3 comprising the amino acid sequence of SEQ ID NO:154, an LCDR 1 comprising the amino acid sequence of SEQ ID NO:172, an LCDR2 comprising the amino acid sequence of SEQ ID NO:179, and an LCDR3 comprising the amino acid sequence of SEQ ID NO:191 (AB-9); - 122 - 3820371.v1 5708.1067001 an HCDR1 comprising the amino acid sequence of SEQ ID NO:112, an HCDR2 comprising the amino acid sequence of SEQ ID NO:127, an HCDR3 comprising the amino acid sequence of SEQ ID NO:151, an LCDR 1 comprising the amino acid sequence of SEQ ID NO:172, an LCDR2 comprising the amino acid sequence of SEQ ID NO:179, and an LCDR3 comprising the amino acid sequence of SEQ ID NO:188 (AB-10); an HCDR1 comprising the amino acid sequence of SEQ ID NO:107, an HCDR2 comprising the amino acid sequence of SEQ ID NO:127, an HCDR3 comprising the amino acid sequence of SEQ ID NO:151, an LCDR 1 comprising the amino acid sequence of SEQ ID NO:172, an LCDR2 comprising the amino acid sequence of SEQ ID NO:179, and an LCDR3 comprising the amino acid sequence of SEQ ID NO:192 (AB-11); an HCDR1 comprising the amino acid sequence of SEQ ID NO:113, an HCDR2 comprising the amino acid sequence of SEQ ID NO:134, an HCDR3 comprising the amino acid sequence of SEQ ID NO:151, an LCDR 1 comprising the amino acid sequence of SEQ ID NO:172, an LCDR2 comprising the amino acid sequence of SEQ ID NO:179, and an LCDR3 comprising the amino acid sequence of SEQ ID NO:184 (AB-12); an HCDR1 comprising the amino acid sequence of SEQ ID NO:114, an HCDR2 comprising the amino acid sequence of SEQ ID NO:135, an HCDR3 comprising the amino acid sequence of SEQ ID NO:156, an LCDR 1 comprising the amino acid sequence of SEQ ID NO:172, an LCDR2 comprising the amino acid sequence of SEQ ID NO:179, and an LCDR3 comprising the amino acid sequence of SEQ ID NO:192 (AB-13); an HCDR1 comprising the amino acid sequence of SEQ ID NO:115, an HCDR2 comprising the amino acid sequence of SEQ ID NO:136, an HCDR3 comprising the amino acid sequence of SEQ ID NO:151, an LCDR 1 comprising the amino acid sequence of SEQ ID NO:172, an LCDR2 comprising the amino acid sequence of SEQ ID NO:179, and an LCDR3 comprising the amino acid sequence of SEQ ID NO:193 (AB-14); an HCDR1 comprising the amino acid sequence of SEQ ID NO:116, an HCDR2 comprising the amino acid sequence of SEQ ID NO:137, an HCDR3 comprising the amino acid sequence of SEQ ID NO:153, an LCDR 1 comprising the amino acid sequence of SEQ ID NO:172, an LCDR2 comprising the amino acid sequence of SEQ ID NO:179, and an LCDR3 comprising the amino acid sequence of SEQ ID NO:188 (AB-15); an HCDR1 comprising the amino acid sequence of SEQ ID NO:114, an HCDR2 comprising the amino acid sequence of SEQ ID NO:138, an HCDR3 comprising the amino acid sequence of SEQ ID NO:157, an LCDR 1 comprising the amino acid sequence of SEQ - 123 - 3820371.v1 5708.1067001 ID NO:172, an LCDR2 comprising the amino acid sequence of SEQ ID NO:179, and an LCDR3 comprising the amino acid sequence of SEQ ID NO:184 (AB-16); an HCDR1 comprising the amino acid sequence of SEQ ID NO:117, an HCDR2 comprising the amino acid sequence of SEQ ID NO:131, an HCDR3 comprising the amino acid sequence of SEQ ID NO:151, an LCDR 1 comprising the amino acid sequence of SEQ ID NO:172, an LCDR2 comprising the amino acid sequence of SEQ ID NO:179, and an LCDR3 comprising the amino acid sequence of SEQ ID NO:189 (AB-17); an HCDR1 comprising the amino acid sequence of SEQ ID NO:118, an HCDR2 comprising the amino acid sequence of SEQ ID NO:139, an HCDR3 comprising the amino acid sequence of SEQ ID NO:158, an LCDR 1 comprising the amino acid sequence of SEQ ID NO:173, an LCDR2 comprising the amino acid sequence of SEQ ID NO:180, and an LCDR3 comprising the amino acid sequence of SEQ ID NO:194 (AB-18); an HCDR1 comprising the amino acid sequence of SEQ ID NO:119, an HCDR2 comprising the amino acid sequence of SEQ ID NO:140, an HCDR3 comprising the amino acid sequence of SEQ ID NO:159, an LCDR 1 comprising the amino acid sequence of SEQ ID NO:174, an LCDR2 comprising the amino acid sequence of SEQ ID NO:181, and an LCDR3 comprising the amino acid sequence of SEQ ID NO:195 (AB-19); an HCDR1 comprising the amino acid sequence of SEQ ID NO:120, an HCDR2 comprising the amino acid sequence of SEQ ID NO:139, an HCDR3 comprising the amino acid sequence of SEQ ID NO:160, an LCDR 1 comprising the amino acid sequence of SEQ ID NO:173, an LCDR2 comprising the amino acid sequence of SEQ ID NO:180, and an LCDR3 comprising the amino acid sequence of SEQ ID NO:194 (AB-20); an HCDR1 comprising the amino acid sequence of SEQ ID NO:120, an HCDR2 comprising the amino acid sequence of SEQ ID NO:139, an HCDR3 comprising the amino acid sequence of SEQ ID NO:160, an LCDR 1 comprising the amino acid sequence of SEQ ID NO:173, an LCDR2 comprising the amino acid sequence of SEQ ID NO:182, and an LCDR3 comprising the amino acid sequence of SEQ ID NO:194 (AB-21); an HCDR1 comprising the amino acid sequence of SEQ ID NO:121, an HCDR2 comprising the amino acid sequence of SEQ ID NO:139, an HCDR3 comprising the amino acid sequence of SEQ ID NO:151, an LCDR 1 comprising the amino acid sequence of SEQ ID NO:173, an LCDR2 comprising the amino acid sequence of SEQ ID NO:180, and an LCDR3 comprising the amino acid sequence of SEQ ID NO:194 (AB-22); - 124 - 3820371.v1 5708.1067001 an HCDR1 comprising the amino acid sequence of SEQ ID NO:120, an HCDR2 comprising the amino acid sequence of SEQ ID NO:139, an HCDR3 comprising the amino acid sequence of SEQ ID NO:160, an LCDR 1 comprising the amino acid sequence of SEQ ID NO:173, an LCDR2 comprising the amino acid sequence of SEQ ID NO:180, and an LCDR3 comprising the amino acid sequence of SEQ ID NO:194 (AB-23); an HCDR1 comprising the amino acid sequence of SEQ ID NO:120, an HCDR2 comprising the amino acid sequence of SEQ ID NO:139, an HCDR3 comprising the amino acid sequence of SEQ ID NO:160, an LCDR 1 comprising the amino acid sequence of SEQ ID NO:173, an LCDR2 comprising the amino acid sequence of SEQ ID NO:180, and an LCDR3 comprising the amino acid sequence of SEQ ID NO:194 (AB-24); an HCDR1 comprising the amino acid sequence of SEQ ID NO:120, an HCDR2 comprising the amino acid sequence of SEQ ID NO:139, an HCDR3 comprising the amino acid sequence of SEQ ID NO:160, an LCDR 1 comprising the amino acid sequence of SEQ ID NO:173, an LCDR2 comprising the amino acid sequence of SEQ ID NO:180, and an LCDR3 comprising the amino acid sequence of SEQ ID NO:194 (AB-25); an HCDR1 comprising the amino acid sequence of SEQ ID NO:120, an HCDR2 comprising the amino acid sequence of SEQ ID NO:139, an HCDR3 comprising the amino acid sequence of SEQ ID NO:160, an LCDR 1 comprising the amino acid sequence of SEQ ID NO:173, an LCDR2 comprising the amino acid sequence of SEQ ID NO:180, and an LCDR3 comprising the amino acid sequence of SEQ ID NO:194 (AB-26); an HCDR1 comprising the amino acid sequence of SEQ ID NO:120, an HCDR2 comprising the amino acid sequence of SEQ ID NO:139, an HCDR3 comprising the amino acid sequence of SEQ ID NO:160, an LCDR 1 comprising the amino acid sequence of SEQ ID NO:173, an LCDR2 comprising the amino acid sequence of SEQ ID NO:180, and an LCDR3 comprising the amino acid sequence of SEQ ID NO:194 (AB-27); an HCDR1 comprising the amino acid sequence of SEQ ID NO:118, an HCDR2 comprising the amino acid sequence of SEQ ID NO:139, an HCDR3 comprising the amino acid sequence of SEQ ID NO:151, an LCDR 1 comprising the amino acid sequence of SEQ ID NO:173, an LCDR2 comprising the amino acid sequence of SEQ ID NO:180, and an LCDR3 comprising the amino acid sequence of SEQ ID NO:194 (AB-28); an HCDR1 comprising the amino acid sequence of SEQ ID NO:120, an HCDR2 comprising the amino acid sequence of SEQ ID NO:139, an HCDR3 comprising the amino acid sequence of SEQ ID NO:161, an LCDR 1 comprising the amino acid sequence of SEQ - 125 - 3820371.v1 5708.1067001 ID NO:173, an LCDR2 comprising the amino acid sequence of SEQ ID NO:180, and an LCDR3 comprising the amino acid sequence of SEQ ID NO:194 (AB-29); an HCDR1 comprising the amino acid sequence of SEQ ID NO:121, an HCDR2 comprising the amino acid sequence of SEQ ID NO:139, an HCDR3 comprising the amino acid sequence of SEQ ID NO:162, an LCDR 1 comprising the amino acid sequence of SEQ ID NO:173, an LCDR2 comprising the amino acid sequence of SEQ ID NO:183, and an LCDR3 comprising the amino acid sequence of SEQ ID NO:194 (AB-30); an HCDR1 comprising the amino acid sequence of SEQ ID NO:121, an HCDR2 comprising the amino acid sequence of SEQ ID NO:141, an HCDR3 comprising the amino acid sequence of SEQ ID NO:163, an LCDR 1 comprising the amino acid sequence of SEQ ID NO:173, an LCDR2 comprising the amino acid sequence of SEQ ID NO:180, and an LCDR3 comprising the amino acid sequence of SEQ ID NO:196 (AB-31); an HCDR1 comprising the amino acid sequence of SEQ ID NO:121, an HCDR2 comprising the amino acid sequence of SEQ ID NO:139, an HCDR3 comprising the amino acid sequence of SEQ ID NO:151, an LCDR 1 comprising the amino acid sequence of SEQ ID NO:173, an LCDR2 comprising the amino acid sequence of SEQ ID NO:180, and an LCDR3 comprising the amino acid sequence of SEQ ID NO:194 (AB-32); an HCDR1 comprising the amino acid sequence of SEQ ID NO:121, an HCDR2 comprising the amino acid sequence of SEQ ID NO:139, an HCDR3 comprising the amino acid sequence of SEQ ID NO:164, an LCDR 1 comprising the amino acid sequence of SEQ ID NO:172, an LCDR2 comprising the amino acid sequence of SEQ ID NO:180, and an LCDR3 comprising the amino acid sequence of SEQ ID NO:194 (AB-33); an HCDR1 comprising the amino acid sequence of SEQ ID NO:121, an HCDR2 comprising the amino acid sequence of SEQ ID NO:139, an HCDR3 comprising the amino acid sequence of SEQ ID NO:162, an LCDR 1 comprising the amino acid sequence of SEQ ID NO:173, an LCDR2 comprising the amino acid sequence of SEQ ID NO:183, and an LCDR3 comprising the amino acid sequence of SEQ ID NO:194 (AB-34); an HCDR1 comprising the amino acid sequence of SEQ ID NO:121, an HCDR2 comprising the amino acid sequence of SEQ ID NO:139, an HCDR3 comprising the amino acid sequence of SEQ ID NO:151, an LCDR 1 comprising the amino acid sequence of SEQ ID NO:173, an LCDR2 comprising the amino acid sequence of SEQ ID NO:180, and an LCDR3 comprising the amino acid sequence of SEQ ID NO:194 (AB-35); - 126 - 3820371.v1 5708.1067001 an HCDR1 comprising the amino acid sequence of SEQ ID NO:122, an HCDR2 comprising the amino acid sequence of SEQ ID NO:139, an HCDR3 comprising the amino acid sequence of SEQ ID NO:151, an LCDR 1 comprising the amino acid sequence of SEQ ID NO:173, an LCDR2 comprising the amino acid sequence of SEQ ID NO:180, and an LCDR3 comprising the amino acid sequence of SEQ ID NO:194 (AB-36); an HCDR1 comprising the amino acid sequence of SEQ ID NO:114, an HCDR2 comprising the amino acid sequence of SEQ ID NO:139, an HCDR3 comprising the amino acid sequence of SEQ ID NO:151, an LCDR 1 comprising the amino acid sequence of SEQ ID NO:172, an LCDR2 comprising the amino acid sequence of SEQ ID NO:183, and an LCDR3 comprising the amino acid sequence of SEQ ID NO:194 (AB-37); an HCDR1 comprising the amino acid sequence of SEQ ID NO:121, an HCDR2 comprising the amino acid sequence of SEQ ID NO:139, an HCDR3 comprising the amino acid sequence of SEQ ID NO:151, an LCDR 1 comprising the amino acid sequence of SEQ ID NO:173, an LCDR2 comprising the amino acid sequence of SEQ ID NO:183, and an LCDR3 comprising the amino acid sequence of SEQ ID NO:194 (AB-38); an HCDR1 comprising the amino acid sequence of SEQ ID NO:118, an HCDR2 comprising the amino acid sequence of SEQ ID NO:139, an HCDR3 comprising the amino acid sequence of SEQ ID NO:165, an LCDR 1 comprising the amino acid sequence of SEQ ID NO:172, an LCDR2 comprising the amino acid sequence of SEQ ID NO:183, and an LCDR3 comprising the amino acid sequence of SEQ ID NO:194 (AB-39); an HCDR1 comprising the amino acid sequence of SEQ ID NO:121, an HCDR2 comprising the amino acid sequence of SEQ ID NO:139, an HCDR3 comprising the amino acid sequence of SEQ ID NO:151, an LCDR 1 comprising the amino acid sequence of SEQ ID NO:173, an LCDR2 comprising the amino acid sequence of SEQ ID NO:180, and an LCDR3 comprising the amino acid sequence of SEQ ID NO:194 (AB-40); an HCDR1 comprising the amino acid sequence of SEQ ID NO:121, an HCDR2 comprising the amino acid sequence of SEQ ID NO:139, an HCDR3 comprising the amino acid sequence of SEQ ID NO:166, an LCDR 1 comprising the amino acid sequence of SEQ ID NO:172, an LCDR2 comprising the amino acid sequence of SEQ ID NO:180, and an LCDR3 comprising the amino acid sequence of SEQ ID NO:194 (AB-41); an HCDR1 comprising the amino acid sequence of SEQ ID NO:123, an HCDR2 comprising the amino acid sequence of SEQ ID NO:142, an HCDR3 comprising the amino acid sequence of SEQ ID NO:151, an LCDR 1 comprising the amino acid sequence of SEQ - 127 - 3820371.v1 5708.1067001 ID NO:173, an LCDR2 comprising the amino acid sequence of SEQ ID NO:180, and an LCDR3 comprising the amino acid sequence of SEQ ID NO:194 (AB-42); an HCDR1 comprising the amino acid sequence of SEQ ID NO:121, an HCDR2 comprising the amino acid sequence of SEQ ID NO:143, an HCDR3 comprising the amino acid sequence of SEQ ID NO:167, an LCDR 1 comprising the amino acid sequence of SEQ ID NO:173, an LCDR2 comprising the amino acid sequence of SEQ ID NO:183, and an LCDR3 comprising the amino acid sequence of SEQ ID NO:194 (AB-43); an HCDR1 comprising the amino acid sequence of SEQ ID NO:124, an HCDR2 comprising the amino acid sequence of SEQ ID NO:144, an HCDR3 comprising the amino acid sequence of SEQ ID NO:151, an LCDR 1 comprising the amino acid sequence of SEQ ID NO:173, an LCDR2 comprising the amino acid sequence of SEQ ID NO:180, and an LCDR3 comprising the amino acid sequence of SEQ ID NO:194 (AB-44); an HCDR1 comprising the amino acid sequence of SEQ ID NO:124, an HCDR2 comprising the amino acid sequence of SEQ ID NO:139, an HCDR3 comprising the amino acid sequence of SEQ ID NO:162, an LCDR 1 comprising the amino acid sequence of SEQ ID NO:173, an LCDR2 comprising the amino acid sequence of SEQ ID NO:183, and an LCDR3 comprising the amino acid sequence of SEQ ID NO:197 (AB-45); an HCDR1 comprising the amino acid sequence of SEQ ID NO:121, an HCDR2 comprising the amino acid sequence of SEQ ID NO:139, an HCDR3 comprising the amino acid sequence of SEQ ID NO:151, an LCDR 1 comprising the amino acid sequence of SEQ ID NO:173, an LCDR2 comprising the amino acid sequence of SEQ ID NO:180, and an LCDR3 comprising the amino acid sequence of SEQ ID NO:194 (AB-46); an HCDR1 comprising the amino acid sequence of SEQ ID NO:121, an HCDR2 comprising the amino acid sequence of SEQ ID NO:139, an HCDR3 comprising the amino acid sequence of SEQ ID NO:162, an LCDR 1 comprising the amino acid sequence of SEQ ID NO:173, an LCDR2 comprising the amino acid sequence of SEQ ID NO:183, and an LCDR3 comprising the amino acid sequence of SEQ ID NO:198 (AB-47); an HCDR1 comprising the amino acid sequence of SEQ ID NO:114, an HCDR2 comprising the amino acid sequence of SEQ ID NO:139, an HCDR3 comprising the amino acid sequence of SEQ ID NO:165, an LCDR 1 comprising the amino acid sequence of SEQ ID NO:172, an LCDR2 comprising the amino acid sequence of SEQ ID NO:183, and an LCDR3 comprising the amino acid sequence of SEQ ID NO:199 (AB-48); - 128 - 3820371.v1 5708.1067001 an HCDR1 comprising the amino acid sequence of SEQ ID NO:114, an HCDR2 comprising the amino acid sequence of SEQ ID NO:139, an HCDR3 comprising the amino acid sequence of SEQ ID NO:151, an LCDR 1 comprising the amino acid sequence of SEQ ID NO:172, an LCDR2 comprising the amino acid sequence of SEQ ID NO:179, and an LCDR3 comprising the amino acid sequence of SEQ ID NO:194 (AB-49); an HCDR1 comprising the amino acid sequence of SEQ ID NO:121, an HCDR2 comprising the amino acid sequence of SEQ ID NO:145, an HCDR3 comprising the amino acid sequence of SEQ ID NO:168, an LCDR 1 comprising the amino acid sequence of SEQ ID NO:173, an LCDR2 comprising the amino acid sequence of SEQ ID NO:180, and an LCDR3 comprising the amino acid sequence of SEQ ID NO:194 (AB-50); an HCDR1 comprising the amino acid sequence of SEQ ID NO:121, an HCDR2 comprising the amino acid sequence of SEQ ID NO:146, an HCDR3 comprising the amino acid sequence of SEQ ID NO:151, an LCDR 1 comprising the amino acid sequence of SEQ ID NO:173, an LCDR2 comprising the amino acid sequence of SEQ ID NO:183, and an LCDR3 comprising the amino acid sequence of SEQ ID NO:194 (AB-51); an HCDR1 comprising the amino acid sequence of SEQ ID NO:124, an HCDR2 comprising the amino acid sequence of SEQ ID NO:139, an HCDR3 comprising the amino acid sequence of SEQ ID NO:151, an LCDR 1 comprising the amino acid sequence of SEQ ID NO:175, an LCDR2 comprising the amino acid sequence of SEQ ID NO:180, and an LCDR3 comprising the amino acid sequence of SEQ ID NO:194 (AB-52); an HCDR1 comprising the amino acid sequence of SEQ ID NO:121, an HCDR2 comprising the amino acid sequence of SEQ ID NO:139, an HCDR3 comprising the amino acid sequence of SEQ ID NO:162, an LCDR 1 comprising the amino acid sequence of SEQ ID NO:176, an LCDR2 comprising the amino acid sequence of SEQ ID NO:183, and an LCDR3 comprising the amino acid sequence of SEQ ID NO:194 (AB-53); an HCDR1 comprising the amino acid sequence of SEQ ID NO:118, an HCDR2 comprising the amino acid sequence of SEQ ID NO:147, an HCDR3 comprising the amino acid sequence of SEQ ID NO:165, an LCDR 1 comprising the amino acid sequence of SEQ ID NO:177, an LCDR2 comprising the amino acid sequence of SEQ ID NO:183, and an LCDR3 comprising the amino acid sequence of SEQ ID NO:200 (AB-54); an HCDR1 comprising the amino acid sequence of SEQ ID NO:121, an HCDR2 comprising the amino acid sequence of SEQ ID NO:139, an HCDR3 comprising the amino acid sequence of SEQ ID NO:151, an LCDR 1 comprising the amino acid sequence of SEQ - 129 - 3820371.v1 5708.1067001 ID NO:173, an LCDR2 comprising the amino acid sequence of SEQ ID NO:183, and an LCDR3 comprising the amino acid sequence of SEQ ID NO:194 (AB-55); an HCDR1 comprising the amino acid sequence of SEQ ID NO:121, an HCDR2 comprising the amino acid sequence of SEQ ID NO:146, an HCDR3 comprising the amino acid sequence of SEQ ID NO:151, an LCDR 1 comprising the amino acid sequence of SEQ ID NO:173, an LCDR2 comprising the amino acid sequence of SEQ ID NO:180, and an LCDR3 comprising the amino acid sequence of SEQ ID NO:201 (AB-56); an HCDR1 comprising the amino acid sequence of SEQ ID NO:118, an HCDR2 comprising the amino acid sequence of SEQ ID NO:139, an HCDR3 comprising the amino acid sequence of SEQ ID NO:165, an LCDR 1 comprising the amino acid sequence of SEQ ID NO:172, an LCDR2 comprising the amino acid sequence of SEQ ID NO:183, and an LCDR3 comprising the amino acid sequence of SEQ ID NO:194 (AB-57); an HCDR1 comprising the amino acid sequence of SEQ ID NO:121, an HCDR2 comprising the amino acid sequence of SEQ ID NO:139, an HCDR3 comprising the amino acid sequence of SEQ ID NO:169, an LCDR 1 comprising the amino acid sequence of SEQ ID NO:173, an LCDR2 comprising the amino acid sequence of SEQ ID NO:183, and an LCDR3 comprising the amino acid sequence of SEQ ID NO:194 (AB-58); an HCDR1 comprising the amino acid sequence of SEQ ID NO:118, an HCDR2 comprising the amino acid sequence of SEQ ID NO:139, an HCDR3 comprising the amino acid sequence of SEQ ID NO:170, an LCDR 1 comprising the amino acid sequence of SEQ ID NO:178, an LCDR2 comprising the amino acid sequence of SEQ ID NO:183, and an LCDR3 comprising the amino acid sequence of SEQ ID NO:194 (AB-59); an HCDR1 comprising the amino acid sequence of SEQ ID NO:118, an HCDR2 comprising the amino acid sequence of SEQ ID NO:147, an HCDR3 comprising the amino acid sequence of SEQ ID NO:170, an LCDR 1 comprising the amino acid sequence of SEQ ID NO:178, an LCDR2 comprising the amino acid sequence of SEQ ID NO:183, and an LCDR3 comprising the amino acid sequence of SEQ ID NO:200 (AB-60); an HCDR1 comprising the amino acid sequence of SEQ ID NO:121, an HCDR2 comprising the amino acid sequence of SEQ ID NO:146, an HCDR3 comprising the amino acid sequence of SEQ ID NO:162, an LCDR 1 comprising the amino acid sequence of SEQ ID NO:176, an LCDR2 comprising the amino acid sequence of SEQ ID NO:183, and an LCDR3 comprising the amino acid sequence of SEQ ID NO:201 (AB-61); - 130 - 3820371.v1 5708.1067001 an HCDR1 comprising the amino acid sequence of SEQ ID NO:118, an HCDR2 comprising the amino acid sequence of SEQ ID NO:148, an HCDR3 comprising the amino acid sequence of SEQ ID NO:165, an LCDR 1 comprising the amino acid sequence of SEQ ID NO:177, an LCDR2 comprising the amino acid sequence of SEQ ID NO:183, and an LCDR3 comprising the amino acid sequence of SEQ ID NO:200 (AB-62); an HCDR1 comprising the amino acid sequence of SEQ ID NO:125, an HCDR2 comprising the amino acid sequence of SEQ ID NO:149, an HCDR3 comprising the amino acid sequence of SEQ ID NO:171, an LCDR 1 comprising the amino acid sequence of SEQ ID NO:172, an LCDR2 comprising the amino acid sequence of SEQ ID NO:183, and an LCDR3 comprising the amino acid sequence of SEQ ID NO:194 (AB-63); an HCDR1 comprising the amino acid sequence of SEQ ID NO:126, an HCDR2 comprising the amino acid sequence of SEQ ID NO:150, an HCDR3 comprising the amino acid sequence of SEQ ID NO:165, an LCDR 1 comprising the amino acid sequence of SEQ ID NO:177, an LCDR2 comprising the amino acid sequence of SEQ ID NO:183, and an LCDR3 comprising the amino acid sequence of SEQ ID NO:200 (AB-64); an HCDR1 comprising the amino acid sequence of SEQ ID NO:118, an HCDR2 comprising the amino acid sequence of SEQ ID NO:139, an HCDR3 comprising the amino acid sequence of SEQ ID NO:227, an LCDR 1 comprising the amino acid sequence of SEQ ID NO:178, an LCDR2 comprising the amino acid sequence of SEQ ID NO:183, and an LCDR3 comprising the amino acid sequence of SEQ ID NO:194 (AB-66); an HCDR1 comprising the amino acid sequence of SEQ ID NO:118, an HCDR2 comprising the amino acid sequence of SEQ ID NO:147, an HCDR3 comprising the amino acid sequence of SEQ ID NO:227, an LCDR 1 comprising the amino acid sequence of SEQ ID NO:229, an LCDR2 comprising the amino acid sequence of SEQ ID NO:183, and an LCDR3 comprising the amino acid sequence of SEQ ID NO:194 (AB-67); an HCDR1 comprising the amino acid sequence of SEQ ID NO:126, an HCDR2 comprising the amino acid sequence of SEQ ID NO:150, an HCDR3 comprising the amino acid sequence of SEQ ID NO:171, an LCDR 1 comprising the amino acid sequence of SEQ ID NO:178, an LCDR2 comprising the amino acid sequence of SEQ ID NO:183, and an LCDR3 comprising the amino acid sequence of SEQ ID NO:200 (AB-68); an HCDR1 comprising the amino acid sequence of SEQ ID NO:118, an HCDR2 comprising the amino acid sequence of SEQ ID NO:139, an HCDR3 comprising the amino acid sequence of SEQ ID NO:170, an LCDR 1 comprising the amino acid sequence of SEQ - 131 - 3820371.v1 5708.1067001 ID NO:178, an LCDR2 comprising the amino acid sequence of SEQ ID NO:183, and an LCDR3 comprising the amino acid sequence of SEQ ID NO:194 (AB-69); an HCDR1 comprising the amino acid sequence of SEQ ID NO:118, an HCDR2 comprising the amino acid sequence of SEQ ID NO:148, an HCDR3 comprising the amino acid sequence of SEQ ID NO:165, an LCDR 1 comprising the amino acid sequence of SEQ ID NO:177, an LCDR2 comprising the amino acid sequence of SEQ ID NO:183, and an LCDR3 comprising the amino acid sequence of SEQ ID NO:200 (AB-70); an HCDR1 comprising the amino acid sequence of SEQ ID NO:118, an HCDR2 comprising the amino acid sequence of SEQ ID NO:142, an HCDR3 comprising the amino acid sequence of SEQ ID NO:227, an LCDR 1 comprising the amino acid sequence of SEQ ID NO:229, an LCDR2 comprising the amino acid sequence of SEQ ID NO:183, and an LCDR3 comprising the amino acid sequence of SEQ ID NO:194 (AB-71); an HCDR1 comprising the amino acid sequence of SEQ ID NO:118, an HCDR2 comprising the amino acid sequence of SEQ ID NO:147, an HCDR3 comprising the amino acid sequence of SEQ ID NO:170, an LCDR 1 comprising the amino acid sequence of SEQ ID NO:178, an LCDR2 comprising the amino acid sequence of SEQ ID NO:183, and an LCDR3 comprising the amino acid sequence of SEQ ID NO:200 (AB-72); an HCDR1 comprising the amino acid sequence of SEQ ID NO:118, an HCDR2 comprising the amino acid sequence of SEQ ID NO:147, an HCDR3 comprising the amino acid sequence of SEQ ID NO:170, an LCDR 1 comprising the amino acid sequence of SEQ ID NO:178, an LCDR2 comprising the amino acid sequence of SEQ ID NO:183, and an LCDR3 comprising the amino acid sequence of SEQ ID NO:200 (AB-73); or an HCDR1 comprising the amino acid sequence of SEQ ID NO:126, an HCDR2 comprising the amino acid sequence of SEQ ID NO:150, an HCDR3 comprising the amino acid sequence of SEQ ID NO:165, an LCDR 1 comprising the amino acid sequence of SEQ ID NO:177, an LCDR2 comprising the amino acid sequence of SEQ ID NO:183, and an LCDR3 comprising the amino acid sequence of SEQ ID NO:200 (AB-76), wherein the polypeptide is an antibody or an antigen-binding fragment thereof. 2. A polypeptide comprising: a) an immunoglobulin heavy chain variable domain (VH) amino acid sequence comprising a heavy chain complementarity determining region 1 (HCDR1), a heavy chain complementarity determining region 2 (HCDR2) and a heavy - 132 - 3820371.v1 5708.1067001 chain complementarity determining region 3 (HCDR3) that are substantially similar to an HCDR1, HCDR2 and HCDR3, respectively, of an amino acid sequence set forth in any of SEQ ID NOs:206-216, SEQ ID NOs:3-17 and SEQ ID NOs:19-58; and b) an immunoglobulin light chain variable domain (VL) amino acid sequence comprising a light chain complementarity determining region 1 (LCDR1), a light chain complementarity determining region 2 (LCDR2) and a light chain complementarity determining region 3 (LCDR3) that are substantially similar to an LCDR1, LCDR2 and LCDR3, respectively, of an amino acid sequence set forth in any of SEQ ID NOs:217-226, SEQ ID NOs:60-69 and SEQ ID NOs:71-106, wherein the polypeptide is an antibody or an antigen-binding fragment thereof. 3. A polypeptide comprising a paratope that is substantially similar to a paratope of an antibody comprising a VH/VL pair selected from: SEQ ID NO:206 and SEQ ID NO:217 (AB-65); SEQ ID NO:215 and SEQ ID NO:104 (AB-75); SEQ ID NO:214 and SEQ ID NO:226 (AB-74); SEQ ID NO:3 and SEQ ID NO:60 (AB-1); SEQ ID NO:4 and SEQ ID NO:61 (AB-2); SEQ ID NO:5 and SEQ ID NO:62 (AB-3); SEQ ID NO:3 and SEQ ID NO:63 (AB-4); SEQ ID NO:6 and SEQ ID NO:64 (AB-5); SEQ ID NO:7 and SEQ ID NO:65 (AB-6); SEQ ID NO:8 and SEQ ID NO:66 (AB-7); SEQ ID NO:9 and SEQ ID NO:60 (AB-8); SEQ ID NO:10 and SEQ ID NO:67 (AB-9); SEQ ID NO:11 and SEQ ID NO:64 (AB-10); SEQ ID NO:3 and SEQ ID NO:68 (AB-11); SEQ ID NO:12 and SEQ ID NO:60 (AB-12); SEQ ID NO:13 and SEQ ID NO:68 (AB-13); SEQ ID NO:14 and SEQ ID NO:69 (AB-14); SEQ ID NO:15 and SEQ ID NO:64 (AB-15); - 133 - 3820371.v1 5708.1067001 SEQ ID NO:16 and SEQ ID NO:60 (AB-16); SEQ ID NO:17 and SEQ ID NO:65 (AB-17); SEQ ID NO:19 and SEQ ID NO:71 (AB-18); SEQ ID NO:20 and SEQ ID NO:72 (AB-19); SEQ ID NO:21 and SEQ ID NO:71 (AB-20); SEQ ID NO:22 and SEQ ID NO:73 (AB-21); SEQ ID NO:23 and SEQ ID NO:71 (AB-22); SEQ ID NO:24 and SEQ ID NO:74 (AB-23); SEQ ID NO:21 and SEQ ID NO:75 (AB-24); SEQ ID NO:21 and SEQ ID NO:76 (AB-25); SEQ ID NO:21 and SEQ ID NO:71 (AB-26); SEQ ID NO:25 and SEQ ID NO:71 (AB-27); SEQ ID NO:26 and SEQ ID NO:71 (AB-28); SEQ ID NO:27 and SEQ ID NO:77 (AB-29); SEQ ID NO:28 and SEQ ID NO:78 (AB-30); SEQ ID NO:29 and SEQ ID NO:79 (AB-31); SEQ ID NO:30 and SEQ ID NO:80 (AB-32); SEQ ID NO:31 and SEQ ID NO:81 (AB-33); SEQ ID NO:28 and SEQ ID NO:82 (AB-34); SEQ ID NO:23 and SEQ ID NO:80 (AB-35); SEQ ID NO:32 and SEQ ID NO:80 (AB-36); SEQ ID NO:33 and SEQ ID NO:83 (AB-37); SEQ ID NO:34 and SEQ ID NO:84 (AB-38); SEQ ID NO:35 and SEQ ID NO:85 (AB-39); SEQ ID NO:23 and SEQ ID NO:86 (AB-40); SEQ ID NO:36 and SEQ ID NO:87 (AB-41); SEQ ID NO:37 and SEQ ID NO:88 (AB-42); SEQ ID NO:38 and SEQ ID NO:89 (AB-43); SEQ ID NO:39 and SEQ ID NO:80 (AB-44); SEQ ID NO:40 and SEQ ID NO:90 (AB-45); SEQ ID NO:41 and SEQ ID NO:91 (AB-46); SEQ ID NO:42 and SEQ ID NO:92 (AB-47); SEQ ID NO:43 and SEQ ID NO:93 (AB-48); - 134 - 3820371.v1 5708.1067001 SEQ ID NO:44 and SEQ ID NO:94 (AB-49); SEQ ID NO:45 and SEQ ID NO:80 (AB-50); SEQ ID NO:46 and SEQ ID NO:95 (AB-51); SEQ ID NO:47 and SEQ ID NO:96 (AB-52); SEQ ID NO:48 and SEQ ID NO:97 (AB-53); SEQ ID NO:49 and SEQ ID NO:98 (AB-54); SEQ ID NO:50 and SEQ ID NO:84 (AB-55); SEQ ID NO:51 and SEQ ID NO:99 (AB-56); SEQ ID NO:35 and SEQ ID NO:83 (AB-57); SEQ ID NO:52 and SEQ ID NO:100 (AB-58); SEQ ID NO:53 and SEQ ID NO:101 (AB-59); SEQ ID NO:54 and SEQ ID NO:102 (AB-60); SEQ ID NO:55 and SEQ ID NO:103 (AB-61); SEQ ID NO:56 and SEQ ID NO:104 (AB-62); SEQ ID NO:57 and SEQ ID NO:105 (AB-63); SEQ ID NO:58 and SEQ ID NO:106 (AB-64); SEQ ID NO:207 and SEQ ID NO:218 (AB-66); SEQ ID NO:208 and SEQ ID NO:219 (AB-67); SEQ ID NO:209 and SEQ ID NO:220 (AB-68); SEQ ID NO:53 and SEQ ID NO:221 (AB-69); SEQ ID NO:210 and SEQ ID NO:222 (AB-70); SEQ ID NO:211 and SEQ ID NO:223 (AB-71); SEQ ID NO:212 and SEQ ID NO:224 (AB-72); SEQ ID NO:213 and SEQ ID NO:225 (AB-73); or SEQ ID NO:216 and SEQ ID NO:106 (AB-76), or any combination of the foregoing, wherein the polypeptide is an antibody or an antigen-binding fragment thereof. 4. The polypeptide of claim 3, comprising an immunoglobulin heavy chain variable domain (VH) and an immunoglobulin light chain variable domain (VL). 5. The polypeptide of any one of claims 2-4, comprising the HCDR1, HCDR2 and HCDR3, and LCDR1, LCDR2 and LCDR3, of an antibody comprising a VH/VL pair selected from: - 135 - 3820371.v1 5708.1067001 SEQ ID NO:206 and SEQ ID NO:217 (AB-65); SEQ ID NO:215 and SEQ ID NO:104 (AB-75); SEQ ID NO:214 and SEQ ID NO:226 (AB-74); SEQ ID NO:3 and SEQ ID NO:60 (AB-1); SEQ ID NO:4 and SEQ ID NO:61 (AB-2); SEQ ID NO:5 and SEQ ID NO:62 (AB-3); SEQ ID NO:3 and SEQ ID NO:63 (AB-4); SEQ ID NO:6 and SEQ ID NO:64 (AB-5); SEQ ID NO:7 and SEQ ID NO:65 (AB-6); SEQ ID NO:8 and SEQ ID NO:66 (AB-7); SEQ ID NO:9 and SEQ ID NO:60 (AB-8); SEQ ID NO:10 and SEQ ID NO:67 (AB-9); SEQ ID NO:11 and SEQ ID NO:64 (AB-10); SEQ ID NO:3 and SEQ ID NO:68 (AB-11); SEQ ID NO:12 and SEQ ID NO:60 (AB-12); SEQ ID NO:13 and SEQ ID NO:68 (AB-13); SEQ ID NO:14 and SEQ ID NO:69 (AB-14); SEQ ID NO:15 and SEQ ID NO:64 (AB-15); SEQ ID NO:16 and SEQ ID NO:60 (AB-16); SEQ ID NO:17 and SEQ ID NO:65 (AB-17); SEQ ID NO:19 and SEQ ID NO:71 (AB-18); SEQ ID NO:20 and SEQ ID NO:72 (AB-19); SEQ ID NO:21 and SEQ ID NO:71 (AB-20); SEQ ID NO:22 and SEQ ID NO:73 (AB-21); SEQ ID NO:23 and SEQ ID NO:71 (AB-22); SEQ ID NO:24 and SEQ ID NO:74 (AB-23); SEQ ID NO:21 and SEQ ID NO:75 (AB-24); SEQ ID NO:21 and SEQ ID NO:76 (AB-25); SEQ ID NO:21 and SEQ ID NO:71 (AB-26); SEQ ID NO:25 and SEQ ID NO:71 (AB-27); SEQ ID NO:26 and SEQ ID NO:71 (AB-28); SEQ ID NO:27 and SEQ ID NO:77 (AB-29); SEQ ID NO:28 and SEQ ID NO:78 (AB-30); - 136 - 3820371.v1 5708.1067001 SEQ ID NO:29 and SEQ ID NO:79 (AB-31); SEQ ID NO:30 and SEQ ID NO:80 (AB-32); SEQ ID NO:31 and SEQ ID NO:81 (AB-33); SEQ ID NO:28 and SEQ ID NO:82 (AB-34); SEQ ID NO:23 and SEQ ID NO:80 (AB-35); SEQ ID NO:32 and SEQ ID NO:80 (AB-36); SEQ ID NO:33 and SEQ ID NO:83 (AB-37); SEQ ID NO:34 and SEQ ID NO:84 (AB-38); SEQ ID NO:35 and SEQ ID NO:85 (AB-39); SEQ ID NO:23 and SEQ ID NO:86 (AB-40); SEQ ID NO:36 and SEQ ID NO:87 (AB-41); SEQ ID NO:37 and SEQ ID NO:88 (AB-42); SEQ ID NO:38 and SEQ ID NO:89 (AB-43); SEQ ID NO:39 and SEQ ID NO:80 (AB-44); SEQ ID NO:40 and SEQ ID NO:90 (AB-45); SEQ ID NO:41 and SEQ ID NO:91 (AB-46); SEQ ID NO:42 and SEQ ID NO:92 (AB-47); SEQ ID NO:43 and SEQ ID NO:93 (AB-48); SEQ ID NO:44 and SEQ ID NO:94 (AB-49); SEQ ID NO:45 and SEQ ID NO:80 (AB-50); SEQ ID NO:46 and SEQ ID NO:95 (AB-51); SEQ ID NO:47 and SEQ ID NO:96 (AB-52); SEQ ID NO:48 and SEQ ID NO:97 (AB-53); SEQ ID NO:49 and SEQ ID NO:98 (AB-54); SEQ ID NO:50 and SEQ ID NO:84 (AB-55); SEQ ID NO:51 and SEQ ID NO:99 (AB-56); SEQ ID NO:35 and SEQ ID NO:83 (AB-57); SEQ ID NO:52 and SEQ ID NO:100 (AB-58); SEQ ID NO:53 and SEQ ID NO:101 (AB-59); SEQ ID NO:54 and SEQ ID NO:102 (AB-60); SEQ ID NO:55 and SEQ ID NO:103 (AB-61); SEQ ID NO:56 and SEQ ID NO:104 (AB-62); SEQ ID NO:57 and SEQ ID NO:105 (AB-63); - 137 - 3820371.v1 5708.1067001 SEQ ID NO:58 and SEQ ID NO:106 (AB-64); SEQ ID NO:207 and SEQ ID NO:218 (AB-66); SEQ ID NO:208 and SEQ ID NO:219 (AB-67); SEQ ID NO:209 and SEQ ID NO:220 (AB-68); SEQ ID NO:53 and SEQ ID NO:221 (AB-69); SEQ ID NO:210 and SEQ ID NO:222 (AB-70); SEQ ID NO:211 and SEQ ID NO:223 (AB-71); SEQ ID NO:212 and SEQ ID NO:224 (AB-72); SEQ ID NO:213 and SEQ ID NO:225 (AB-73); or SEQ ID NO:216 and SEQ ID NO:106 (AB-76). 6. The polypeptide of claim 1, 2 or 5, further comprising a paratope that is identical to a paratope of an antibody comprising a VH/VL pair selected from: SEQ ID NO:206 and SEQ ID NO:217 (AB-65); SEQ ID NO:215 and SEQ ID NO:104 (AB-75); SEQ ID NO:214 and SEQ ID NO:226 (AB-74); SEQ ID NO:3 and SEQ ID NO:60 (AB-1); SEQ ID NO:4 and SEQ ID NO:61 (AB-2); SEQ ID NO:5 and SEQ ID NO:62 (AB-3); SEQ ID NO:3 and SEQ ID NO:63 (AB-4); SEQ ID NO:6 and SEQ ID NO:64 (AB-5); SEQ ID NO:7 and SEQ ID NO:65 (AB-6); SEQ ID NO:8 and SEQ ID NO:66 (AB-7); SEQ ID NO:9 and SEQ ID NO:60 (AB-8); SEQ ID NO:10 and SEQ ID NO:67 (AB-9); SEQ ID NO:11 and SEQ ID NO:64 (AB-10); SEQ ID NO:3 and SEQ ID NO:68 (AB-11); SEQ ID NO:12 and SEQ ID NO:60 (AB-12); SEQ ID NO:13 and SEQ ID NO:68 (AB-13); SEQ ID NO:14 and SEQ ID NO:69 (AB-14); SEQ ID NO:15 and SEQ ID NO:64 (AB-15); SEQ ID NO:16 and SEQ ID NO:60 (AB-16); SEQ ID NO:17 and SEQ ID NO:65 (AB-17); - 138 - 3820371.v1 5708.1067001 SEQ ID NO:19 and SEQ ID NO:71 (AB-18); SEQ ID NO:20 and SEQ ID NO:72 (AB-19); SEQ ID NO:21 and SEQ ID NO:71 (AB-20); SEQ ID NO:22 and SEQ ID NO:73 (AB-21); SEQ ID NO:23 and SEQ ID NO:71 (AB-22); SEQ ID NO:24 and SEQ ID NO:74 (AB-23); SEQ ID NO:21 and SEQ ID NO:75 (AB-24); SEQ ID NO:21 and SEQ ID NO:76 (AB-25); SEQ ID NO:21 and SEQ ID NO:71 (AB-26); SEQ ID NO:25 and SEQ ID NO:71 (AB-27); SEQ ID NO:26 and SEQ ID NO:71 (AB-28); SEQ ID NO:27 and SEQ ID NO:77 (AB-29); SEQ ID NO:28 and SEQ ID NO:78 (AB-30); SEQ ID NO:29 and SEQ ID NO:79 (AB-31); SEQ ID NO:30 and SEQ ID NO:80 (AB-32); SEQ ID NO:31 and SEQ ID NO:81 (AB-33); SEQ ID NO:28 and SEQ ID NO:82 (AB-34); SEQ ID NO:23 and SEQ ID NO:80 (AB-35); SEQ ID NO:32 and SEQ ID NO:80 (AB-36); SEQ ID NO:33 and SEQ ID NO:83 (AB-37); SEQ ID NO:34 and SEQ ID NO:84 (AB-38); SEQ ID NO:35 and SEQ ID NO:85 (AB-39); SEQ ID NO:23 and SEQ ID NO:86 (AB-40); SEQ ID NO:36 and SEQ ID NO:87 (AB-41); SEQ ID NO:37 and SEQ ID NO:88 (AB-42); SEQ ID NO:38 and SEQ ID NO:89 (AB-43); SEQ ID NO:39 and SEQ ID NO:80 (AB-44); SEQ ID NO:40 and SEQ ID NO:90 (AB-45); SEQ ID NO:41 and SEQ ID NO:91 (AB-46); SEQ ID NO:42 and SEQ ID NO:92 (AB-47); SEQ ID NO:43 and SEQ ID NO:93 (AB-48); SEQ ID NO:44 and SEQ ID NO:94 (AB-49); SEQ ID NO:45 and SEQ ID NO:80 (AB-50); - 139 - 3820371.v1 5708.1067001 SEQ ID NO:46 and SEQ ID NO:95 (AB-51); SEQ ID NO:47 and SEQ ID NO:96 (AB-52); SEQ ID NO:48 and SEQ ID NO:97 (AB-53); SEQ ID NO:49 and SEQ ID NO:98 (AB-54); SEQ ID NO:50 and SEQ ID NO:84 (AB-55); SEQ ID NO:51 and SEQ ID NO:99 (AB-56); SEQ ID NO:35 and SEQ ID NO:83 (AB-57); SEQ ID NO:52 and SEQ ID NO:100 (AB-58); SEQ ID NO:53 and SEQ ID NO:101 (AB-59); SEQ ID NO:54 and SEQ ID NO:102 (AB-60); SEQ ID NO:55 and SEQ ID NO:103 (AB-61); SEQ ID NO:56 and SEQ ID NO:104 (AB-62); SEQ ID NO:57 and SEQ ID NO:105 (AB-63); SEQ ID NO:58 and SEQ ID NO:106 (AB-64); SEQ ID NO:206 and SEQ ID NO:217 (AB-65); SEQ ID NO:207 and SEQ ID NO:218 (AB-66); SEQ ID NO:208 and SEQ ID NO:219 (AB-67); SEQ ID NO:209 and SEQ ID NO:220 (AB-68); SEQ ID NO:53 and SEQ ID NO:221 (AB-69); SEQ ID NO:210 and SEQ ID NO:222 (AB-70); SEQ ID NO:211 and SEQ ID NO:223 (AB-71); SEQ ID NO:212 and SEQ ID NO:224 (AB-72); SEQ ID NO:213 and SEQ ID NO:225 (AB-73); or SEQ ID NO:216 and SEQ ID NO:106 (AB-76). 7. A polypeptide comprising an immunoglobulin heavy chain variable domain (VH) comprising: a) the amino acid sequence of SEQ ID NO:2, wherein: X1 is L or F; X2 is G, A, S, T or P; X3 is V, F or absent; X4 is S or absent; X5 is S, G, N or absent; - 140 - 3820371.v1 5708.1067001 X6 is F, D, I, T, S or V; X7 is A, S, R, N or K; X8 is A, H or T; X9 is M or I; X10 is S or G; X11 is S or G; X12 is S or G; X13 is G, D, A, R, E or T; X14 is H, D, A, S or N; X15 is A or I; X16 is H, A, I, Y or V; X17 is S or D; X18 is Y, T or H; or X19 is A, Y or T, or any combination of the foregoing; or b) the amino acid sequence of SEQ ID NO:18, wherein: X1 is V or E; X2 is L or I; X3 is V or A; X4 is G or S; X5 is H, Q or L; X6 is P or L; X7 is T or A; X8 is F, G or S; X9 is G, D or S; X10 is Y, S or A; X11 is T, Y or A; X12 is L or I; X13 is K, R or E; X14 is V or M; X15 is V, T or I; X16 is K, R, T or S; X17 is C, G, Q or S; - 141 - 3820371.v1 5708.1067001 X18 is K, G or S; X19 is G or S; X20 is C or Y; X21 is V or F; X22 is V or G; X23 is R or T; X24 is R, T or A; X25 is K, R or N; X26 is D or N; X27 is C or Y; X28 is H, Q or E; X29 is P or L; X30 is V, E or A; X31 is S or E; X32 is Y or T; X33 is N, S, Q, T or absent; X34 is S or absent; X35 is S or absent; X36 is D, S or absent; X37 is V, T, I or absent; X38 is Y or absent X39 is Y, T or N; X40 is D or A; X41 is Y, S or A; X42 is K or Q; X43 is V or I; X44 is V or I; or X45 is S or absent, or any combination of the foregoing. 8. The polypeptide of claim 7, further comprising an immunoglobulin light chain variable domain (VL) comprising: a) the amino acid sequence of SEQ ID NO:59, wherein: - 142 - 3820371.v1 5708.1067001 X20 is H, Q, A, S, Y, R or K; or X21 is A, S, T or G, or a combination of the foregoing; or b) the amino acid sequence of SEQ ID NO:70, wherein: X46 is V, I or F; X47 is V, K, T, M, R or L; X48 is P or T; X49 is P or Q; X50 is P, F or S; X51 is P or S; X52 is V or L; X53 is H or Q; X54 is D, G or Y; X55 is D, T or N; X56 is C, Y or A; X57 is K or E; X58 is M, T, I or S; X59 is Y or S; X60 is R, G, S or D; X61 is R or S; X62 is Y, I or F; X63 is Y or S; X64 is V, R or T; X65 is T or S; X66 is T or I; X67 is H or Q; X68 is H, F or Y; X69 is C or Y; X70 is T or S; X71 is Y, T or W; X72 is P or A; or X73 is L or Y, or any combination of the foregoing. - 143 - 3820371.v1 5708.1067001 9. The polypeptide of any one of claims 3-8, wherein the VH comprises a heavy chain complementarity determining region 1 (HCDR1), a heavy chain complementarity determining region 2 (HCDR2) and a heavy chain complementarity determining region 3 (HCDR3) that are identical in amino acid sequence to the HCDR1, HCDR2 and HCDR3, respectively, of a VH amino acid sequence set forth in any one of SEQ ID NOs:206-216, SEQ ID NOs:3-17 and SEQ ID NOs:19-58. 10. The polypeptide of any one of claims 3-9, wherein the VL comprises a light chain complementarity determining region 1 (LCDR1), light chain complementarity determining region 2 (LCDR2) and light chain complementarity determining region 3 (LCDR3) that are identical in amino acid sequence to the LCDR1, LCDR2 and LCDR3, respectively, of a VL amino acid sequence set forth in any one of SEQ ID NOs:217-226, SEQ ID NOs:60-69 and SEQ ID NOs:71-106. 11. The polypeptide of any one of claims 1, 2, 5 and 7-10, wherein the polypeptide comprises a paratope that is identical to a paratope of a VH/VL combination selected from the amino acid sequence of: a) SEQ ID NO:206/SEQ ID NO:217 (AB-65), SEQ ID NO:215/SEQ ID NO:104 (AB-75), SEQ ID NO:214/SEQ ID NO:226 (AB-74), SEQ ID NO:207/SEQ ID NO:218 (AB-66), SEQ ID NO:208/SEQ ID NO:219 (AB-67), SEQ ID NO:209/SEQ ID NO:220 (AB-68), SEQ ID NO:53/SEQ ID NO:221 (AB-69), SEQ ID NO:210/SEQ ID NO:222 (AB-70), SEQ ID NO:211/SEQ ID NO:223 (AB-71), SEQ ID NO:212/SEQ ID NO:224 (AB-72), SEQ ID NO:213/SEQ ID NO:225 (AB-73), or SEQ ID NO:216/SEQ ID NO:106 (AB-76); b) SEQ ID NO:3/SEQ ID NO:60 (AB-1), SEQ ID NO:4/SEQ ID NO:61 (AB-2), SEQ ID NO:5/SEQ ID NO:62 (AB-3), SEQ ID NO:3/SEQ ID NO:63 (AB-4), SEQ ID NO:6/SEQ ID NO:64 (AB-5), SEQ ID NO:7/SEQ ID NO:65 (AB-6); SEQ ID NO:8/SEQ ID NO:66 (AB-7), SEQ ID NO:9/SEQ ID NO:60 (AB-8); SEQ ID NO:10/SEQ ID NO:67 (AB-9), SEQ ID NO:11/SEQ ID NO:64 (AB- 10), SEQ ID NO:3/SEQ ID NO:68 (AB-11); SEQ ID NO:12/SEQ ID NO:60 (AB-12); SEQ ID NO:13/SEQ ID NO:68 (AB-13); SEQ ID NO:14/SEQ ID NO:69 (AB-14), SEQ ID NO:15/SEQ ID NO:64 (AB-15), SEQ ID NO:16/SEQ ID NO:60 (AB-16), or SEQ ID NO:17/SEQ ID NO:65 (AB-17); or - 144 - 3820371.v1 5708.1067001 c) SEQ ID NO:19/SEQ ID NO:71 (AB-18), SEQ ID NO:20/SEQ ID NO:72 (AB-19), SEQ ID NO:21/SEQ ID NO:71 (AB-20), SEQ ID NO:22/SEQ ID NO:73 (AB-21), SEQ ID NO:23/SEQ ID NO:71 (AB-22), SEQ ID NO:24/SEQ ID NO:74 (AB-23), SEQ ID NO:21/SEQ ID NO:75 (AB-24), SEQ ID NO:21/SEQ ID NO:76 (AB-25), SEQ ID NO:21/SEQ ID NO:71 (AB-26), SEQ ID NO:25/SEQ ID NO:71 (AB-27), SEQ ID NO:26/SEQ ID NO:71 (AB-28), SEQ ID NO:27/SEQ ID NO:77 (AB-29), SEQ ID NO:28/SEQ ID NO:78 (AB-30), SEQ ID NO:29/SEQ ID NO:79 (AB-31), SEQ ID NO:30/SEQ ID NO:80 (AB-32), SEQ ID NO:31/SEQ ID NO:81 (AB-33), SEQ ID NO:28/SEQ ID NO:82 (AB-34), SEQ ID NO:23/SEQ ID NO:80 (AB-35), SEQ ID NO:32/SEQ ID NO:80 (AB-36), SEQ ID NO:33/SEQ ID NO:83 (AB-37), SEQ ID NO:34/SEQ ID NO:84 (AB-38), SEQ ID NO:35/SEQ ID NO:85 (AB-39), SEQ ID NO:23/SEQ ID NO:86 (AB-40), SEQ ID NO:36/SEQ ID NO:87 (AB-41), SEQ ID NO:37/SEQ ID NO:88 (AB-42), SEQ ID NO:38/SEQ ID NO:89 (AB-43); SEQ ID NO:39/SEQ ID NO:80 (AB-44), SEQ ID NO:40/SEQ ID NO:90 (AB-45); SEQ ID NO:41/SEQ ID NO:91 (AB-46), SEQ ID NO:42/SEQ ID NO:92 (AB-47), SEQ ID NO:43/SEQ ID NO:93 (AB-48), SEQ ID NO:44/SEQ ID NO:94 (AB-49); SEQ ID NO:45/SEQ ID NO:80 (AB-50), SEQ ID NO:46/SEQ ID NO:95 (AB-51); SEQ ID NO:47/SEQ ID NO:96 (AB-52), SEQ ID NO:48/SEQ ID NO:97 (AB-53); SEQ ID NO:49/SEQ ID NO:98 (AB-54), SEQ ID NO:50/SEQ ID NO:84 (AB-55); SEQ ID NO:51/SEQ ID NO:99 (AB-56), SEQ ID NO:35/SEQ ID NO:83 (AB-57), SEQ ID NO:52/SEQ ID NO:100 (AB-58), SEQ ID NO:53/SEQ ID NO:101 (AB-59); SEQ ID NO:54/SEQ ID NO:102 (AB-60), SEQ ID NO:55/SEQ ID NO:103 (AB-61); SEQ ID NO:56/SEQ ID NO:104 (AB-62); SEQ ID NO:57/SEQ ID NO:105 (AB-63), or SEQ ID NO:58/SEQ ID NO:106 (AB-64). 12. The polypeptide of any one of claims 1-11, wherein the VH has at least 85% sequence identity to an amino acid sequence set forth in any one of SEQ ID NOs:206-216, SEQ ID NOs:3-17 and SEQ ID NOs:19-58. - 145 - 3820371.v1 5708.1067001 13. The polypeptide of any one of claims 1-12, wherein the VH comprises about 1-10 amino acid substitutions, relative to an amino acid sequence set forth in any one of SEQ ID NOs:206-216, SEQ ID NOs:3-17 and SEQ ID NOs:19-58. 14. The polypeptide of any one of claims 1-13, wherein the VL has at least 85% sequence identity to an amino acid sequence set forth in any one of SEQ ID NOs:217-226, SEQ ID NOs:60-69 and SEQ ID NOs:71-106. 15. The polypeptide of any one of claims 1-14, wherein the VL comprises about 1-10 amino acid substitutions, relative to an amino acid sequence set forth in any one of SEQ ID NOs:217-226, SEQ ID NOs:60-69 and SEQ ID NOs:71-106. 16. The polypeptide of claim 13 or 15, wherein the amino acid substitutions are conservative substitutions. 17. The polypeptide of claim 16, wherein the amino acid substitutions are highly conservative substitutions. 18. The polypeptide of any one of claims 2-17, wherein the VH and VL are humanized, contain human framework regions, or a combination thereof. 19. The polypeptide of any one of claims 1-18, wherein the polypeptide is an antibody comprising an antibody heavy chain constant domain, optionally wherein the antibody heavy chain constant domain is an IgG1 or IgG2 constant domain. 20. The polypeptide of claim 19, wherein: a) the antibody heavy chain constant domain is an IgG2 constant domain; b) the antibody heavy chain constant domain comprises one or more mutations which increase serum half-life of the antibody or antigen-binding fragment thereof in humans; c) the antibody heavy chain constant domain comprises, relative to a wild-type human IgG constant domain, amino acid substitutions with tyrosine, threonine and glutamic acid at amino acid residues 252, 254 and 256, respectively, wherein the amino acid residues are numbered according to the EU index as in Kabat, or any combination of the foregoing. - 146 - 3820371.v1 5708.1067001 21. The polypeptide of claim 19 or 20, further comprising an antibody light chain constant domain sequence. 22. The polypeptide of claim 21, wherein the antibody light chain constant domain is a κ light chain constant domain. 23. The polypeptide of claim 21, wherein the antibody light chain constant domain is a λ light chain constant domain. 24. The polypeptide of 1-18, wherein the polypeptide is an antigen binding fragment selected from Fab, F(ab’)2, Fab’, scFv, or Fv. 25. The polypeptide of any one of claims 1-24, wherein the polypeptide is conjugated to a heterologous moiety. 26. The polypeptide of claim 25, wherein the heterologous moiety is a therapeutic agent, a diagnostic agent or a combination thereof. 27. The polypeptide of claim 25, wherein the heterologous moiety is selected from the group consisting of polyethylene glycol (PEG), hexadecanoic acid, a hydrogel, a lipid nanoparticle, a polymer nanoparticle, and a heterologous polypeptide sequence, or a combination thereof. 28. The polypeptide of claim 27, wherein the polymer nanoparticle comprises poly(lactic- co-glycolic) acid (PLGA). 29. The polypeptide of claim 25, wherein the heterologous polypeptide sequence comprises a carrier polypeptide. 30. The polypeptide of claim 29, wherein the carrier polypeptide is albumin or an Fc polypeptide. 31. A fusion protein comprising the polypeptide of any one of claims 1-30. 32. A polynucleotide (e.g., DNA or RNA; linear or circular; optionally containing one or more modified nucleotides) comprising a sequence encoding the polypeptide of any one of claims 1-30 or the fusion protein of claim 31. - 147 - 3820371.v1 5708.1067001 33. A vector (e.g., an expression vector, including a viral-delivery vector) comprising the polynucleotide of claim 32. 34. A host cell comprising the polynucleotide of claim 32 or the vector of claim 33. 35. A composition comprising the polypeptide of any one of claims 1-30 or the fusion protein of claim 31 or the polynucleotide of claim 32. 36. The composition of claim 35, further comprising one or more pharmaceutical excipients, diluents, or carriers. 37. A method of treating a subject in need thereof, comprising administering an effective amount of the composition of claim 35 or 36 to the subject. 38. A method of increasing PD-1 signaling in a cell in a subject, comprising contacting the cell with an effective amount of the composition of claim 35 or 36. 39. The method of claim 37 or 38, wherein the subject has, or is suspected of having an inflammatory disease, condition, or disorder. 40. The method of any one of claims 37-39, wherein the inflammatory disease, condition, or disorder is an autoimmune disease. 41. The method of claim 40, wherein the autoimmune disease is selected from the group consisting of achalasia, Addison’s disease, adult Still's disease, agammaglobulinemia, alopecia areata, amyloidosis, ankylosing spondylitis, anti-GBM/anti-TBM nephritis, antiphospholipid syndrome, atopic dermatitis and other autoimmune dermatologic or mixed dermatologic-rheumatologic syndromes, autoimmune angioedema, autoimmune dermatitis, autoimmune dysautonomia, autoimmune encephalomyelitis, autoimmune hepatitis, autoimmune inner ear disease (AIED), autoimmune myocarditis, autoimmune oophoritis, autoimmune orchitis, autoimmune pancreatitis, autoimmune retinopathy, autoimmune urticaria, axonal and neuronal neuropathy (AMAN), Baló disease, Behcet’s disease, benign mucosal pemphigoid, bullous pemphigoid, Castleman disease (CD), celiac disease, Chagas disease, chronic inflammatory demyelinating polyneuropathy (CIDP), chronic recurrent multifocal osteomyelitis (CRMO), Churg-Strauss Syndrome (CSS) or eosinophilic - 148 - 3820371.v1 5708.1067001 granulomatosis (EGPA), cicatricial pemphigoid, Cogan’s syndrome, cold agglutinin disease, congenital heart block, Coxsackie myocarditis, CREST syndrome, Crohn’s disease, dermatitis herpetiformis, dermatomyositis, Devic’s disease (neuromyelitis optica), discoid lupus, Dressler’s syndrome, endometriosis, eosinophilic esophagitis (EoE), eosinophilic fasciitis, erythema nodosum, essential mixed cryoglobulinemia, Evans syndrome, fibromyalgia, fibrosing alveolitis, giant cell arteritis (temporal arteritis), giant cell myocarditis, glomerulonephritis, Goodpasture’s syndrome, granulomatosis with polyangiitis, Graves’ disease, Guillain-Barre syndrome, Hashimoto’s thyroiditis, hemolytic anemia, Henoch-Schonlein purpura (HSP), herpes gestationis or pemphigoid gestationis (PG), hidradenitis suppurativa (HS) (acne inversa), hypogammalglobulinemia, IgA nephropathy, IgG4-related sclerosing disease, immune thrombocytopenic purpura (ITP), inclusion body myositis (IBM), interstitial cystitis (IC), juvenile arthritis, juvenile diabetes (Type 1 diabetes), juvenile myositis (JM), Kawasaki disease, Lambert-Eaton syndrome, leukocytoclastic vasculitis, lichen planus, lichen sclerosus, ligneous conjunctivitis, linear IgA disease (LAD), Lyme disease chronic, Meniere’s disease, microscopic polyangiitis (MPA), mixed connective tissue disease (MCTD), Mooren’s ulcer, Mucha-Habermann disease, multifocal motor neuropathy (MMN) or MMNCB, multiple sclerosis, myasthenia gravis, myositis, narcolepsy, neonatal lupus, neuromyelitis optica and other neurologic syndromes that do not formally meet the definition of MS, neutropenia, ocular cicatricial pemphigoid, optic neuritis, palindromic rheumatism (PR), PANDAS, paraneoplastic cerebellar degeneration (PCD), paroxysmal nocturnal hemoglobinuria (PNH), Parry Romberg syndrome, pars planitis (peripheral uveitis), Parsonage-Turner syndrome, pemphigus, peripheral neuropathy, perivenous encephalomyelitis, pernicious anemia (PA), POEMS syndrome, polyarteritis nodosa, polyglandular syndromes type I, II and III, polymyalgia rheumatica, polymyositis, postmyocardial infarction syndrome, postpericardiotomy syndrome, primary biliary cirrhosis, primary sclerosing cholangitis, progesterone dermatitis, psoriasis, psoriatic arthritis, pure red cell aplasia (PRCA), pyoderma gangrenosum, Raynaud’s phenomenon, reactive arthritis, reflex sympathetic dystrophy, relapsing polychondritis, restless legs syndrome (RLS), retroperitoneal fibrosis, rheumatic fever, rheumatoid arthritis and other autoimmune arthritis, sarcoidosis, Schmidt syndrome, scleritis, scleroderma, Sjögren’s syndrome, sperm and testicular - 149 - 3820371.v1 5708.1067001 autoimmunity, stiff person syndrome (SPS), subacute bacterial endocarditis (SBE), Susac’s syndrome, sympathetic ophthalmia (SO), systemic lupus erythematosus (SLE) and other lupus-like conditions that do not meet the formal definition of SLE, Takayasu’s arteritis, temporal arteritis/giant cell arteritis, thrombocytopenic purpura (TTP), thyroid eye disease (TED), Tolosa-Hunt syndrome (THS), transverse myelitis, Type 1 diabetes, ulcerative colitis (UC), undifferentiated connective tissue disease (UCTD), uveitis, vasculitis, vitiligo, and Vogt-Koyanagi-Harada Disease. 42. The method of any one of claims 37-39, wherein the inflammatory disease, condition, or disorder is an inflammatory bowel disease (IBD). 43. The method of any one of claims 37-42, wherein the subject is 18 years or older. 44. The method of any one of claims 37-43, further comprising administering a therapeutically effective amount of an additional therapeutic agent to the subject. 45. The method of any one of claims 44, wherein the additional therapeutic agent is disease-modifying anti-rheumatic drugs (DMARs), anti-TNF agents, TNF-Fcs, non- steroidal anti-inflammatory drugs (NSAIDs), Immune Selective Anti-Inflammatory Derivatives (ImSAIDs), corticosteroids (e.g., glucocorticoids), TRegs, autophagy- related (ATG) proteins, α-l-guluronic acid (ALG), interferons, anti-inflammatory interleukins (e.g., IL-2, IL-10), macrolides, an insulin preparation (e.g., human insulin, insulin glargine, insulin lispro, insulin detemir, or insulin aspart), a sulfonylurea agent (e.g., glibenclamide, gliclazide, or glimepiride), a quick-acting insulin secretion promoter (e.g., nateglinide), a biguanide preparation (e.g., metformin), an insulin sensitizer (e.g., pioglitazone), an alpha-glucosidase inhibitor (e.g., acarbose or voglibose), a diabetic neuropathy therapeutic agent (e.g., epalrestat, mexiletine, or imidapril), a GLP-1 analog preparation (e.g., liraglutide, exenatide, or lixisenatide), a DPP-4 inhibitor (e.g., sitagliptin, vildagliptin, or alogliptin), a steroid agent (e.g., cortisone acetate, hydrocortisone, hydrocortisone sodium phosphate, hydrocortisone sodium succinate, fludrocortisone acetate, prednisolone, prednisolone acetate, prednisolone sodium succinate, prednisolone butylacetate, prednisolone sodium phosphate, halopredone acetate, methylprednisolone, methylprednisolone acetate, methylprednisolone sodium succinate, triamsinolone, triamsinolone acetate, - 150 - 3820371.v1 5708.1067001 triamsinolone acetonide, dexamethasone, dexamethasone acetate, dexamethasone sodium phosphate, dexamethasone palmitate, paramethasone acetate, or betamethasone), interferon beta-1a, interferon beta-1b, glatiramer acetate, mitoxantrone, azathioprine, cyclophosphamide, cyclosporin, methotrexate, cladribine, adrenocorticotropic hormone (ACTH), corticotropin, mizoribine, tacrolimus, fingolimod, or alemtuzumab. 46. The method of any one of claims 37-45, wherein the subject is a human. - 151 - 3820371.v1 |
Description:
5708.1067001 Antigen Binding Molecules Targeting Programmed Cell Death Protein 1 (PD-1) RELATED APPLICATION(S) [0001] This application claims the benefit of U.S. Provisional Application No. 63/402,410, filed on August 30, 2022. The entire teachings of the above application(s) are incorporated herein by reference. INCORPORATION BY REFERENCE OF MATERIAL IN XML [0002] This application incorporates by reference the Sequence Listing contained in the following eXtensible Markup Language (XML) file being submitted concurrently herewith: a) File name: 57081067001.xml; created August 23, 2023, 314,382 Bytes in size. BACKGROUND [0003] Programmed cell death protein 1 (PD-1) is a checkpoint protein expressed on activated and tolerized T cells. Activation of PD-1 leads to a downregulation of PD-1 expression, reduced cytokine release, and suppression of immune responses. While antagonizing PD-1 has been a common approach in oncology, agonizing PD-1 is a relatively underexplored approach that may prove useful for inhibiting excessive immune-system activation that can drive the pathology of inflammatory disorders, such as certain autoimmune diseases, for example, inflammatory bowel diseases (IBDs). Accordingly, modulating PD-1 signaling by agonism has potential to ameliorate such diseases and conditions, and promote health. SUMMARY [0004] The disclosure provided herein is based, in part, on the discovery of polypeptides that specifically bind to PD-1. Accordingly, the disclosure generally relates to polypeptides (e.g., antibodies), compositions (e.g., pharmaceutical compositions) and methods that are useful for binding to PD-1 and, in some embodiments, modulating (e.g., increasing, enhancing) PD-1 signaling (e.g., in vivo). [0005] Provided herein, among other things, are polypeptides (e.g., antibodies and antigen binding fragments thereof) that specifically bind PD-1 (e.g., full-length human PD-1) - 1 - 3820371.v1 5708.1067001 or a variant thereof. In some embodiments, polypeptides disclosed herein function as agonists of PD-1 signaling. [0006] The disclosure provides, among other things, a polypeptide comprising a paratope that is substantially similar to a paratope of an antibody comprising a VH/VL pair selected from: SEQ ID NO:206 and SEQ ID NO:217 (AB-65); SEQ ID NO:215 and SEQ ID NO:104 (AB-75); SEQ ID NO:214 and SEQ ID NO:226 (AB-74); SEQ ID NO:3 and SEQ ID NO:60 (AB-1); SEQ ID NO:4 and SEQ ID NO:61 (AB-2); SEQ ID NO:5 and SEQ ID NO:62 (AB-3); SEQ ID NO:3 and SEQ ID NO:63 (AB-4); SEQ ID NO:6 and SEQ ID NO:64 (AB-5); SEQ ID NO:7 and SEQ ID NO:65 (AB-6); SEQ ID NO:8 and SEQ ID NO:66 (AB-7); SEQ ID NO:9 and SEQ ID NO:60 (AB-8); SEQ ID NO:10 and SEQ ID NO:67 (AB-9); SEQ ID NO:11 and SEQ ID NO:64 (AB-10); SEQ ID NO:3 and SEQ ID NO:68 (AB-11); SEQ ID NO:12 and SEQ ID NO:60 (AB-12); SEQ ID NO:13 and SEQ ID NO:68 (AB-13); SEQ ID NO:14 and SEQ ID NO:69 (AB-14); SEQ ID NO:15 and SEQ ID NO:64 (AB-15); SEQ ID NO:16 and SEQ ID NO:60 (AB-16); SEQ ID NO:17 and SEQ ID NO:65 (AB-17); SEQ ID NO:19 and SEQ ID NO:71 (AB-18); SEQ ID NO:20 and SEQ ID NO:72 (AB-19); SEQ ID NO:21 and SEQ ID NO:71 (AB-20); SEQ ID NO:22 and SEQ ID NO:73 (AB-21); SEQ ID NO:23 and SEQ ID NO:71 (AB-22); SEQ ID NO:24 and SEQ ID NO:74 (AB-23); SEQ ID NO:21 and SEQ ID NO:75 (AB-24); SEQ ID NO:21 and SEQ ID NO:76 (AB-25); - 2 - 3820371.v1 5708.1067001 SEQ ID NO:21 and SEQ ID NO:71 (AB-26); SEQ ID NO:25 and SEQ ID NO:71 (AB-27); SEQ ID NO:26 and SEQ ID NO:71 (AB-28); SEQ ID NO:27 and SEQ ID NO:77 (AB-29); SEQ ID NO:28 and SEQ ID NO:78 (AB-30); SEQ ID NO:29 and SEQ ID NO:79 (AB-31); SEQ ID NO:30 and SEQ ID NO:80 (AB-32); SEQ ID NO:31 and SEQ ID NO:81 (AB-33); SEQ ID NO:28 and SEQ ID NO:82 (AB-34); SEQ ID NO:23 and SEQ ID NO:80 (AB-35); SEQ ID NO:32 and SEQ ID NO:80 (AB-36); SEQ ID NO:33 and SEQ ID NO:83 (AB-37); SEQ ID NO:34 and SEQ ID NO:84 (AB-38); SEQ ID NO:35 and SEQ ID NO:85 (AB-39); SEQ ID NO:23 and SEQ ID NO:86 (AB-40); SEQ ID NO:36 and SEQ ID NO:87 (AB-41); SEQ ID NO:37 and SEQ ID NO:88 (AB-42); SEQ ID NO:38 and SEQ ID NO:89 (AB-43); SEQ ID NO:39 and SEQ ID NO:80 (AB-44); SEQ ID NO:40 and SEQ ID NO:90 (AB-45); SEQ ID NO:41 and SEQ ID NO:91 (AB-46); SEQ ID NO:42 and SEQ ID NO:92 (AB-47); SEQ ID NO:43 and SEQ ID NO:93 (AB-48); SEQ ID NO:44 and SEQ ID NO:94 (AB-49); SEQ ID NO:45 and SEQ ID NO:80 (AB-50); SEQ ID NO:46 and SEQ ID NO:95 (AB-51); SEQ ID NO:47 and SEQ ID NO:96 (AB-52); SEQ ID NO:48 and SEQ ID NO:97 (AB-53); SEQ ID NO:49 and SEQ ID NO:98 (AB-54); SEQ ID NO:50 and SEQ ID NO:84 (AB-55); SEQ ID NO:51 and SEQ ID NO:99 (AB-56); SEQ ID NO:35 and SEQ ID NO:83 (AB-57); SEQ ID NO:52 and SEQ ID NO:100 (AB-58); - 3 - 3820371.v1 5708.1067001 SEQ ID NO:53 and SEQ ID NO:101 (AB-59); SEQ ID NO:54 and SEQ ID NO:102 (AB-60); SEQ ID NO:55 and SEQ ID NO:103 (AB-61); SEQ ID NO:56 and SEQ ID NO:104 (AB-62); SEQ ID NO:57 and SEQ ID NO:105 (AB-63); SEQ ID NO:58 and SEQ ID NO:106 (AB-64); SEQ ID NO:207 and SEQ ID NO:218 (AB-66); SEQ ID NO:208 and SEQ ID NO:219 (AB-67); SEQ ID NO:209 and SEQ ID NO:220 (AB-68); SEQ ID NO:53 and SEQ ID NO:221 (AB-69); SEQ ID NO:210 and SEQ ID NO:222 (AB-70); SEQ ID NO:211 and SEQ ID NO:223 (AB-71); SEQ ID NO:212 and SEQ ID NO:224 (AB-72); SEQ ID NO:213 and SEQ ID NO:225 (AB-73); or SEQ ID NO:216 and SEQ ID NO:106 (AB-76), or any combination of the foregoing. [0007] The disclosure also provides, among other things, a polypeptide comprising: an immunoglobulin heavy chain variable domain (VH) amino acid sequence comprising a heavy chain complementarity determining region 1 (HCDR1), a heavy chain complementarity determining region 2 (HCDR2) and a heavy chain complementarity determining region 3 (HCDR3) that are substantially similar to an HCDR1, an HCDR2 and an HCDR3, respectively, of a V H amino acid sequence set forth in any of SEQ ID NOs:3-17, SEQ ID NOs:19-58, and SEQ ID NOs:206-216; and an immunoglobulin light chain variable domain (VL) amino acid sequence comprising a light chain complementarity determining region 1 (LCDR1), a light chain complementarity determining region 2 (LCDR2) and a light chain complementarity determining region 3 (LCDR3) that are substantially similar to an LCDR1, an LCDR2 and an LCDR3, respectively, of a VL amino acid sequence set forth in any of SEQ ID NOs:60-69, SEQ ID NOs:71-106, and SEQ ID NOs:217-226. [0008] In some embodiments, a polypeptide comprises the HCDR1, HCDR2 and HCDR3, and the LCDR1, LCDR2 and LCDR3, of an antibody comprising a VH/VL pair selected from: SEQ ID NO:206 and SEQ ID NO:217 (AB-65); - 4 - 3820371.v1 5708.1067001 SEQ ID NO:215 and SEQ ID NO:104 (AB-75); SEQ ID NO:214 and SEQ ID NO:226 (AB-74); SEQ ID NO:3 and SEQ ID NO:60 (AB-1); SEQ ID NO:4 and SEQ ID NO:61 (AB-2); SEQ ID NO:5 and SEQ ID NO:62 (AB-3); SEQ ID NO:3 and SEQ ID NO:63 (AB-4); SEQ ID NO:6 and SEQ ID NO:64 (AB-5); SEQ ID NO:7 and SEQ ID NO:65 (AB-6); SEQ ID NO:8 and SEQ ID NO:66 (AB-7); SEQ ID NO:9 and SEQ ID NO:60 (AB-8); SEQ ID NO:10 and SEQ ID NO:67 (AB-9); SEQ ID NO:11 and SEQ ID NO:64 (AB-10); SEQ ID NO:3 and SEQ ID NO:68 (AB-11); SEQ ID NO:12 and SEQ ID NO:60 (AB-12); SEQ ID NO:13 and SEQ ID NO:68 (AB-13); SEQ ID NO:14 and SEQ ID NO:69 (AB-14); SEQ ID NO:15 and SEQ ID NO:64 (AB-15); SEQ ID NO:16 and SEQ ID NO:60 (AB-16); SEQ ID NO:17 and SEQ ID NO:65 (AB-17); SEQ ID NO:19 and SEQ ID NO:71 (AB-18); SEQ ID NO:20 and SEQ ID NO:72 (AB-19); SEQ ID NO:21 and SEQ ID NO:71 (AB-20); SEQ ID NO:22 and SEQ ID NO:73 (AB-21); SEQ ID NO:23 and SEQ ID NO:71 (AB-22); SEQ ID NO:24 and SEQ ID NO:74 (AB-23); SEQ ID NO:21 and SEQ ID NO:75 (AB-24); SEQ ID NO:21 and SEQ ID NO:76 (AB-25); SEQ ID NO:21 and SEQ ID NO:71 (AB-26); SEQ ID NO:25 and SEQ ID NO:71 (AB-27); SEQ ID NO:26 and SEQ ID NO:71 (AB-28); SEQ ID NO:27 and SEQ ID NO:77 (AB-29); SEQ ID NO:28 and SEQ ID NO:78 (AB-30); SEQ ID NO:29 and SEQ ID NO:79 (AB-31); - 5 - 3820371.v1 5708.1067001 SEQ ID NO:30 and SEQ ID NO:80 (AB-32); SEQ ID NO:31 and SEQ ID NO:81 (AB-33); SEQ ID NO:28 and SEQ ID NO:82 (AB-34); SEQ ID NO:23 and SEQ ID NO:80 (AB-35); SEQ ID NO:32 and SEQ ID NO:80 (AB-36); SEQ ID NO:33 and SEQ ID NO:83 (AB-37); SEQ ID NO:34 and SEQ ID NO:84 (AB-38); SEQ ID NO:35 and SEQ ID NO:85 (AB-39); SEQ ID NO:23 and SEQ ID NO:86 (AB-40); SEQ ID NO:36 and SEQ ID NO:87 (AB-41); SEQ ID NO:37 and SEQ ID NO:88 (AB-42); SEQ ID NO:38 and SEQ ID NO:89 (AB-43); SEQ ID NO:39 and SEQ ID NO:80 (AB-44); SEQ ID NO:40 and SEQ ID NO:90 (AB-45); SEQ ID NO:41 and SEQ ID NO:91 (AB-46); SEQ ID NO:42 and SEQ ID NO:92 (AB-47); SEQ ID NO:43 and SEQ ID NO:93 (AB-48); SEQ ID NO:44 and SEQ ID NO:94 (AB-49); SEQ ID NO:45 and SEQ ID NO:80 (AB-50); SEQ ID NO:46 and SEQ ID NO:95 (AB-51); SEQ ID NO:47 and SEQ ID NO:96 (AB-52); SEQ ID NO:48 and SEQ ID NO:97 (AB-53); SEQ ID NO:49 and SEQ ID NO:98 (AB-54); SEQ ID NO:50 and SEQ ID NO:84 (AB-55); SEQ ID NO:51 and SEQ ID NO:99 (AB-56); SEQ ID NO:35 and SEQ ID NO:83 (AB-57); SEQ ID NO:52 and SEQ ID NO:100 (AB-58); SEQ ID NO:53 and SEQ ID NO:101 (AB-59); SEQ ID NO:54 and SEQ ID NO:102 (AB-60); SEQ ID NO:55 and SEQ ID NO:103 (AB-61); SEQ ID NO:56 and SEQ ID NO:104 (AB-62); SEQ ID NO:57 and SEQ ID NO:105 (AB-63); SEQ ID NO:58 and SEQ ID NO:106 (AB-64); - 6 - 3820371.v1 5708.1067001 SEQ ID NO:207 and SEQ ID NO:218 (AB-66); SEQ ID NO:208 and SEQ ID NO:219 (AB-67); SEQ ID NO:209 and SEQ ID NO:220 (AB-68); SEQ ID NO:53 and SEQ ID NO:221 (AB-69); SEQ ID NO:210 and SEQ ID NO:222 (AB-70); SEQ ID NO:211 and SEQ ID NO:223 (AB-71); SEQ ID NO:212 and SEQ ID NO:224 (AB-72); SEQ ID NO:213 and SEQ ID NO:225 (AB-73); or SEQ ID NO:216 and SEQ ID NO:106 (AB-76). [0009] In some embodiments, a polypeptide comprises a paratope that is identical to a paratope of an antibody comprising a VH/VL pair selected from: SEQ ID NO:206 and SEQ ID NO:217 (AB-65); SEQ ID NO:215 and SEQ ID NO:104 (AB-75); SEQ ID NO:214 and SEQ ID NO:226 (AB-74); SEQ ID NO:3 and SEQ ID NO:60 (AB-1); SEQ ID NO:4 and SEQ ID NO:61 (AB-2); SEQ ID NO:5 and SEQ ID NO:62 (AB-3); SEQ ID NO:3 and SEQ ID NO:63 (AB-4); SEQ ID NO:6 and SEQ ID NO:64 (AB-5); SEQ ID NO:7 and SEQ ID NO:65 (AB-6); SEQ ID NO:8 and SEQ ID NO:66 (AB-7); SEQ ID NO:9 and SEQ ID NO:60 (AB-8); SEQ ID NO:10 and SEQ ID NO:67 (AB-9); SEQ ID NO:11 and SEQ ID NO:64 (AB-10); SEQ ID NO:3 and SEQ ID NO:68 (AB-11); SEQ ID NO:12 and SEQ ID NO:60 (AB-12); SEQ ID NO:13 and SEQ ID NO:68 (AB-13); SEQ ID NO:14 and SEQ ID NO:69 (AB-14); SEQ ID NO:15 and SEQ ID NO:64 (AB-15); SEQ ID NO:16 and SEQ ID NO:60 (AB-16); SEQ ID NO:17 and SEQ ID NO:65 (AB-17); SEQ ID NO:19 and SEQ ID NO:71 (AB-18); SEQ ID NO:20 and SEQ ID NO:72 (AB-19); - 7 - 3820371.v1 5708.1067001 SEQ ID NO:21 and SEQ ID NO:71 (AB-20); SEQ ID NO:22 and SEQ ID NO:73 (AB-21); SEQ ID NO:23 and SEQ ID NO:71 (AB-22); SEQ ID NO:24 and SEQ ID NO:74 (AB-23); SEQ ID NO:21 and SEQ ID NO:75 (AB-24); SEQ ID NO:21 and SEQ ID NO:76 (AB-25); SEQ ID NO:21 and SEQ ID NO:71 (AB-26); SEQ ID NO:25 and SEQ ID NO:71 (AB-27); SEQ ID NO:26 and SEQ ID NO:71 (AB-28); SEQ ID NO:27 and SEQ ID NO:77 (AB-29); SEQ ID NO:28 and SEQ ID NO:78 (AB-30); SEQ ID NO:29 and SEQ ID NO:79 (AB-31); SEQ ID NO:30 and SEQ ID NO:80 (AB-32); SEQ ID NO:31 and SEQ ID NO:81 (AB-33); SEQ ID NO:28 and SEQ ID NO:82 (AB-34); SEQ ID NO:23 and SEQ ID NO:80 (AB-35); SEQ ID NO:32 and SEQ ID NO:80 (AB-36); SEQ ID NO:33 and SEQ ID NO:83 (AB-37); SEQ ID NO:34 and SEQ ID NO:84 (AB-38); SEQ ID NO:35 and SEQ ID NO:85 (AB-39); SEQ ID NO:23 and SEQ ID NO:86 (AB-40); SEQ ID NO:36 and SEQ ID NO:87 (AB-41); SEQ ID NO:37 and SEQ ID NO:88 (AB-42); SEQ ID NO:38 and SEQ ID NO:89 (AB-43); SEQ ID NO:39 and SEQ ID NO:80 (AB-44); SEQ ID NO:40 and SEQ ID NO:90 (AB-45); SEQ ID NO:41 and SEQ ID NO:91 (AB-46); SEQ ID NO:42 and SEQ ID NO:92 (AB-47); SEQ ID NO:43 and SEQ ID NO:93 (AB-48); SEQ ID NO:44 and SEQ ID NO:94 (AB-49); SEQ ID NO:45 and SEQ ID NO:80 (AB-50); SEQ ID NO:46 and SEQ ID NO:95 (AB-51); SEQ ID NO:47 and SEQ ID NO:96 (AB-52); - 8 - 3820371.v1 5708.1067001 SEQ ID NO:48 and SEQ ID NO:97 (AB-53); SEQ ID NO:49 and SEQ ID NO:98 (AB-54); SEQ ID NO:50 and SEQ ID NO:84 (AB-55); SEQ ID NO:51 and SEQ ID NO:99 (AB-56); SEQ ID NO:35 and SEQ ID NO:83 (AB-57); SEQ ID NO:52 and SEQ ID NO:100 (AB-58); SEQ ID NO:53 and SEQ ID NO:101 (AB-59); SEQ ID NO:54 and SEQ ID NO:102 (AB-60); SEQ ID NO:55 and SEQ ID NO:103 (AB-61); SEQ ID NO:56 and SEQ ID NO:104 (AB-62); SEQ ID NO:57 and SEQ ID NO:105 (AB-63); SEQ ID NO:58 and SEQ ID NO:106 (AB-64); SEQ ID NO:207 and SEQ ID NO:218 (AB-66); SEQ ID NO:208 and SEQ ID NO:219 (AB-67); SEQ ID NO:209 and SEQ ID NO:220 (AB-68); SEQ ID NO:53 and SEQ ID NO:221 (AB-69); SEQ ID NO:210 and SEQ ID NO:222 (AB-70); SEQ ID NO:211 and SEQ ID NO:223 (AB-71); SEQ ID NO:212 and SEQ ID NO:224 (AB-72); SEQ ID NO:213 and SEQ ID NO:225 (AB-73); or SEQ ID NO:216 and SEQ ID NO:106 (AB-76). [0010] The disclosure also provides, among other things, a polypeptide comprising: an HCDR1 comprising the amino acid sequence of SEQ ID NO:118, an HCDR2 comprising the amino acid sequence of SEQ ID NO:147, an HCDR3 comprising the amino acid sequence of SEQ ID NO:227, an LCDR 1 comprising the amino acid sequence of SEQ ID NO:229, an LCDR2 comprising the amino acid sequence of SEQ ID NO:183, and an LCDR3 comprising the amino acid sequence of SEQ ID NO:200 (AB-65); an HCDR1 comprising the amino acid sequence of SEQ ID NO:118, an HCDR2 comprising the amino acid sequence of SEQ ID NO:148, an HCDR3 comprising the amino acid sequence of SEQ ID NO:228, an LCDR 1 comprising the amino acid sequence of SEQ ID NO:177, an LCDR2 comprising the amino acid sequence of SEQ ID NO:183, and an LCDR3 comprising the amino acid sequence of SEQ ID NO:200 (AB-75); - 9 - 3820371.v1 5708.1067001 an HCDR1 comprising the amino acid sequence of SEQ ID NO:118, an HCDR2 comprising the amino acid sequence of SEQ ID NO:139, an HCDR3 comprising the amino acid sequence of SEQ ID NO:170, an LCDR 1 comprising the amino acid sequence of SEQ ID NO:178, an LCDR2 comprising the amino acid sequence of SEQ ID NO:183, and an LCDR3 comprising the amino acid sequence of SEQ ID NO:194 (AB-74); an HCDR1 comprising the amino acid sequence of SEQ ID NO:107, an HCDR2 comprising the amino acid sequence of SEQ ID NO:127, an HCDR3 comprising the amino acid sequence of SEQ ID NO:151, an LCDR 1 comprising the amino acid sequence of SEQ ID NO:172, an LCDR2 comprising the amino acid sequence of SEQ ID NO:179, and an LCDR3 comprising the amino acid sequence of SEQ ID NO:184 (AB-1); an HCDR1 comprising the amino acid sequence of SEQ ID NO:107, an HCDR2 comprising the amino acid sequence of SEQ ID NO:127, an HCDR3 comprising the amino acid sequence of SEQ ID NO:152, an LCDR 1 comprising the amino acid sequence of SEQ ID NO:172, an LCDR2 comprising the amino acid sequence of SEQ ID NO:179, and an LCDR3 comprising the amino acid sequence of SEQ ID NO:185 (AB-2); an HCDR1 comprising the amino acid sequence of SEQ ID NO:108, an HCDR2 comprising the amino acid sequence of SEQ ID NO:128, an HCDR3 comprising the amino acid sequence of SEQ ID NO:153, an LCDR 1 comprising the amino acid sequence of SEQ ID NO:172, an LCDR2 comprising the amino acid sequence of SEQ ID NO:179, and an LCDR3 comprising the amino acid sequence of SEQ ID NO:186 (AB-3); an HCDR1 comprising the amino acid sequence of SEQ ID NO:107, an HCDR2 comprising the amino acid sequence of SEQ ID NO:127, an HCDR3 comprising the amino acid sequence of SEQ ID NO:151, an LCDR 1 comprising the amino acid sequence of SEQ ID NO:172, an LCDR2 comprising the amino acid sequence of SEQ ID NO:179, and an LCDR3 comprising the amino acid sequence of SEQ ID NO:187 (AB-4); an HCDR1 comprising the amino acid sequence of SEQ ID NO:109, an HCDR2 comprising the amino acid sequence of SEQ ID NO:129, an HCDR3 comprising the amino acid sequence of SEQ ID NO:151, an LCDR 1 comprising the amino acid sequence of SEQ ID NO:172, an LCDR2 comprising the amino acid sequence of SEQ ID NO:179, and an LCDR3 comprising the amino acid sequence of SEQ ID NO:188 (AB-5); an HCDR1 comprising the amino acid sequence of SEQ ID NO:110, an HCDR2 comprising the amino acid sequence of SEQ ID NO:130, an HCDR3 comprising the amino acid sequence of SEQ ID NO:154, an LCDR 1 comprising the amino acid sequence of SEQ - 10 - 3820371.v1 5708.1067001 ID NO:172, an LCDR2 comprising the amino acid sequence of SEQ ID NO:179, and an LCDR3 comprising the amino acid sequence of SEQ ID NO:189 (AB-6); an HCDR1 comprising the amino acid sequence of SEQ ID NO:109, an HCDR2 comprising the amino acid sequence of SEQ ID NO:131, an HCDR3 comprising the amino acid sequence of SEQ ID NO:151, an LCDR 1 comprising the amino acid sequence of SEQ ID NO:172, an LCDR2 comprising the amino acid sequence of SEQ ID NO:179, and an LCDR3 comprising the amino acid sequence of SEQ ID NO:190 (AB-7); an HCDR1 comprising the amino acid sequence of SEQ ID NO:111, an HCDR2 comprising the amino acid sequence of SEQ ID NO:132, an HCDR3 comprising the amino acid sequence of SEQ ID NO:155, an LCDR 1 comprising the amino acid sequence of SEQ ID NO:172, an LCDR2 comprising the amino acid sequence of SEQ ID NO:179, and an LCDR3 comprising the amino acid sequence of SEQ ID NO:184 (AB-8); an HCDR1 comprising the amino acid sequence of SEQ ID NO:111, an HCDR2 comprising the amino acid sequence of SEQ ID NO:133, an HCDR3 comprising the amino acid sequence of SEQ ID NO:154, an LCDR 1 comprising the amino acid sequence of SEQ ID NO:172, an LCDR2 comprising the amino acid sequence of SEQ ID NO:179, and an LCDR3 comprising the amino acid sequence of SEQ ID NO:191 (AB-9); an HCDR1 comprising the amino acid sequence of SEQ ID NO:112, an HCDR2 comprising the amino acid sequence of SEQ ID NO:127, an HCDR3 comprising the amino acid sequence of SEQ ID NO:151, an LCDR 1 comprising the amino acid sequence of SEQ ID NO:172, an LCDR2 comprising the amino acid sequence of SEQ ID NO:179, and an LCDR3 comprising the amino acid sequence of SEQ ID NO:188 (AB-10); an HCDR1 comprising the amino acid sequence of SEQ ID NO:107, an HCDR2 comprising the amino acid sequence of SEQ ID NO:127, an HCDR3 comprising the amino acid sequence of SEQ ID NO:151, an LCDR 1 comprising the amino acid sequence of SEQ ID NO:172, an LCDR2 comprising the amino acid sequence of SEQ ID NO:179, and an LCDR3 comprising the amino acid sequence of SEQ ID NO:192 (AB-11); an HCDR1 comprising the amino acid sequence of SEQ ID NO:113, an HCDR2 comprising the amino acid sequence of SEQ ID NO:134, an HCDR3 comprising the amino acid sequence of SEQ ID NO:151, an LCDR 1 comprising the amino acid sequence of SEQ ID NO:172, an LCDR2 comprising the amino acid sequence of SEQ ID NO:179, and an LCDR3 comprising the amino acid sequence of SEQ ID NO:184 (AB-12); - 11 - 3820371.v1 5708.1067001 an HCDR1 comprising the amino acid sequence of SEQ ID NO:114, an HCDR2 comprising the amino acid sequence of SEQ ID NO:135, an HCDR3 comprising the amino acid sequence of SEQ ID NO:156, an LCDR 1 comprising the amino acid sequence of SEQ ID NO:172, an LCDR2 comprising the amino acid sequence of SEQ ID NO:179, and an LCDR3 comprising the amino acid sequence of SEQ ID NO:192 (AB-13); an HCDR1 comprising the amino acid sequence of SEQ ID NO:115, an HCDR2 comprising the amino acid sequence of SEQ ID NO:136, an HCDR3 comprising the amino acid sequence of SEQ ID NO:151, an LCDR 1 comprising the amino acid sequence of SEQ ID NO:172, an LCDR2 comprising the amino acid sequence of SEQ ID NO:179, and an LCDR3 comprising the amino acid sequence of SEQ ID NO:193 (AB-14); an HCDR1 comprising the amino acid sequence of SEQ ID NO:116, an HCDR2 comprising the amino acid sequence of SEQ ID NO:137, an HCDR3 comprising the amino acid sequence of SEQ ID NO:153, an LCDR 1 comprising the amino acid sequence of SEQ ID NO:172, an LCDR2 comprising the amino acid sequence of SEQ ID NO:179, and an LCDR3 comprising the amino acid sequence of SEQ ID NO:188 (AB-15); an HCDR1 comprising the amino acid sequence of SEQ ID NO:114, an HCDR2 comprising the amino acid sequence of SEQ ID NO:138, an HCDR3 comprising the amino acid sequence of SEQ ID NO:157, an LCDR 1 comprising the amino acid sequence of SEQ ID NO:172, an LCDR2 comprising the amino acid sequence of SEQ ID NO:179, and an LCDR3 comprising the amino acid sequence of SEQ ID NO:184 (AB-16); an HCDR1 comprising the amino acid sequence of SEQ ID NO:117, an HCDR2 comprising the amino acid sequence of SEQ ID NO:131, an HCDR3 comprising the amino acid sequence of SEQ ID NO:151, an LCDR 1 comprising the amino acid sequence of SEQ ID NO:172, an LCDR2 comprising the amino acid sequence of SEQ ID NO:179, and an LCDR3 comprising the amino acid sequence of SEQ ID NO:189 (AB-17); an HCDR1 comprising the amino acid sequence of SEQ ID NO:118, an HCDR2 comprising the amino acid sequence of SEQ ID NO:139, an HCDR3 comprising the amino acid sequence of SEQ ID NO:158, an LCDR 1 comprising the amino acid sequence of SEQ ID NO:173, an LCDR2 comprising the amino acid sequence of SEQ ID NO:180, and an LCDR3 comprising the amino acid sequence of SEQ ID NO:194 (AB-18); an HCDR1 comprising the amino acid sequence of SEQ ID NO:119, an HCDR2 comprising the amino acid sequence of SEQ ID NO:140, an HCDR3 comprising the amino acid sequence of SEQ ID NO:159, an LCDR 1 comprising the amino acid sequence of SEQ - 12 - 3820371.v1 5708.1067001 ID NO:174, an LCDR2 comprising the amino acid sequence of SEQ ID NO:181, and an LCDR3 comprising the amino acid sequence of SEQ ID NO:195 (AB-19); an HCDR1 comprising the amino acid sequence of SEQ ID NO:120, an HCDR2 comprising the amino acid sequence of SEQ ID NO:139, an HCDR3 comprising the amino acid sequence of SEQ ID NO:160, an LCDR 1 comprising the amino acid sequence of SEQ ID NO:173, an LCDR2 comprising the amino acid sequence of SEQ ID NO:180, and an LCDR3 comprising the amino acid sequence of SEQ ID NO:194 (AB-20); an HCDR1 comprising the amino acid sequence of SEQ ID NO:120, an HCDR2 comprising the amino acid sequence of SEQ ID NO:139, an HCDR3 comprising the amino acid sequence of SEQ ID NO:160, an LCDR 1 comprising the amino acid sequence of SEQ ID NO:173, an LCDR2 comprising the amino acid sequence of SEQ ID NO:182, and an LCDR3 comprising the amino acid sequence of SEQ ID NO:194 (AB-21); an HCDR1 comprising the amino acid sequence of SEQ ID NO:121, an HCDR2 comprising the amino acid sequence of SEQ ID NO:139, an HCDR3 comprising the amino acid sequence of SEQ ID NO:151, an LCDR 1 comprising the amino acid sequence of SEQ ID NO:173, an LCDR2 comprising the amino acid sequence of SEQ ID NO:180, and an LCDR3 comprising the amino acid sequence of SEQ ID NO:194 (AB-22); an HCDR1 comprising the amino acid sequence of SEQ ID NO:120, an HCDR2 comprising the amino acid sequence of SEQ ID NO:139, an HCDR3 comprising the amino acid sequence of SEQ ID NO:160, an LCDR 1 comprising the amino acid sequence of SEQ ID NO:173, an LCDR2 comprising the amino acid sequence of SEQ ID NO:180, and an LCDR3 comprising the amino acid sequence of SEQ ID NO:194 (AB-23); an HCDR1 comprising the amino acid sequence of SEQ ID NO:120, an HCDR2 comprising the amino acid sequence of SEQ ID NO:139, an HCDR3 comprising the amino acid sequence of SEQ ID NO:160, an LCDR 1 comprising the amino acid sequence of SEQ ID NO:173, an LCDR2 comprising the amino acid sequence of SEQ ID NO:180, and an LCDR3 comprising the amino acid sequence of SEQ ID NO:194 (AB-24); an HCDR1 comprising the amino acid sequence of SEQ ID NO:120, an HCDR2 comprising the amino acid sequence of SEQ ID NO:139, an HCDR3 comprising the amino acid sequence of SEQ ID NO:160, an LCDR 1 comprising the amino acid sequence of SEQ ID NO:173, an LCDR2 comprising the amino acid sequence of SEQ ID NO:180, and an LCDR3 comprising the amino acid sequence of SEQ ID NO:194 (AB-25); - 13 - 3820371.v1 5708.1067001 an HCDR1 comprising the amino acid sequence of SEQ ID NO:120, an HCDR2 comprising the amino acid sequence of SEQ ID NO:139, an HCDR3 comprising the amino acid sequence of SEQ ID NO:160, an LCDR 1 comprising the amino acid sequence of SEQ ID NO:173, an LCDR2 comprising the amino acid sequence of SEQ ID NO:180, and an LCDR3 comprising the amino acid sequence of SEQ ID NO:194 (AB-26); an HCDR1 comprising the amino acid sequence of SEQ ID NO:120, an HCDR2 comprising the amino acid sequence of SEQ ID NO:139, an HCDR3 comprising the amino acid sequence of SEQ ID NO:160, an LCDR 1 comprising the amino acid sequence of SEQ ID NO:173, an LCDR2 comprising the amino acid sequence of SEQ ID NO:180, and an LCDR3 comprising the amino acid sequence of SEQ ID NO:194 (AB-27); an HCDR1 comprising the amino acid sequence of SEQ ID NO:118, an HCDR2 comprising the amino acid sequence of SEQ ID NO:139, an HCDR3 comprising the amino acid sequence of SEQ ID NO:151, an LCDR 1 comprising the amino acid sequence of SEQ ID NO:173, an LCDR2 comprising the amino acid sequence of SEQ ID NO:180, and an LCDR3 comprising the amino acid sequence of SEQ ID NO:194 (AB-28); an HCDR1 comprising the amino acid sequence of SEQ ID NO:120, an HCDR2 comprising the amino acid sequence of SEQ ID NO:139, an HCDR3 comprising the amino acid sequence of SEQ ID NO:161, an LCDR 1 comprising the amino acid sequence of SEQ ID NO:173, an LCDR2 comprising the amino acid sequence of SEQ ID NO:180, and an LCDR3 comprising the amino acid sequence of SEQ ID NO:194 (AB-29); an HCDR1 comprising the amino acid sequence of SEQ ID NO:121, an HCDR2 comprising the amino acid sequence of SEQ ID NO:139, an HCDR3 comprising the amino acid sequence of SEQ ID NO:162, an LCDR 1 comprising the amino acid sequence of SEQ ID NO:173, an LCDR2 comprising the amino acid sequence of SEQ ID NO:183, and an LCDR3 comprising the amino acid sequence of SEQ ID NO:194 (AB-30); an HCDR1 comprising the amino acid sequence of SEQ ID NO:121, an HCDR2 comprising the amino acid sequence of SEQ ID NO:141, an HCDR3 comprising the amino acid sequence of SEQ ID NO:163, an LCDR 1 comprising the amino acid sequence of SEQ ID NO:173, an LCDR2 comprising the amino acid sequence of SEQ ID NO:180, and an LCDR3 comprising the amino acid sequence of SEQ ID NO:196 (AB-31); an HCDR1 comprising the amino acid sequence of SEQ ID NO:121, an HCDR2 comprising the amino acid sequence of SEQ ID NO:139, an HCDR3 comprising the amino acid sequence of SEQ ID NO:151, an LCDR 1 comprising the amino acid sequence of SEQ - 14 - 3820371.v1 5708.1067001 ID NO:173, an LCDR2 comprising the amino acid sequence of SEQ ID NO:180, and an LCDR3 comprising the amino acid sequence of SEQ ID NO:194 (AB-32); an HCDR1 comprising the amino acid sequence of SEQ ID NO:121, an HCDR2 comprising the amino acid sequence of SEQ ID NO:139, an HCDR3 comprising the amino acid sequence of SEQ ID NO:164, an LCDR 1 comprising the amino acid sequence of SEQ ID NO:172, an LCDR2 comprising the amino acid sequence of SEQ ID NO:180, and an LCDR3 comprising the amino acid sequence of SEQ ID NO:194 (AB-33); an HCDR1 comprising the amino acid sequence of SEQ ID NO:121, an HCDR2 comprising the amino acid sequence of SEQ ID NO:139, an HCDR3 comprising the amino acid sequence of SEQ ID NO:162, an LCDR 1 comprising the amino acid sequence of SEQ ID NO:173, an LCDR2 comprising the amino acid sequence of SEQ ID NO:183, and an LCDR3 comprising the amino acid sequence of SEQ ID NO:194 (AB-34); an HCDR1 comprising the amino acid sequence of SEQ ID NO:121, an HCDR2 comprising the amino acid sequence of SEQ ID NO:139, an HCDR3 comprising the amino acid sequence of SEQ ID NO:151, an LCDR 1 comprising the amino acid sequence of SEQ ID NO:173, an LCDR2 comprising the amino acid sequence of SEQ ID NO:180, and an LCDR3 comprising the amino acid sequence of SEQ ID NO:194 (AB-35); an HCDR1 comprising the amino acid sequence of SEQ ID NO:122, an HCDR2 comprising the amino acid sequence of SEQ ID NO:139, an HCDR3 comprising the amino acid sequence of SEQ ID NO:151, an LCDR 1 comprising the amino acid sequence of SEQ ID NO:173, an LCDR2 comprising the amino acid sequence of SEQ ID NO:180, and an LCDR3 comprising the amino acid sequence of SEQ ID NO:194 (AB-36); an HCDR1 comprising the amino acid sequence of SEQ ID NO:114, an HCDR2 comprising the amino acid sequence of SEQ ID NO:139, an HCDR3 comprising the amino acid sequence of SEQ ID NO:151, an LCDR 1 comprising the amino acid sequence of SEQ ID NO:172, an LCDR2 comprising the amino acid sequence of SEQ ID NO:183, and an LCDR3 comprising the amino acid sequence of SEQ ID NO:194 (AB-37); an HCDR1 comprising the amino acid sequence of SEQ ID NO:121, an HCDR2 comprising the amino acid sequence of SEQ ID NO:139, an HCDR3 comprising the amino acid sequence of SEQ ID NO:151, an LCDR 1 comprising the amino acid sequence of SEQ ID NO:173, an LCDR2 comprising the amino acid sequence of SEQ ID NO:183, and an LCDR3 comprising the amino acid sequence of SEQ ID NO:194 (AB-38); - 15 - 3820371.v1 5708.1067001 an HCDR1 comprising the amino acid sequence of SEQ ID NO:118, an HCDR2 comprising the amino acid sequence of SEQ ID NO:139, an HCDR3 comprising the amino acid sequence of SEQ ID NO:165, an LCDR 1 comprising the amino acid sequence of SEQ ID NO:172, an LCDR2 comprising the amino acid sequence of SEQ ID NO:183, and an LCDR3 comprising the amino acid sequence of SEQ ID NO:194 (AB-39); an HCDR1 comprising the amino acid sequence of SEQ ID NO:121, an HCDR2 comprising the amino acid sequence of SEQ ID NO:139, an HCDR3 comprising the amino acid sequence of SEQ ID NO:151, an LCDR 1 comprising the amino acid sequence of SEQ ID NO:173, an LCDR2 comprising the amino acid sequence of SEQ ID NO:180, and an LCDR3 comprising the amino acid sequence of SEQ ID NO:194 (AB-40); an HCDR1 comprising the amino acid sequence of SEQ ID NO:121, an HCDR2 comprising the amino acid sequence of SEQ ID NO:139, an HCDR3 comprising the amino acid sequence of SEQ ID NO:166, an LCDR 1 comprising the amino acid sequence of SEQ ID NO:172, an LCDR2 comprising the amino acid sequence of SEQ ID NO:180, and an LCDR3 comprising the amino acid sequence of SEQ ID NO:194 (AB-41); an HCDR1 comprising the amino acid sequence of SEQ ID NO:123, an HCDR2 comprising the amino acid sequence of SEQ ID NO:142, an HCDR3 comprising the amino acid sequence of SEQ ID NO:151, an LCDR 1 comprising the amino acid sequence of SEQ ID NO:173, an LCDR2 comprising the amino acid sequence of SEQ ID NO:180, and an LCDR3 comprising the amino acid sequence of SEQ ID NO:194 (AB-42); an HCDR1 comprising the amino acid sequence of SEQ ID NO:121, an HCDR2 comprising the amino acid sequence of SEQ ID NO:143, an HCDR3 comprising the amino acid sequence of SEQ ID NO:167, an LCDR 1 comprising the amino acid sequence of SEQ ID NO:173, an LCDR2 comprising the amino acid sequence of SEQ ID NO:183, and an LCDR3 comprising the amino acid sequence of SEQ ID NO:194 (AB-43); an HCDR1 comprising the amino acid sequence of SEQ ID NO:124, an HCDR2 comprising the amino acid sequence of SEQ ID NO:144, an HCDR3 comprising the amino acid sequence of SEQ ID NO:151, an LCDR 1 comprising the amino acid sequence of SEQ ID NO:173, an LCDR2 comprising the amino acid sequence of SEQ ID NO:180, and an LCDR3 comprising the amino acid sequence of SEQ ID NO:194 (AB-44); an HCDR1 comprising the amino acid sequence of SEQ ID NO:124, an HCDR2 comprising the amino acid sequence of SEQ ID NO:139, an HCDR3 comprising the amino acid sequence of SEQ ID NO:162, an LCDR 1 comprising the amino acid sequence of SEQ - 16 - 3820371.v1 5708.1067001 ID NO:173, an LCDR2 comprising the amino acid sequence of SEQ ID NO:183, and an LCDR3 comprising the amino acid sequence of SEQ ID NO:197 (AB-45); an HCDR1 comprising the amino acid sequence of SEQ ID NO:121, an HCDR2 comprising the amino acid sequence of SEQ ID NO:139, an HCDR3 comprising the amino acid sequence of SEQ ID NO:151, an LCDR 1 comprising the amino acid sequence of SEQ ID NO:173, an LCDR2 comprising the amino acid sequence of SEQ ID NO:180, and an LCDR3 comprising the amino acid sequence of SEQ ID NO:194 (AB-46); an HCDR1 comprising the amino acid sequence of SEQ ID NO:121, an HCDR2 comprising the amino acid sequence of SEQ ID NO:139, an HCDR3 comprising the amino acid sequence of SEQ ID NO:162, an LCDR 1 comprising the amino acid sequence of SEQ ID NO:173, an LCDR2 comprising the amino acid sequence of SEQ ID NO:183, and an LCDR3 comprising the amino acid sequence of SEQ ID NO:198 (AB-47); an HCDR1 comprising the amino acid sequence of SEQ ID NO:114, an HCDR2 comprising the amino acid sequence of SEQ ID NO:139, an HCDR3 comprising the amino acid sequence of SEQ ID NO:165, an LCDR 1 comprising the amino acid sequence of SEQ ID NO:172, an LCDR2 comprising the amino acid sequence of SEQ ID NO:183, and an LCDR3 comprising the amino acid sequence of SEQ ID NO:199 (AB-48); an HCDR1 comprising the amino acid sequence of SEQ ID NO:114, an HCDR2 comprising the amino acid sequence of SEQ ID NO:139, an HCDR3 comprising the amino acid sequence of SEQ ID NO:151, an LCDR 1 comprising the amino acid sequence of SEQ ID NO:172, an LCDR2 comprising the amino acid sequence of SEQ ID NO:179, and an LCDR3 comprising the amino acid sequence of SEQ ID NO:194 (AB-49); an HCDR1 comprising the amino acid sequence of SEQ ID NO:121, an HCDR2 comprising the amino acid sequence of SEQ ID NO:145, an HCDR3 comprising the amino acid sequence of SEQ ID NO:168, an LCDR 1 comprising the amino acid sequence of SEQ ID NO:173, an LCDR2 comprising the amino acid sequence of SEQ ID NO:180, and an LCDR3 comprising the amino acid sequence of SEQ ID NO:194 (AB-50); an HCDR1 comprising the amino acid sequence of SEQ ID NO:121, an HCDR2 comprising the amino acid sequence of SEQ ID NO:146, an HCDR3 comprising the amino acid sequence of SEQ ID NO:151, an LCDR 1 comprising the amino acid sequence of SEQ ID NO:173, an LCDR2 comprising the amino acid sequence of SEQ ID NO:183, and an LCDR3 comprising the amino acid sequence of SEQ ID NO:194 (AB-51); - 17 - 3820371.v1 5708.1067001 an HCDR1 comprising the amino acid sequence of SEQ ID NO:124, an HCDR2 comprising the amino acid sequence of SEQ ID NO:139, an HCDR3 comprising the amino acid sequence of SEQ ID NO:151, an LCDR 1 comprising the amino acid sequence of SEQ ID NO:175, an LCDR2 comprising the amino acid sequence of SEQ ID NO:180, and an LCDR3 comprising the amino acid sequence of SEQ ID NO:194 (AB-52); an HCDR1 comprising the amino acid sequence of SEQ ID NO:121, an HCDR2 comprising the amino acid sequence of SEQ ID NO:139, an HCDR3 comprising the amino acid sequence of SEQ ID NO:162, an LCDR 1 comprising the amino acid sequence of SEQ ID NO:176, an LCDR2 comprising the amino acid sequence of SEQ ID NO:183, and an LCDR3 comprising the amino acid sequence of SEQ ID NO:194 (AB-53); an HCDR1 comprising the amino acid sequence of SEQ ID NO:118, an HCDR2 comprising the amino acid sequence of SEQ ID NO:147, an HCDR3 comprising the amino acid sequence of SEQ ID NO:165, an LCDR 1 comprising the amino acid sequence of SEQ ID NO:177, an LCDR2 comprising the amino acid sequence of SEQ ID NO:183, and an LCDR3 comprising the amino acid sequence of SEQ ID NO:200 (AB-54); an HCDR1 comprising the amino acid sequence of SEQ ID NO:121, an HCDR2 comprising the amino acid sequence of SEQ ID NO:139, an HCDR3 comprising the amino acid sequence of SEQ ID NO:151, an LCDR 1 comprising the amino acid sequence of SEQ ID NO:173, an LCDR2 comprising the amino acid sequence of SEQ ID NO:183, and an LCDR3 comprising the amino acid sequence of SEQ ID NO:194 (AB-55); an HCDR1 comprising the amino acid sequence of SEQ ID NO:121, an HCDR2 comprising the amino acid sequence of SEQ ID NO:146, an HCDR3 comprising the amino acid sequence of SEQ ID NO:151, an LCDR 1 comprising the amino acid sequence of SEQ ID NO:173, an LCDR2 comprising the amino acid sequence of SEQ ID NO:180, and an LCDR3 comprising the amino acid sequence of SEQ ID NO:201 (AB-56); an HCDR1 comprising the amino acid sequence of SEQ ID NO:118, an HCDR2 comprising the amino acid sequence of SEQ ID NO:139, an HCDR3 comprising the amino acid sequence of SEQ ID NO:165, an LCDR 1 comprising the amino acid sequence of SEQ ID NO:172, an LCDR2 comprising the amino acid sequence of SEQ ID NO:183, and an LCDR3 comprising the amino acid sequence of SEQ ID NO:194 (AB-57); an HCDR1 comprising the amino acid sequence of SEQ ID NO:121, an HCDR2 comprising the amino acid sequence of SEQ ID NO:139, an HCDR3 comprising the amino acid sequence of SEQ ID NO:169, an LCDR 1 comprising the amino acid sequence of SEQ - 18 - 3820371.v1 5708.1067001 ID NO:173, an LCDR2 comprising the amino acid sequence of SEQ ID NO:183, and an LCDR3 comprising the amino acid sequence of SEQ ID NO:194 (AB-58); an HCDR1 comprising the amino acid sequence of SEQ ID NO:118, an HCDR2 comprising the amino acid sequence of SEQ ID NO:139, an HCDR3 comprising the amino acid sequence of SEQ ID NO:170, an LCDR 1 comprising the amino acid sequence of SEQ ID NO:178, an LCDR2 comprising the amino acid sequence of SEQ ID NO:183, and an LCDR3 comprising the amino acid sequence of SEQ ID NO:194 (AB-59); an HCDR1 comprising the amino acid sequence of SEQ ID NO:118, an HCDR2 comprising the amino acid sequence of SEQ ID NO:147, an HCDR3 comprising the amino acid sequence of SEQ ID NO:170, an LCDR 1 comprising the amino acid sequence of SEQ ID NO:178, an LCDR2 comprising the amino acid sequence of SEQ ID NO:183, and an LCDR3 comprising the amino acid sequence of SEQ ID NO:200 (AB-60); an HCDR1 comprising the amino acid sequence of SEQ ID NO:121, an HCDR2 comprising the amino acid sequence of SEQ ID NO:146, an HCDR3 comprising the amino acid sequence of SEQ ID NO:162, an LCDR 1 comprising the amino acid sequence of SEQ ID NO:176, an LCDR2 comprising the amino acid sequence of SEQ ID NO:183, and an LCDR3 comprising the amino acid sequence of SEQ ID NO:201 (AB-61); an HCDR1 comprising the amino acid sequence of SEQ ID NO:118, an HCDR2 comprising the amino acid sequence of SEQ ID NO:148, an HCDR3 comprising the amino acid sequence of SEQ ID NO:165, an LCDR 1 comprising the amino acid sequence of SEQ ID NO:177, an LCDR2 comprising the amino acid sequence of SEQ ID NO:183, and an LCDR3 comprising the amino acid sequence of SEQ ID NO:200 (AB-62); an HCDR1 comprising the amino acid sequence of SEQ ID NO:125, an HCDR2 comprising the amino acid sequence of SEQ ID NO:149, an HCDR3 comprising the amino acid sequence of SEQ ID NO:171, an LCDR 1 comprising the amino acid sequence of SEQ ID NO:172, an LCDR2 comprising the amino acid sequence of SEQ ID NO:183, and an LCDR3 comprising the amino acid sequence of SEQ ID NO:194 (AB-63); an HCDR1 comprising the amino acid sequence of SEQ ID NO:126, an HCDR2 comprising the amino acid sequence of SEQ ID NO:150, an HCDR3 comprising the amino acid sequence of SEQ ID NO:165, an LCDR 1 comprising the amino acid sequence of SEQ ID NO:177, an LCDR2 comprising the amino acid sequence of SEQ ID NO:183, and an LCDR3 comprising the amino acid sequence of SEQ ID NO:200 (AB-64); - 19 - 3820371.v1 5708.1067001 an HCDR1 comprising the amino acid sequence of SEQ ID NO:118, an HCDR2 comprising the amino acid sequence of SEQ ID NO:139, an HCDR3 comprising the amino acid sequence of SEQ ID NO:227, an LCDR 1 comprising the amino acid sequence of SEQ ID NO:178, an LCDR2 comprising the amino acid sequence of SEQ ID NO:183, and an LCDR3 comprising the amino acid sequence of SEQ ID NO:194 (AB-66); an HCDR1 comprising the amino acid sequence of SEQ ID NO:118, an HCDR2 comprising the amino acid sequence of SEQ ID NO:147, an HCDR3 comprising the amino acid sequence of SEQ ID NO:227, an LCDR 1 comprising the amino acid sequence of SEQ ID NO:229, an LCDR2 comprising the amino acid sequence of SEQ ID NO:183, and an LCDR3 comprising the amino acid sequence of SEQ ID NO:194 (AB-67); an HCDR1 comprising the amino acid sequence of SEQ ID NO:126, an HCDR2 comprising the amino acid sequence of SEQ ID NO:150, an HCDR3 comprising the amino acid sequence of SEQ ID NO:171, an LCDR 1 comprising the amino acid sequence of SEQ ID NO:178, an LCDR2 comprising the amino acid sequence of SEQ ID NO:183, and an LCDR3 comprising the amino acid sequence of SEQ ID NO:200 (AB-68); an HCDR1 comprising the amino acid sequence of SEQ ID NO:118, an HCDR2 comprising the amino acid sequence of SEQ ID NO:139, an HCDR3 comprising the amino acid sequence of SEQ ID NO:170, an LCDR 1 comprising the amino acid sequence of SEQ ID NO:178, an LCDR2 comprising the amino acid sequence of SEQ ID NO:183, and an LCDR3 comprising the amino acid sequence of SEQ ID NO:194 (AB-69); an HCDR1 comprising the amino acid sequence of SEQ ID NO:118, an HCDR2 comprising the amino acid sequence of SEQ ID NO:148, an HCDR3 comprising the amino acid sequence of SEQ ID NO:165, an LCDR 1 comprising the amino acid sequence of SEQ ID NO:177, an LCDR2 comprising the amino acid sequence of SEQ ID NO:183, and an LCDR3 comprising the amino acid sequence of SEQ ID NO:200 (AB-70); an HCDR1 comprising the amino acid sequence of SEQ ID NO:118, an HCDR2 comprising the amino acid sequence of SEQ ID NO:142, an HCDR3 comprising the amino acid sequence of SEQ ID NO:227, an LCDR 1 comprising the amino acid sequence of SEQ ID NO:229, an LCDR2 comprising the amino acid sequence of SEQ ID NO:183, and an LCDR3 comprising the amino acid sequence of SEQ ID NO:194 (AB-71); an HCDR1 comprising the amino acid sequence of SEQ ID NO:118, an HCDR2 comprising the amino acid sequence of SEQ ID NO:147, an HCDR3 comprising the amino acid sequence of SEQ ID NO:170, an LCDR 1 comprising the amino acid sequence of SEQ - 20 - 3820371.v1 5708.1067001 ID NO:178, an LCDR2 comprising the amino acid sequence of SEQ ID NO:183, and an LCDR3 comprising the amino acid sequence of SEQ ID NO:200 (AB-72); an HCDR1 comprising the amino acid sequence of SEQ ID NO:118, an HCDR2 comprising the amino acid sequence of SEQ ID NO:147, an HCDR3 comprising the amino acid sequence of SEQ ID NO:170, an LCDR 1 comprising the amino acid sequence of SEQ ID NO:178, an LCDR2 comprising the amino acid sequence of SEQ ID NO:183, and an LCDR3 comprising the amino acid sequence of SEQ ID NO:200 (AB-73); or an HCDR1 comprising the amino acid sequence of SEQ ID NO:126, an HCDR2 comprising the amino acid sequence of SEQ ID NO:150, an HCDR3 comprising the amino acid sequence of SEQ ID NO:165, an LCDR 1 comprising the amino acid sequence of SEQ ID NO:177, an LCDR2 comprising the amino acid sequence of SEQ ID NO:183, and an LCDR3 comprising the amino acid sequence of SEQ ID NO:200 (AB-76). [0011] The disclosure further provides, among other things, a polypeptide that comprises a VH comprising: a) the amino acid sequence of SEQ ID NO:2, wherein: X 1 is L or F; X 2 is G, A, S, T or P; X3 is V, F or absent; X 4 is S or absent; X 5 is S, G, N or absent; X6 is F, D, I, T, S or V; X 7 is A, S, R, N or K; X 8 is A, H or T; X9 is M or I; X10 is S or G; X 11 is S or G; X12 is S or G; X13 is G, D, A, R, E or T; X 14 is H, D, A, S or N; X 15 is A or I; X16 is H, A, I, Y or V; X 17 is S or D; X 18 is Y, T or H; or - 21 - 3820371.v1 5708.1067001 X19 is A, Y or T, or any combination of the foregoing; or b) the amino acid sequence of SEQ ID NO:18, wherein: X1 is V or E; X2 is L or I; X 3 is V or A; X 4 is G or S; X5 is H, Q or L; X 6 is P or L; X 7 is T or A; X8 is F, G or S; X9 is G, D or S; X 10 is Y, S or A; X11 is T, Y or A; X12 is L or I; X 13 is K, R or E; X 14 is V or M; X15 is V, T or I; X 16 is K, R, T or S; X 17 is C, G, Q or S; X18 is K, G or S; X 19 is G or S; X 20 is C or Y; X21 is V or F; X22 is V or G; X 23 is R or T; X24 is R, T or A; X25 is K, R or N; X 26 is D or N; X 27 is C or Y; X28 is H, Q or E; X 29 is P or L; X 30 is V, E or A; - 22 - 3820371.v1 5708.1067001 X31 is S or E; X32 is Y or T; X 33 is N, S, Q, T or absent; X34 is S or absent; X35 is S or absent; X 36 is D, S or absent; X 37 is V, T, I or absent; X38 is Y or absent; X 39 is Y, T or N; X 40 is D or A; X41 is Y, S or A; X42 is K or Q; X 43 is V or I; X44 is V or I; or X45 is S or absent, or any combination of the foregoing. [0012] In some embodiments, a polypeptide comprises: a) a VL comprising the amino acid sequence of SEQ ID NO:59, wherein: X 20 is H, Q, A, S, Y, R or K; or X 21 is A, S, T or G, or any combination of the foregoing; or b) a V L comprising the amino acid sequence of SEQ ID NO:70, wherein: X 46 is V, I or F; X47 is V, K, T, M, R or L; X48 is P or T; X 49 is P or Q; X50 is P, F or S; X51 is P or S; X 52 is V or L; X 53 is H or Q; X54 is D, G or Y; X 55 is D, T or N; X 56 is C, Y or A; - 23 - 3820371.v1 5708.1067001 X57 is K or E; X58 is M, T, I or S; X 59 is Y or S; X60 is R, G, S or D; X61 is R or S; X 62 is Y, I or F; X 63 is Y or S; X64 is V, R or T; X 65 is T or S; X 66 is T or I; X67 is H or Q; X68 is H, F or Y; X 69 is C or Y; X70 is T or S; X71 is Y, T or W; X 72 is P or A; or X 73 is L or Y, or any combination of the foregoing. [0013] In some embodiments, a polypeptide disclosed herein modulates (e.g., increases, enhances, promotes) binding between PD-1 and one or more of its ligands, such as PD-L1 and PD-L2. In some embodiments, a polypeptide disclosed herein modulates (e.g., increases, enhances, promotes) PD-1-mediated signaling in vitro, ex vivo, and/or in vivo. [0014] In some embodiments, a polypeptide is a fusion protein. [0015] In some embodiments, the disclosure provides a polynucleotide encoding a polypeptide disclosed herein, a vector comprising such polynucleotide, and/or a host cell comprising such polynucleotide and/or vector. [0016] In some embodiments, the disclosure provides methods of treating a patient and/or subject in need thereof (e.g., a subject having a disease or condition, such as an inflammatory disease or condition), comprising administering to the subject an effective amount (e.g., a therapeutically effective amount) of one or more of any of the polypeptides disclosed herein and/or a composition (e.g., pharmaceutical composition) comprising one or more of any of the polypeptides disclosed herein. - 24 - 3820371.v1 5708.1067001 [0017] In some embodiments, the disclosure provides a method of modulating (e.g., increasing, enhancing, promoting) PD-1-mediated signaling in a cell (e.g., a cell in a subject), comprising contacting the cell with a composition comprising a polypeptide disclosed herein or a composition (e.g., pharmaceutical composition) comprising a polypeptide disclosed herein. BRIEF DESCRIPTION OF THE DRAWINGS [0018] The foregoing will be apparent from the following more particular description of example embodiments, as illustrated in the accompanying drawings in which like reference characters refer to the same parts throughout the different views. The drawings are not necessarily to scale, emphasis instead being placed upon illustrating embodiments. [0019] FIG.1 depicts the amino acid sequence of human programmed cell death-1 (PD- 1) (SEQ ID NO:1). Epitope residues predicted to be bound by one or more antibodies disclosed herein are indicated by asterisks. [0020] FIGs.2A and 2B depict an alignment of non-limiting examples of heavy chain variable domain (VH) amino acid sequences that are useful in polypeptides as disclosed herein. The heavy chain complementarity determining region (HCDR) amino acid sequences as determined by ImMunoGeneTics (IMGT) numbering (www.imgt.org/IMGTScientificChart/Nomenclature/IMGT-FRCDRdef
inition.html, also accessible at www.imgt.org/) are indicated using bold letters within boxed portions of the sequences. Green highlighting indicates non-limiting examples of variable residues (designated throughout this disclosure by “Xn”) in the depicted sequences. Also see a first VH consensus sequence (SEQ ID NO:2) in Table 4. “*” indicates predicted paratope residues. Paratope positions are defined as antibody residues that, when the antibody is bound to human PD-1, are within 5 angstroms of the PD-1 antigen. [0021] FIGs.3A-3D depict an alignment of non-limiting examples of VH amino acid sequences that are useful in polypeptides as disclosed herein. The HCDR amino acid sequences as determined by IMGT numbering are indicated using bold letters within boxed portions of the sequences. Green highlighting indicates non-limiting examples of variable residues (designated throughout this disclosure by “Xn”) in the depicted sequences. Also see a second V H consensus sequence (SEQ ID NO:18) in Table 4. “*” indicates predicted paratope residues. Paratope positions are defined as antibody residues that, when the antibody is bound to human PD-1, are within 5 angstroms of the PD-1 antigen. - 25 - 3820371.v1 5708.1067001 [0022] FIGs.4A and 4B depict an alignment of non-limiting examples of light chain variable domain (VL) amino acid sequences that are useful in polypeptides as disclosed herein. The light chain complementarity determining region (LCDR) amino acid sequences as determined by IMGT numbering are indicated using bold letters within boxed portions of the sequences. Green highlighting indicates non-limiting examples of variable residues (designated throughout this disclosure by “Xn”) in the depicted sequences. Also see a first V L consensus sequence (SEQ ID NO:59) in Table 5. “*” indicates predicted paratope residues. Paratope positions are defined as antibody residues that, when the antibody is bound to human PD-1, are within 5 angstroms of the PD-1 antigen. [0023] FIGs.5A-5D depict an alignment of non-limiting examples of V L amino acid sequences that are useful in polypeptides as disclosed herein. The LCDR amino acid sequences as determined by IMGT numbering are indicated using bold letters within boxed portions of the sequences. Green highlighting indicates non-limiting examples of variable residues (designated throughout this disclosure by “Xn”) in the depicted sequences. Also see a second VL consensus sequence (SEQ ID NO:70) in Table 5. “*” indicates predicted paratope residues. Paratope positions are defined as antibody residues that, when the antibody is bound to human PD-1, are within 5 angstroms of the PD-1 antigen. [0024] FIGs.6A-6D depict structural validation of an example de-novo generated PD-1- agonizing antibody disclosed herein (AB-49). FIG.6A shows the structure of PD-1 (light gray surface) with the desired epitope region shown in dark gray. FIG.6B shows a computationally-generated model of AB-49 bound to the desired epitope on PD-1. FIG.6C shows a crystal structure of the Fab fragment of AB-49 in FIG.6B alone, solved at 2.46 Å resolution. FIG.6D shows superpositions of the Fab-alone crystal structure and the corresponding computational model. DETAILED DESCRIPTION [0025] A description of example embodiments follows. [0026] Several aspects of the disclosure are described below, with reference to examples for illustrative purposes only. It should be understood that numerous specific details, relationships, and methods are set forth to provide a full understanding of the disclosure. One having ordinary skill in the relevant art, however, will readily recognize that the disclosure can be practiced without one or more of the specific details or practiced with other methods, protocols, reagents, cell lines and animals. The disclosure is not limited by the illustrated - 26 - 3820371.v1 5708.1067001 ordering of acts or events, as some acts may occur in different orders and/or concurrently with other acts or events. Furthermore, not all illustrated acts, steps or events are required to implement a methodology in accordance with the disclosure. Polypeptides that Specifically Bind Programmed Cell Death-1 (PD-1) [0027] Provided herein, among other things, are polypeptides that specifically bind to PD-1 (e.g., full-length human PD-1, e.g., SEQ ID NO: 1). In some embodiments, a polypeptide modulates (e.g., increases, enhances, promotes) binding between PD-1 and one or more of its ligands, PD-L1 and PD-L2 and/or modulates (e.g., increases, enhances, promotes) PD-1-mediated signaling. [0028] The term “polypeptide” “peptide” or “protein” denotes a polymer of at least two amino acids covalently linked by an amide bond, regardless of length or post-translational modification (e.g., glycosylation or phosphorylation). A protein, peptide or polypeptide can comprise any suitable L-and/or D-amino acid, for example, common α-amino acids (e.g., alanine, glycine, valine), non-α-amino acids (e.g., β-alanine, 4-aminobutyric acid, 6- aminocaproic acid, sarcosine, statine), and unusual amino acids (e.g., citrulline, homocitruline, homoserine, norleucine, norvaline, ornithine). The amino, carboxyl and/or other functional groups on a peptide can be free (e.g., unmodified) or protected with a suitable protecting group. Suitable protecting groups for amino and carboxyl groups, and methods for adding or removing protecting groups are known in the art and are disclosed in, for example, Green and Wuts, “Protecting Groups in Organic Synthesis,” John Wiley and Sons, 1991. The functional groups of a protein, peptide or polypeptide can also be derivatized (e.g., alkylated) or labeled (e.g., with a detectable label, such as a fluorogen or a hapten) using methods known in the art. A protein, peptide or polypeptide can comprise one or more modifications (e.g., amino acid linkers, acylation, acetylation, amidation, methylation, terminal modifiers (e.g., cyclizing modifications), N-methyl-α-amino group substitution), if desired. In addition, a protein, peptide or polypeptide can be an analog of a known and/or naturally-occurring peptide, for example, a peptide analog having conservative amino acid residue substitution(s). [0029] A non-limiting example of human PD-1 sequences is GenBank: AIC54874.1 (SEQ ID NO:1). [0030] MQIPQAPWPVVWAVLQLGWRPGWFLDSPDRPWNPPTFSPALLVVTEGD NATFTCSFSNTSESFVLNWYRMSPSNQTDKLAAFPEDRSQPGQDCRFRVTQLPNGRD - 27 - 3820371.v1 5708.1067001 FHMSVVRARRNDSGTYLCGAISLAPKAQIKESLRAELRVTERRAEVPTAHPSPSPRPA GQFQTLVVGVVGGLLGSLVLLVWVLAVICSRAARGTIGARRTGQPLKEDPSAVPVFS VDYGELDFQWREKTPEPPVPCVPEQTEYATIVFPSGMGTSSPARRGSADGPRSAQPL RPEDGHCSWPL (SEQ ID NO:1) [0031] A non-limiting example of cyno monkey PD-1 sequences is GenBank: ABR15750.1 (SEQ ID NO:205). [0032] MQIPQAPWPVVWAVLQLGWRPGWFLESPDRPWNPPTFSPALLLVTEGDN ATFTCSFSNASESFVLNWYRMSPSNQTDKLAAFPEDRSQPGRDCRFRVTQLPNGRDF HMSVVRARRNDSGTYLCGAISLAPKAQIKESLRAELRVTERRAEVPTAHPSPSPRPAG QFQALVVGVVGGLLGSLVLLVWVLAVICSRAAQGTIEARRTGQPLKEDPSAVPVFSV DYGELDFQWREKTPEPPAPCVPEQTEYATIVFPSGLGTSSPARRGSADGPRSPRPLRP EDGHCSWPL (SEQ ID NO:205) [0033] As used herein, PD-1 includes full-length PD-1 proteins (e.g., having the amino acid sequence of SEQ ID NO:1 (GenBank: AIC54874.1) or homologs thereof) and truncated forms thereof, mutant and engineered versions of full-length and truncated PD-1 proteins, and modified forms (e.g., post-translationally modified forms) of full-length and truncated PD-1 proteins. [0034] In some embodiments, a polypeptide disclosed herein binds to a PD-1 protein comprising the amino acid sequence of SEQ ID NO:1. In some embodiments, a polypeptide binds to a PD-1 protein comprising the amino acid sequence of SEQ ID NO:1 and a PD-1 protein comprising the amino acid sequence of SEQ ID NO:205. [0035] In some embodiments, a polypeptide disclosed herein binds to one or more epitope residues of a PD-1 protein (e.g., one or more epitope residues in SEQ ID NO:1). In some embodiments, a polypeptide is capable of binding to one or more epitope residues in the full-length human PD-1, for example, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15 or 16 residues of the full-length human PD-1. In some embodiments, a polypeptide is capable of binding to one or more epitope residues (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15 or all 16 residues) selected from D48, N49, T51, T53, P83, E84, R96, V97, T98, L100, P101, N102, D105, H107, S109 and V111 of SEQ ID NO:1. [0036] In some embodiments, a polypeptide binds to a mutant, engineered or modified form of PD-1. In some embodiments, the mutant, engineered or modified form of PD-1 comprises an amino acid sequence that has at least about 90% sequence identity to a wildtype full-length PD-1 sequence (e.g., SEQ ID NO:1), for example, having at least about: 91%, - 28 - 3820371.v1 5708.1067001 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 99.1%, 99.2%, 99.3%, 99.4%, 99.5%, 99.6%, 99.7%, 99.8%, or 99.9% sequence identity to a wildtype full-length PD-1 sequence. In some embodiments, the sequence identity is about: 90-99.9%, 90-99.8%, 92-99.8%, 92-99.6%, 94- 99.6%, 94-99.5%, 95-99.5%, 95-99.4%, 96-99.4%, 96-99.2%, 97-99.2% or 97-99%. [0037] As used herein, the term “sequence identity,” refers to the extent to which two nucleotide sequences, or two amino acid sequences, have the same residues at the same positions when the sequences are aligned to achieve a maximal level of identity, expressed as a percentage. For sequence alignment and comparison, typically one sequence is designated as a reference sequence, to which a test sequence is compared. The sequence identity is expressed as the percentage of positions across the entire length of the reference sequence where the reference and test sequences share the same nucleotide or amino acid upon alignment of the reference and test sequences to achieve a maximal level of identity. As an example, two sequences are considered to have 70% sequence identity when, upon alignment to achieve a maximal level of identity, the test sequence has the same nucleotide or amino acid residue at 70% of the same positions over the entire length of the reference sequence. [0038] Alignment of sequences for comparison to achieve maximal levels of identity can be readily performed by a person of ordinary skill in the art using an appropriate alignment method or algorithm. In some instances, the alignment can include introduced gaps to provide for the maximal level of identity. Examples include the local homology algorithm of Smith & Waterman, Adv. Appl. Math.2:482 (1981), the homology alignment algorithm of Needleman & Wunsch, J. Mol. Biol.48:443 (1970), the search for similarity method of Pearson & Lipman, Proc. Nat'l. Acad. Sci. USA 85:2444 (1988), computerized implementations of these algorithms (GAP, BESTFIT, FASTA, and TFASTA in the Wisconsin Genetics Software Package, Genetics Computer Group, 575 Science Dr., Madison, Wis.), and visual inspection (see generally Ausubel et al., Current Protocols in Molecular Biology). [0039] When using a sequence comparison algorithm, test and reference sequences are input into a computer, subsequent coordinates are designated, if necessary, and sequence algorithm program parameters are designated. The sequence comparison algorithm then calculates the percent sequence identity for the test sequence(s) relative to the reference sequence, based on the designated program parameters. A commonly used tool for determining percent sequence identity is Protein Basic Local Alignment Search Tool (BLASTP) available through National Center for Biotechnology Information, National - 29 - 3820371.v1 5708.1067001 Library of Medicine, of the United States National Institutes of Health. (Altschul et al., 1990). [0040] In some embodiments, the disclosure provides a polypeptide that specifically binds PD-1. In some embodiments, a polypeptide comprises a paratope that is substantially similar to a paratope of an antibody comprising a VH/VL pair selected from: SEQ ID NO:206 and SEQ ID NO:217 (AB-65); SEQ ID NO:215 and SEQ ID NO:104 (AB-75); SEQ ID NO:214 and SEQ ID NO:226 (AB-74); SEQ ID NO:3 and SEQ ID NO:60 (AB-1); SEQ ID NO:4 and SEQ ID NO:61 (AB-2); SEQ ID NO:5 and SEQ ID NO:62 (AB-3); SEQ ID NO:3 and SEQ ID NO:63 (AB-4); SEQ ID NO:6 and SEQ ID NO:64 (AB-5); SEQ ID NO:7 and SEQ ID NO:65 (AB-6); SEQ ID NO:8 and SEQ ID NO:66 (AB-7); SEQ ID NO:9 and SEQ ID NO:60 (AB-8); SEQ ID NO:10 and SEQ ID NO:67 (AB-9); SEQ ID NO:11 and SEQ ID NO:64 (AB-10); SEQ ID NO:3 and SEQ ID NO:68 (AB-11); SEQ ID NO:12 and SEQ ID NO:60 (AB-12); SEQ ID NO:13 and SEQ ID NO:68 (AB-13); SEQ ID NO:14 and SEQ ID NO:69 (AB-14); SEQ ID NO:15 and SEQ ID NO:64 (AB-15); SEQ ID NO:16 and SEQ ID NO:60 (AB-16); SEQ ID NO:17 and SEQ ID NO:65 (AB-17); SEQ ID NO:19 and SEQ ID NO:71 (AB-18); SEQ ID NO:20 and SEQ ID NO:72 (AB-19); SEQ ID NO:21 and SEQ ID NO:71 (AB-20); SEQ ID NO:22 and SEQ ID NO:73 (AB-21); SEQ ID NO:23 and SEQ ID NO:71 (AB-22); SEQ ID NO:24 and SEQ ID NO:74 (AB-23); SEQ ID NO:21 and SEQ ID NO:75 (AB-24); SEQ ID NO:21 and SEQ ID NO:76 (AB-25); - 30 - 3820371.v1 5708.1067001 SEQ ID NO:21 and SEQ ID NO:71 (AB-26); SEQ ID NO:25 and SEQ ID NO:71 (AB-27); SEQ ID NO:26 and SEQ ID NO:71 (AB-28); SEQ ID NO:27 and SEQ ID NO:77 (AB-29); SEQ ID NO:28 and SEQ ID NO:78 (AB-30); SEQ ID NO:29 and SEQ ID NO:79 (AB-31); SEQ ID NO:30 and SEQ ID NO:80 (AB-32); SEQ ID NO:31 and SEQ ID NO:81 (AB-33); SEQ ID NO:28 and SEQ ID NO:82 (AB-34); SEQ ID NO:23 and SEQ ID NO:80 (AB-35); SEQ ID NO:32 and SEQ ID NO:80 (AB-36); SEQ ID NO:33 and SEQ ID NO:83 (AB-37); SEQ ID NO:34 and SEQ ID NO:84 (AB-38); SEQ ID NO:35 and SEQ ID NO:85 (AB-39); SEQ ID NO:23 and SEQ ID NO:86 (AB-40); SEQ ID NO:36 and SEQ ID NO:87 (AB-41); SEQ ID NO:37 and SEQ ID NO:88 (AB-42); SEQ ID NO:38 and SEQ ID NO:89 (AB-43); SEQ ID NO:39 and SEQ ID NO:80 (AB-44); SEQ ID NO:40 and SEQ ID NO:90 (AB-45); SEQ ID NO:41 and SEQ ID NO:91 (AB-46); SEQ ID NO:42 and SEQ ID NO:92 (AB-47); SEQ ID NO:43 and SEQ ID NO:93 (AB-48); SEQ ID NO:44 and SEQ ID NO:94 (AB-49); SEQ ID NO:45 and SEQ ID NO:80 (AB-50); SEQ ID NO:46 and SEQ ID NO:95 (AB-51); SEQ ID NO:47 and SEQ ID NO:96 (AB-52); SEQ ID NO:48 and SEQ ID NO:97 (AB-53); SEQ ID NO:49 and SEQ ID NO:98 (AB-54); SEQ ID NO:50 and SEQ ID NO:84 (AB-55); SEQ ID NO:51 and SEQ ID NO:99 (AB-56); SEQ ID NO:35 and SEQ ID NO:83 (AB-57); SEQ ID NO:52 and SEQ ID NO:100 (AB-58); - 31 - 3820371.v1 5708.1067001 SEQ ID NO:53 and SEQ ID NO:101 (AB-59); SEQ ID NO:54 and SEQ ID NO:102 (AB-60); SEQ ID NO:55 and SEQ ID NO:103 (AB-61); SEQ ID NO:56 and SEQ ID NO:104 (AB-62); SEQ ID NO:57 and SEQ ID NO:105 (AB-63); SEQ ID NO:58 and SEQ ID NO:106 (AB-64); SEQ ID NO:207 and SEQ ID NO:218 (AB-66); SEQ ID NO:208 and SEQ ID NO:219 (AB-67); SEQ ID NO:209 and SEQ ID NO:220 (AB-68); SEQ ID NO:53 and SEQ ID NO:221 (AB-69); SEQ ID NO:210 and SEQ ID NO:222 (AB-70); SEQ ID NO:211 and SEQ ID NO:223 (AB-71); SEQ ID NO:212 and SEQ ID NO:224 (AB-72); SEQ ID NO:213 and SEQ ID NO:225 (AB-73); or SEQ ID NO:216 and SEQ ID NO:106 (AB-76), or any combination of the foregoing. [0041] In some embodiments, a polypeptide comprises a paratope that is substantially similar to a paratope of an antibody comprising a VH/VL pair selected from: SEQ ID NO:206 and SEQ ID NO:217 (AB-65); SEQ ID NO:215 and SEQ ID NO:104 (AB-75); or SEQ ID NO:214 and SEQ ID NO:226 (AB-74), or any combination of the foregoing. [0042] In some embodiments, a polypeptide comprises a paratope that is substantially similar to a paratope of an antibody, wherein the antibody comprises a VH comprising the amino acid sequence of SEQ ID NO:206 and a VL comprising the amino acid sequence of SEQ ID NO:217 (AB-65). [0043] In some embodiments, a polypeptide comprises a paratope that is substantially similar to a paratope of an antibody, wherein the antibody comprises a VH comprising the amino acid sequence of SEQ ID NO:215, and a V L comprising the amino acid sequence of SEQ ID NO:104 (AB-75). [0044] In some embodiments, a polypeptide comprises a paratope that is substantially similar to a paratope of an antibody, wherein the antibody comprises a V H comprising the - 32 - 3820371.v1 5708.1067001 amino acid sequence of SEQ ID NO:214, and a VL comprising the amino acid sequence of SEQ ID NO:226 (AB-74). [0045] In some embodiments, the disclosure provides a polypeptide that specifically binds PD-1. In some embodiments, a polypeptide comprises a paratope that is identical to a paratope of an antibody comprising a VH/VL pair selected from: SEQ ID NO:206 and SEQ ID NO:217 (AB-65); SEQ ID NO:215 and SEQ ID NO:104 (AB-75); SEQ ID NO:214 and SEQ ID NO:226 (AB-74); SEQ ID NO:3 and SEQ ID NO:60 (AB-1); SEQ ID NO:4 and SEQ ID NO:61 (AB-2); SEQ ID NO:5 and SEQ ID NO:62 (AB-3); SEQ ID NO:3 and SEQ ID NO:63 (AB-4); SEQ ID NO:6 and SEQ ID NO:64 (AB-5); SEQ ID NO:7 and SEQ ID NO:65 (AB-6); SEQ ID NO:8 and SEQ ID NO:66 (AB-7); SEQ ID NO:9 and SEQ ID NO:60 (AB-8); SEQ ID NO:10 and SEQ ID NO:67 (AB-9); SEQ ID NO:11 and SEQ ID NO:64 (AB-10); SEQ ID NO:3 and SEQ ID NO:68 (AB-11); SEQ ID NO:12 and SEQ ID NO:60 (AB-12); SEQ ID NO:13 and SEQ ID NO:68 (AB-13); SEQ ID NO:14 and SEQ ID NO:69 (AB-14); SEQ ID NO:15 and SEQ ID NO:64 (AB-15); SEQ ID NO:16 and SEQ ID NO:60 (AB-16); SEQ ID NO:17 and SEQ ID NO:65 (AB-17); SEQ ID NO:19 and SEQ ID NO:71 (AB-18); SEQ ID NO:20 and SEQ ID NO:72 (AB-19); SEQ ID NO:21 and SEQ ID NO:71 (AB-20); SEQ ID NO:22 and SEQ ID NO:73 (AB-21); SEQ ID NO:23 and SEQ ID NO:71 (AB-22); SEQ ID NO:24 and SEQ ID NO:74 (AB-23); SEQ ID NO:21 and SEQ ID NO:75 (AB-24); SEQ ID NO:21 and SEQ ID NO:76 (AB-25); - 33 - 3820371.v1 5708.1067001 SEQ ID NO:21 and SEQ ID NO:71 (AB-26); SEQ ID NO:25 and SEQ ID NO:71 (AB-27); SEQ ID NO:26 and SEQ ID NO:71 (AB-28); SEQ ID NO:27 and SEQ ID NO:77 (AB-29); SEQ ID NO:28 and SEQ ID NO:78 (AB-30); SEQ ID NO:29 and SEQ ID NO:79 (AB-31); SEQ ID NO:30 and SEQ ID NO:80 (AB-32); SEQ ID NO:31 and SEQ ID NO:81 (AB-33); SEQ ID NO:28 and SEQ ID NO:82 (AB-34); SEQ ID NO:23 and SEQ ID NO:80 (AB-35); SEQ ID NO:32 and SEQ ID NO:80 (AB-36); SEQ ID NO:33 and SEQ ID NO:83 (AB-37); SEQ ID NO:34 and SEQ ID NO:84 (AB-38); SEQ ID NO:35 and SEQ ID NO:85 (AB-39); SEQ ID NO:23 and SEQ ID NO:86 (AB-40); SEQ ID NO:36 and SEQ ID NO:87 (AB-41); SEQ ID NO:37 and SEQ ID NO:88 (AB-42); SEQ ID NO:38 and SEQ ID NO:89 (AB-43); SEQ ID NO:39 and SEQ ID NO:80 (AB-44); SEQ ID NO:40 and SEQ ID NO:90 (AB-45); SEQ ID NO:41 and SEQ ID NO:91 (AB-46); SEQ ID NO:42 and SEQ ID NO:92 (AB-47); SEQ ID NO:43 and SEQ ID NO:93 (AB-48); SEQ ID NO:44 and SEQ ID NO:94 (AB-49); SEQ ID NO:45 and SEQ ID NO:80 (AB-50); SEQ ID NO:46 and SEQ ID NO:95 (AB-51); SEQ ID NO:47 and SEQ ID NO:96 (AB-52); SEQ ID NO:48 and SEQ ID NO:97 (AB-53); SEQ ID NO:49 and SEQ ID NO:98 (AB-54); SEQ ID NO:50 and SEQ ID NO:84 (AB-55); SEQ ID NO:51 and SEQ ID NO:99 (AB-56); SEQ ID NO:35 and SEQ ID NO:83 (AB-57); SEQ ID NO:52 and SEQ ID NO:100 (AB-58); - 34 - 3820371.v1 5708.1067001 SEQ ID NO:53 and SEQ ID NO:101 (AB-59); SEQ ID NO:54 and SEQ ID NO:102 (AB-60); SEQ ID NO:55 and SEQ ID NO:103 (AB-61); SEQ ID NO:56 and SEQ ID NO:104 (AB-62); SEQ ID NO:57 and SEQ ID NO:105 (AB-63); SEQ ID NO:58 and SEQ ID NO:106 (AB-64); SEQ ID NO:207 and SEQ ID NO:218 (AB-66); SEQ ID NO:208 and SEQ ID NO:219 (AB-67); SEQ ID NO:209 and SEQ ID NO:220 (AB-68); SEQ ID NO:53 and SEQ ID NO:221 (AB-69); SEQ ID NO:210 and SEQ ID NO:222 (AB-70); SEQ ID NO:211 and SEQ ID NO:223 (AB-71); SEQ ID NO:212 and SEQ ID NO:224 (AB-72); SEQ ID NO:213 and SEQ ID NO:225 (AB-73); or SEQ ID NO:216 and SEQ ID NO:106 (AB-76), or any combination of the foregoing. [0046] In some embodiments, a polypeptide comprises a paratope that is identical to a paratope of an antibody comprising a VH/VL pair selected from: SEQ ID NO:206 and SEQ ID NO:217 (AB-65); SEQ ID NO:215 and SEQ ID NO:104 (AB-75); or SEQ ID NO:214 and SEQ ID NO:226 (AB-74), or any combination of the foregoing. [0047] In some embodiments, a polypeptide comprises a paratope that is identical to a paratope of an antibody comprising a VH comprising the amino acid sequence of SEQ ID NO:206 and a VL comprising the amino acid sequence of SEQ ID NO:217 (AB-65). [0048] In some embodiments, a polypeptide comprises a paratope that is identical to a paratope of an antibody comprising a VH comprising the amino acid sequence of SEQ ID NO:215, and a VL comprising the amino acid sequence of SEQ ID NO:104 (AB-75). [0049] In some embodiments, a polypeptide comprises a paratope that is identical to a paratope of an antibody comprising a V H comprising the amino acid sequence of SEQ ID NO:214, and a VL comprising the amino acid sequence of SEQ ID NO:226 (AB-74). [0050] See Table 4 for SEQ ID NOs:3-17, SEQ ID NOs:19-58, and SEQ ID NOs:206- 216; Table 5 for SEQ ID NOs:60-69, SEQ ID NOs:71-106, and SEQ ID NOs:217-226. FIGs. - 35 - 3820371.v1 5708.1067001 2A-2B for paratope residues of antibodies comprising SEQ ID Nos:3-17, FIGs.3A-3D for paratope residues of antibodies comprising SEQ ID Nos:19-58, FIGs.4A-4B for paratope residues of antibodies comprising SEQ ID Nos:60-69, and FIGs.5A-5D for paratope residues of antibodies comprising SEQ ID NOs:71-106. [0051] Amino acid residues of a paratope contribute to an antibody’s interaction with an epitope of its target protein. An interaction can be a hydrogen bond, a salt bridge, a van der Waals interaction, an electrostatic interaction, a hydrophobic interaction, pi-interaction effects, an ionic bond, and/or any combination thereof. An interaction can be direct, or indirect, e.g., via a coordinated intermediate molecule, such as an ion or water. The residues of a paratope, in some embodiments, comprise only residues that are part of a defined CDR. In some embodiments, the residues of a paratope further comprise one or more residues that are not part of a defined CDR (e.g., residues within a defined framework region). [0052] In some embodiments, a paratope is oriented less than about 5.0 angstroms from an epitope on a target antigen when the polypeptide is bound to the target antigen, e.g., less than about: 4.5, 4.0, 3.5, 3.0, 2.5, 2.4, 2.3, 2.2, 2.1, 2.0, 1.9, 1.8, 1.7, 1.6, 1.5, 1.4, 1.3, 1.2, 1.1, 1.0 or 0.9 angstroms, or about: 0.9-5.0, 0.9-4.8.1.0-5, 1.0-4.5, 1.0-4.0, 1.0-3.5, 1.1-3.5, 1.1-3.0, 1.2-3.0, 1.2-2.5, 1.3-2.5, 1.3-2.4, 1.4-2.4, 1.4-2.3, 1.5-2.3, 1.5-2.2, 1.6-2.2, 1.6-2.1, 1.7-2.1, 1.7-2.0 or 1.8-2.0 angstroms, from the epitope. In some embodiments, all of the amino acid residues constituting the paratope are oriented less than about 5.0 angstroms from an epitope on a target antigen when the polypeptide is bound to the target antigen. In some embodiments, less than all of the amino acid residues constituting the paratope (e.g., about 40%, about 50%, about 60%, about 70%, about 80%, about 90%, about 95%, about 96%, about 97%, about 98%, or about 99% of the amino acid residues)) in the paratope are oriented less than about 5.0 angstroms from an epitope on a target antigen when the polypeptide is bound to the target antigen. [0053] As used herein, the term “substantially similar to” refers to a polypeptide disclosed herein that is substantially similar in amino acid sequence (e.g., has at least about 80%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, or at least about 99% of the amino acid residues amino acid sequence identity) and substantially preserves one or more functional properties of a specified polypeptide disclosed herein. In some embodiments, the one or more functional properties are selected from, without limitation, a substantially similar binding affinity, a substantially similar - 36 - 3820371.v1 5708.1067001 binding specificity, a substantially similar inhibitory activity, a substantially similar neutralization activity, and a substantially similar self-association property. [0054] In some embodiments, a polypeptide comprises a paratope that is substantially similar to a paratope of a polypeptide selected from any one of AB-1 to AB-76. In some embodiments, a polypeptide comprises a paratope comprising only conservative substitutions (e.g., only highly conservative substitutions) relative to a paratope of a polypeptide selected from any one of AB-1 to AB-76. In some embodiments, a polypeptide comprises a paratope comprising up to 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14 or 15 conservative substitutions (e.g., up to 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14 or 15 highly conservative substitutions) relative to a paratope of a polypeptide selected from any one of AB-1 to AB-76. In some embodiments, a polypeptide comprises a paratope having 100% sequence identity to a paratope of a polypeptide selected from any one of AB-1 to AB-76. [0055] In some embodiments, a polypeptide comprises a paratope that is substantially similar to the paratope of an antibody comprising a VH/VL pair selected from: SEQ ID NO:206 and SEQ ID NO:217 (AB-65); SEQ ID NO:215 and SEQ ID NO:104 (AB-75); SEQ ID NO:214 and SEQ ID NO:226 (AB-74); SEQ ID NO:3 and SEQ ID NO:60 (AB-1); SEQ ID NO:4 and SEQ ID NO:61 (AB-2); SEQ ID NO:5 and SEQ ID NO:62 (AB-3); SEQ ID NO:3 and SEQ ID NO:63 (AB-4); SEQ ID NO:6 and SEQ ID NO:64 (AB-5); SEQ ID NO:7 and SEQ ID NO:65 (AB-6); SEQ ID NO:8 and SEQ ID NO:66 (AB-7); SEQ ID NO:9 and SEQ ID NO:60 (AB-8); SEQ ID NO:10 and SEQ ID NO:67 (AB-9); SEQ ID NO:11 and SEQ ID NO:64 (AB-10); SEQ ID NO:3 and SEQ ID NO:68 (AB-11); SEQ ID NO:12 and SEQ ID NO:60 (AB-12); SEQ ID NO:13 and SEQ ID NO:68 (AB-13); SEQ ID NO:14 and SEQ ID NO:69 (AB-14); SEQ ID NO:15 and SEQ ID NO:64 (AB-15); SEQ ID NO:16 and SEQ ID NO:60 (AB-16); - 37 - 3820371.v1 5708.1067001 SEQ ID NO:17 and SEQ ID NO:65 (AB-17); SEQ ID NO:19 and SEQ ID NO:71 (AB-18); SEQ ID NO:20 and SEQ ID NO:72 (AB-19); SEQ ID NO:21 and SEQ ID NO:71 (AB-20); SEQ ID NO:22 and SEQ ID NO:73 (AB-21); SEQ ID NO:23 and SEQ ID NO:71 (AB-22); SEQ ID NO:24 and SEQ ID NO:74 (AB-23); SEQ ID NO:21 and SEQ ID NO:75 (AB-24); SEQ ID NO:21 and SEQ ID NO:76 (AB-25); SEQ ID NO:21 and SEQ ID NO:71 (AB-26); SEQ ID NO:25 and SEQ ID NO:71 (AB-27); SEQ ID NO:26 and SEQ ID NO:71 (AB-28); SEQ ID NO:27 and SEQ ID NO:77 (AB-29); SEQ ID NO:28 and SEQ ID NO:78 (AB-30); SEQ ID NO:29 and SEQ ID NO:79 (AB-31); SEQ ID NO:30 and SEQ ID NO:80 (AB-32); SEQ ID NO:31 and SEQ ID NO:81 (AB-33); SEQ ID NO:28 and SEQ ID NO:82 (AB-34); SEQ ID NO:23 and SEQ ID NO:80 (AB-35); SEQ ID NO:32 and SEQ ID NO:80 (AB-36); SEQ ID NO:33 and SEQ ID NO:83 (AB-37); SEQ ID NO:34 and SEQ ID NO:84 (AB-38); SEQ ID NO:35 and SEQ ID NO:85 (AB-39); SEQ ID NO:23 and SEQ ID NO:86 (AB-40); SEQ ID NO:36 and SEQ ID NO:87 (AB-41); SEQ ID NO:37 and SEQ ID NO:88 (AB-42); SEQ ID NO:38 and SEQ ID NO:89 (AB-43); SEQ ID NO:39 and SEQ ID NO:80 (AB-44); SEQ ID NO:40 and SEQ ID NO:90 (AB-45); SEQ ID NO:41 and SEQ ID NO:91 (AB-46); SEQ ID NO:42 and SEQ ID NO:92 (AB-47); SEQ ID NO:43 and SEQ ID NO:93 (AB-48); SEQ ID NO:44 and SEQ ID NO:94 (AB-49); - 38 - 3820371.v1 5708.1067001 SEQ ID NO:45 and SEQ ID NO:80 (AB-50); SEQ ID NO:46 and SEQ ID NO:95 (AB-51); SEQ ID NO:47 and SEQ ID NO:96 (AB-52); SEQ ID NO:48 and SEQ ID NO:97 (AB-53); SEQ ID NO:49 and SEQ ID NO:98 (AB-54); SEQ ID NO:50 and SEQ ID NO:84 (AB-55); SEQ ID NO:51 and SEQ ID NO:99 (AB-56); SEQ ID NO:35 and SEQ ID NO:83 (AB-57); SEQ ID NO:52 and SEQ ID NO:100 (AB-58); SEQ ID NO:53 and SEQ ID NO:101 (AB-59); SEQ ID NO:54 and SEQ ID NO:102 (AB-60); SEQ ID NO:55 and SEQ ID NO:103 (AB-61); SEQ ID NO:56 and SEQ ID NO:104 (AB-62); SEQ ID NO:57 and SEQ ID NO:105 (AB-63); SEQ ID NO:58 and SEQ ID NO:106 (AB-64); SEQ ID NO:207 and SEQ ID NO:218 (AB-66); SEQ ID NO:208 and SEQ ID NO:219 (AB-67); SEQ ID NO:209 and SEQ ID NO:220 (AB-68); SEQ ID NO:53 and SEQ ID NO:221 (AB-69); SEQ ID NO:210 and SEQ ID NO:222 (AB-70); SEQ ID NO:211 and SEQ ID NO:223 (AB-71); SEQ ID NO:212 and SEQ ID NO:224 (AB-72); SEQ ID NO:213 and SEQ ID NO:225 (AB-73); or SEQ ID NO:216 and SEQ ID NO:106 (AB-76), or any combination of the foregoing. [0056] In some embodiments, the paratope comprises amino acid residues corresponding to each of A50, X11 (position 54), X15 (position 59), and V106 of SEQ ID NO: 2 and D1, I2, Q27, Y32, Y49, Y50, F91, X20 (position 92), X21 (position 93), Y94 and P95 of SEQ ID NO: 59, or a subset thereof. [0057] In some embodiments, a polypeptide comprising a paratope disclosed herein comprises an immunoglobulin heavy chain variable domain (VH) and an immunoglobulin light chain variable domain (V L ). In some embodiments, the paratope residues are contained within the V H and V L of a polypeptide. - 39 - 3820371.v1 5708.1067001 [0058] In some embodiments, a polypeptide comprises an immunoglobulin light chain variable region, an immunoglobulin heavy chain variable region, or an immunoglobulin light chain variable region and an immunoglobulin heavy chain variable region. In some embodiments, a polypeptide comprises six CDRs of a polypeptide disclosed herein. In some embodiments, a polypeptide has fewer than six (e.g., 1, 2, 3, 4 or 5) of the CDRs of a polypeptide disclosed herein. [0059] In some embodiments, the disclosure provides a polypeptide that specifically binds PD-1, wherein the polypeptide comprises: a V H amino acid sequence comprising a heavy chain complementarity determining region 1 (HCDR1), a heavy chain complementarity determining region 2 (HCDR2) and a heavy chain complementarity determining region 3 (HCDR3) that are substantially similar in amino acid sequence to an HCDR1, an HCDR2 and an HCDR3, respectively, of a VH amino acid sequence set forth in any of SEQ ID NOs:3-17, SEQ ID NOs:19-58, and SEQ ID NOs:206-216; and a VL amino acid sequence comprising a light chain complementarity determining region 1 (LCDR1), a light chain complementarity determining region 2 (LCDR2) and a light chain complementarity determining region 3 (LCDR3) that are substantially similar in amino acid sequence to an LCDR1, an LCDR2 and an LCDR3, respectively, of a VL amino acid sequence set forth in any of SEQ ID NOs:60-69, SEQ ID NOs:71-106, and SEQ ID NOs:217-226. [0060] In some embodiments, a polypeptide comprises an HCDR1, an HCDR2, an HCDR3, an LCDR1, an LCDR2 and an LCDR3 that substantially preserve one or more functional properties (e.g., binding to PD-1, PD-1 agonist activity, increased PD-1 signaling) of an HCDR1, an HCDR2, an HCDR3, an LCDR1, an LCDR2 and an LCDR3 of a polypeptide selected from any one of AB-1 to AB-76. [0061] In some embodiments, a polypeptide comprises an HCDR1, an HCDR2, an HCDR3, an LCDR1, an LCDR2 and an LCDR3 comprising only one or more conservative substitutions (e.g., only one or more highly conservative substitutions), relative an HCDR1, an HCDR2, an HCDR3, an LCDR1, an LCDR2 and an LCDR3 of a polypeptide selected from any one of AB-1 to AB-76. [0062] In some embodiments, a polypeptide comprises an HCDR1, an HCDR2, an HCDR3, an LCDR1, an LCDR2 and an LCDR3 comprising up to 1, 2, or 3 conservative substitutions (e.g., up to 1, 2, or 3 highly conservative substitutions), relative to an HCDR1, - 40 - 3820371.v1 5708.1067001 an HCDR2, an HCDR3, an LCDR1, an LCDR2 and an LCDR3 of a polypeptide selected from any one of AB-1 to AB-76. [0063] In some embodiments, a polypeptide disclosed herein comprises an HCDR1, an HCDR2, an HCDR3, an LCDR1, an LCDR2 and an LCDR3 having 100% sequence identity to an HCDR1, an HCDR2, an HCDR3, an LCDR1, an LCDR2 and an LCDR3 of a polypeptide selected from any one of AB-1 to AB-76. [0064] In some embodiments, a polypeptide comprises an HCDR1, an HCDR2 and an HCDR3, and an LCDR1, an LCDR2 and an LCDR3, of an antibody comprising a VH/VL pair selected from: SEQ ID NO:206 and SEQ ID NO:217 (AB-65); SEQ ID NO:215 and SEQ ID NO:104 (AB-75); SEQ ID NO:214 and SEQ ID NO:226 (AB-74); SEQ ID NO:3 and SEQ ID NO:60 (AB-1); SEQ ID NO:4 and SEQ ID NO:61 (AB-2); SEQ ID NO:5 and SEQ ID NO:62 (AB-3); SEQ ID NO:3 and SEQ ID NO:63 (AB-4); SEQ ID NO:6 and SEQ ID NO:64 (AB-5); SEQ ID NO:7 and SEQ ID NO:65 (AB-6); SEQ ID NO:8 and SEQ ID NO:66 (AB-7); SEQ ID NO:9 and SEQ ID NO:60 (AB-8); SEQ ID NO:10 and SEQ ID NO:67 (AB-9); SEQ ID NO:11 and SEQ ID NO:64 (AB-10); SEQ ID NO:3 and SEQ ID NO:68 (AB-11); SEQ ID NO:12 and SEQ ID NO:60 (AB-12); SEQ ID NO:13 and SEQ ID NO:68 (AB-13); SEQ ID NO:14 and SEQ ID NO:69 (AB-14); SEQ ID NO:15 and SEQ ID NO:64 (AB-15); SEQ ID NO:16 and SEQ ID NO:60 (AB-16); SEQ ID NO:17 and SEQ ID NO:65 (AB-17); SEQ ID NO:19 and SEQ ID NO:71 (AB-18); SEQ ID NO:20 and SEQ ID NO:72 (AB-19); SEQ ID NO:21 and SEQ ID NO:71 (AB-20); SEQ ID NO:22 and SEQ ID NO:73 (AB-21); - 41 - 3820371.v1 5708.1067001 SEQ ID NO:23 and SEQ ID NO:71 (AB-22); SEQ ID NO:24 and SEQ ID NO:74 (AB-23); SEQ ID NO:21 and SEQ ID NO:75 (AB-24); SEQ ID NO:21 and SEQ ID NO:76 (AB-25); SEQ ID NO:21 and SEQ ID NO:71 (AB-26); SEQ ID NO:25 and SEQ ID NO:71 (AB-27); SEQ ID NO:26 and SEQ ID NO:71 (AB-28); SEQ ID NO:27 and SEQ ID NO:77 (AB-29); SEQ ID NO:28 and SEQ ID NO:78 (AB-30); SEQ ID NO:29 and SEQ ID NO:79 (AB-31); SEQ ID NO:30 and SEQ ID NO:80 (AB-32); SEQ ID NO:31 and SEQ ID NO:81 (AB-33); SEQ ID NO:28 and SEQ ID NO:82 (AB-34); SEQ ID NO:23 and SEQ ID NO:80 (AB-35); SEQ ID NO:32 and SEQ ID NO:80 (AB-36); SEQ ID NO:33 and SEQ ID NO:83 (AB-37); SEQ ID NO:34 and SEQ ID NO:84 (AB-38); SEQ ID NO:35 and SEQ ID NO:85 (AB-39); SEQ ID NO:23 and SEQ ID NO:86 (AB-40); SEQ ID NO:36 and SEQ ID NO:87 (AB-41); SEQ ID NO:37 and SEQ ID NO:88 (AB-42); SEQ ID NO:38 and SEQ ID NO:89 (AB-43); SEQ ID NO:39 and SEQ ID NO:80 (AB-44); SEQ ID NO:40 and SEQ ID NO:90 (AB-45); SEQ ID NO:41 and SEQ ID NO:91 (AB-46); SEQ ID NO:42 and SEQ ID NO:92 (AB-47); SEQ ID NO:43 and SEQ ID NO:93 (AB-48); SEQ ID NO:44 and SEQ ID NO:94 (AB-49); SEQ ID NO:45 and SEQ ID NO:80 (AB-50); SEQ ID NO:46 and SEQ ID NO:95 (AB-51); SEQ ID NO:47 and SEQ ID NO:96 (AB-52); SEQ ID NO:48 and SEQ ID NO:97 (AB-53); SEQ ID NO:49 and SEQ ID NO:98 (AB-54); - 42 - 3820371.v1 5708.1067001 SEQ ID NO:50 and SEQ ID NO:84 (AB-55); SEQ ID NO:51 and SEQ ID NO:99 (AB-56); SEQ ID NO:35 and SEQ ID NO:83 (AB-57); SEQ ID NO:52 and SEQ ID NO:100 (AB-58); SEQ ID NO:53 and SEQ ID NO:101 (AB-59); SEQ ID NO:54 and SEQ ID NO:102 (AB-60); SEQ ID NO:55 and SEQ ID NO:103 (AB-61); SEQ ID NO:56 and SEQ ID NO:104 (AB-62); SEQ ID NO:57 and SEQ ID NO:105 (AB-63); SEQ ID NO:58 and SEQ ID NO:106 (AB-64); SEQ ID NO:207 and SEQ ID NO:218 (AB-66); SEQ ID NO:208 and SEQ ID NO:219 (AB-67); SEQ ID NO:209 and SEQ ID NO:220 (AB-68); SEQ ID NO:53 and SEQ ID NO:221 (AB-69); SEQ ID NO:210 and SEQ ID NO:222 (AB-70); SEQ ID NO:211 and SEQ ID NO:223 (AB-71); SEQ ID NO:212 and SEQ ID NO:224 (AB-72); SEQ ID NO:213 and SEQ ID NO:225 (AB-73), or SEQ ID NO:216 and SEQ ID NO:106 (AB-76). [0065] In some embodiments, a polypeptide comprises an HCDR1, an HCDR2 and an HCDR3, and an LCDR1, an LCDR2 and an LCDR3, of an antibody comprising a VH/VL pair selected from: SEQ ID NO:206 and SEQ ID NO:217 (AB-65); SEQ ID NO:215 and SEQ ID NO:104 (AB-75); or SEQ ID NO:214 and SEQ ID NO:226 (AB-74). [0066] In some embodiments, a polypeptide comprises an HCDR1, an HCDR2 and an HCDR3, and an LCDR1, an LCDR2 and an LCDR3, of an antibody comprising a VH comprising the amino acid sequence of SEQ ID NO:206 and a VL comprising the amino acid sequence of SEQ ID NO:217 (AB-65). [0067] In some embodiments, a polypeptide comprises an HCDR1, an HCDR2 and an HCDR3, and an LCDR1, an LCDR2 and an LCDR3, of an antibody comprising a VH comprising the amino acid sequence of SEQ ID NO:215, and a V L comprising the amino acid sequence of SEQ ID NO:104 (AB-75). - 43 - 3820371.v1 5708.1067001 [0068] In some embodiments, a polypeptide comprises an HCDR1, an HCDR2 and an HCDR3, and an LCDR1, an LCDR2 and an LCDR3, of an antibody comprising a VH comprising the amino acid sequence of SEQ ID NO:214, and a V L comprising the amino acid sequence of SEQ ID NO:226 (AB-74). [0069] A CDR (e.g., HCDR1, HCDR2, HCDR3, LCDR1, LCDR2 and/or LCDR3) can be a CDR defined by any art-recognized method for identifying CDR residues of an antibody, as described further herein (e.g., a CDR as defined by Kabat, a CDR as defined by Chothia, a CDR as defined by IMGT). [0070] In some embodiments, a polypeptide comprises a paratope that is substantially similar to the paratope of an antibody comprising a V H /V L pair selected from: SEQ ID NO:206 and SEQ ID NO:217 (AB-65); SEQ ID NO:215 and SEQ ID NO:104 (AB-75); SEQ ID NO:214 and SEQ ID NO:226 (AB-74); SEQ ID NO:3 and SEQ ID NO:60 (AB-1); SEQ ID NO:4 and SEQ ID NO:61 (AB-2); SEQ ID NO:5 and SEQ ID NO:62 (AB-3); SEQ ID NO:3 and SEQ ID NO:63 (AB-4); SEQ ID NO:6 and SEQ ID NO:64 (AB-5); SEQ ID NO:7 and SEQ ID NO:65 (AB-6); SEQ ID NO:8 and SEQ ID NO:66 (AB-7); SEQ ID NO:9 and SEQ ID NO:60 (AB-8); SEQ ID NO:10 and SEQ ID NO:67 (AB-9); SEQ ID NO:11 and SEQ ID NO:64 (AB-10); SEQ ID NO:3 and SEQ ID NO:68 (AB-11); SEQ ID NO:12 and SEQ ID NO:60 (AB-12); SEQ ID NO:13 and SEQ ID NO:68 (AB-13); SEQ ID NO:14 and SEQ ID NO:69 (AB-14); SEQ ID NO:15 and SEQ ID NO:64 (AB-15); SEQ ID NO:16 and SEQ ID NO:60 (AB-16); SEQ ID NO:17 and SEQ ID NO:65 (AB-17); SEQ ID NO:19 and SEQ ID NO:71 (AB-18); SEQ ID NO:20 and SEQ ID NO:72 (AB-19); SEQ ID NO:21 and SEQ ID NO:71 (AB-20); - 44 - 3820371.v1 5708.1067001 SEQ ID NO:22 and SEQ ID NO:73 (AB-21); SEQ ID NO:23 and SEQ ID NO:71 (AB-22); SEQ ID NO:24 and SEQ ID NO:74 (AB-23); SEQ ID NO:21 and SEQ ID NO:75 (AB-24); SEQ ID NO:21 and SEQ ID NO:76 (AB-25); SEQ ID NO:21 and SEQ ID NO:71 (AB-26); SEQ ID NO:25 and SEQ ID NO:71 (AB-27); SEQ ID NO:26 and SEQ ID NO:71 (AB-28); SEQ ID NO:27 and SEQ ID NO:77 (AB-29); SEQ ID NO:28 and SEQ ID NO:78 (AB-30); SEQ ID NO:29 and SEQ ID NO:79 (AB-31); SEQ ID NO:30 and SEQ ID NO:80 (AB-32); SEQ ID NO:31 and SEQ ID NO:81 (AB-33); SEQ ID NO:28 and SEQ ID NO:82 (AB-34); SEQ ID NO:23 and SEQ ID NO:80 (AB-35); SEQ ID NO:32 and SEQ ID NO:80 (AB-36); SEQ ID NO:33 and SEQ ID NO:83 (AB-37); SEQ ID NO:34 and SEQ ID NO:84 (AB-38); SEQ ID NO:35 and SEQ ID NO:85 (AB-39); SEQ ID NO:23 and SEQ ID NO:86 (AB-40); SEQ ID NO:36 and SEQ ID NO:87 (AB-41); SEQ ID NO:37 and SEQ ID NO:88 (AB-42); SEQ ID NO:38 and SEQ ID NO:89 (AB-43); SEQ ID NO:39 and SEQ ID NO:80 (AB-44); SEQ ID NO:40 and SEQ ID NO:90 (AB-45); SEQ ID NO:41 and SEQ ID NO:91 (AB-46); SEQ ID NO:42 and SEQ ID NO:92 (AB-47); SEQ ID NO:43 and SEQ ID NO:93 (AB-48); SEQ ID NO:44 and SEQ ID NO:94 (AB-49); SEQ ID NO:45 and SEQ ID NO:80 (AB-50); SEQ ID NO:46 and SEQ ID NO:95 (AB-51); SEQ ID NO:47 and SEQ ID NO:96 (AB-52); SEQ ID NO:48 and SEQ ID NO:97 (AB-53); - 45 - 3820371.v1 5708.1067001 SEQ ID NO:49 and SEQ ID NO:98 (AB-54); SEQ ID NO:50 and SEQ ID NO:84 (AB-55); SEQ ID NO:51 and SEQ ID NO:99 (AB-56); SEQ ID NO:35 and SEQ ID NO:83 (AB-57); SEQ ID NO:52 and SEQ ID NO:100 (AB-58); SEQ ID NO:53 and SEQ ID NO:101 (AB-59); SEQ ID NO:54 and SEQ ID NO:102 (AB-60); SEQ ID NO:55 and SEQ ID NO:103 (AB-61); SEQ ID NO:56 and SEQ ID NO:104 (AB-62); SEQ ID NO:57 and SEQ ID NO:105 (AB-63); SEQ ID NO:58 and SEQ ID NO:106 (AB-64); SEQ ID NO:207 and SEQ ID NO:218 (AB-66); SEQ ID NO:208 and SEQ ID NO:219 (AB-67); SEQ ID NO:209 and SEQ ID NO:220 (AB-68); SEQ ID NO:53 and SEQ ID NO:221 (AB-69); SEQ ID NO:210 and SEQ ID NO:222 (AB-70); SEQ ID NO:211 and SEQ ID NO:223 (AB-71); SEQ ID NO:212 and SEQ ID NO:224 (AB-72); SEQ ID NO:213 and SEQ ID NO:225 (AB-73); or SEQ ID NO:216 and SEQ ID NO:106 (AB-76). [0071] In some embodiments, a polypeptide comprises a paratope that is identical to the paratope of an antibody comprising a V H /V L pair selected from: SEQ ID NO:206 and SEQ ID NO:217 (AB-65); SEQ ID NO:215 and SEQ ID NO:104 (AB-75); SEQ ID NO:214 and SEQ ID NO:226 (AB-74); SEQ ID NO:3 and SEQ ID NO:60 (AB-1); SEQ ID NO:4 and SEQ ID NO:61 (AB-2); SEQ ID NO:5 and SEQ ID NO:62 (AB-3); SEQ ID NO:3 and SEQ ID NO:63 (AB-4); SEQ ID NO:6 and SEQ ID NO:64 (AB-5); SEQ ID NO:7 and SEQ ID NO:65 (AB-6); SEQ ID NO:8 and SEQ ID NO:66 (AB-7); SEQ ID NO:9 and SEQ ID NO:60 (AB-8); - 46 - 3820371.v1 5708.1067001 SEQ ID NO:10 and SEQ ID NO:67 (AB-9); SEQ ID NO:11 and SEQ ID NO:64 (AB-10); SEQ ID NO:3 and SEQ ID NO:68 (AB-11); SEQ ID NO:12 and SEQ ID NO:60 (AB-12); SEQ ID NO:13 and SEQ ID NO:68 (AB-13); SEQ ID NO:14 and SEQ ID NO:69 (AB-14); SEQ ID NO:15 and SEQ ID NO:64 (AB-15); SEQ ID NO:16 and SEQ ID NO:60 (AB-16); SEQ ID NO:17 and SEQ ID NO:65 (AB-17); SEQ ID NO:19 and SEQ ID NO:71 (AB-18); SEQ ID NO:20 and SEQ ID NO:72 (AB-19); SEQ ID NO:21 and SEQ ID NO:71 (AB-20); SEQ ID NO:22 and SEQ ID NO:73 (AB-21); SEQ ID NO:23 and SEQ ID NO:71 (AB-22); SEQ ID NO:24 and SEQ ID NO:74 (AB-23); SEQ ID NO:21 and SEQ ID NO:75 (AB-24); SEQ ID NO:21 and SEQ ID NO:76 (AB-25); SEQ ID NO:21 and SEQ ID NO:71 (AB-26); SEQ ID NO:25 and SEQ ID NO:71 (AB-27); SEQ ID NO:26 and SEQ ID NO:71 (AB-28); SEQ ID NO:27 and SEQ ID NO:77 (AB-29); SEQ ID NO:28 and SEQ ID NO:78 (AB-30); SEQ ID NO:29 and SEQ ID NO:79 (AB-31); SEQ ID NO:30 and SEQ ID NO:80 (AB-32); SEQ ID NO:31 and SEQ ID NO:81 (AB-33); SEQ ID NO:28 and SEQ ID NO:82 (AB-34); SEQ ID NO:23 and SEQ ID NO:80 (AB-35); SEQ ID NO:32 and SEQ ID NO:80 (AB-36); SEQ ID NO:33 and SEQ ID NO:83 (AB-37); SEQ ID NO:34 and SEQ ID NO:84 (AB-38); SEQ ID NO:35 and SEQ ID NO:85 (AB-39); SEQ ID NO:23 and SEQ ID NO:86 (AB-40); SEQ ID NO:36 and SEQ ID NO:87 (AB-41); - 47 - 3820371.v1 5708.1067001 SEQ ID NO:37 and SEQ ID NO:88 (AB-42); SEQ ID NO:38 and SEQ ID NO:89 (AB-43); SEQ ID NO:39 and SEQ ID NO:80 (AB-44); SEQ ID NO:40 and SEQ ID NO:90 (AB-45); SEQ ID NO:41 and SEQ ID NO:91 (AB-46); SEQ ID NO:42 and SEQ ID NO:92 (AB-47); SEQ ID NO:43 and SEQ ID NO:93 (AB-48); SEQ ID NO:44 and SEQ ID NO:94 (AB-49); SEQ ID NO:45 and SEQ ID NO:80 (AB-50); SEQ ID NO:46 and SEQ ID NO:95 (AB-51); SEQ ID NO:47 and SEQ ID NO:96 (AB-52); SEQ ID NO:48 and SEQ ID NO:97 (AB-53); SEQ ID NO:49 and SEQ ID NO:98 (AB-54); SEQ ID NO:50 and SEQ ID NO:84 (AB-55); SEQ ID NO:51 and SEQ ID NO:99 (AB-56); SEQ ID NO:35 and SEQ ID NO:83 (AB-57); SEQ ID NO:52 and SEQ ID NO:100 (AB-58); SEQ ID NO:53 and SEQ ID NO:101 (AB-59); SEQ ID NO:54 and SEQ ID NO:102 (AB-60); SEQ ID NO:55 and SEQ ID NO:103 (AB-61); SEQ ID NO:56 and SEQ ID NO:104 (AB-62); SEQ ID NO:57 and SEQ ID NO:105 (AB-63); SEQ ID NO:58 and SEQ ID NO:106 (AB-64); SEQ ID NO:207 and SEQ ID NO:218 (AB-66); SEQ ID NO:208 and SEQ ID NO:219 (AB-67); SEQ ID NO:209 and SEQ ID NO:220 (AB-68); SEQ ID NO:53 and SEQ ID NO:221 (AB-69); SEQ ID NO:210 and SEQ ID NO:222 (AB-70); SEQ ID NO:211 and SEQ ID NO:223 (AB-71); SEQ ID NO:212 and SEQ ID NO:224 (AB-72); SEQ ID NO:213 and SEQ ID NO:225 (AB-73); or SEQ ID NO:216 and SEQ ID NO:106 (AB-76). [0072] The disclosure also provides, among other things, a polypeptide comprising: - 48 - 3820371.v1 5708.1067001 an HCDR1 comprising the amino acid sequence of SEQ ID NO:118, an HCDR2 comprising the amino acid sequence of SEQ ID NO:147, an HCDR3 comprising the amino acid sequence of SEQ ID NO:227, an LCDR 1 comprising the amino acid sequence of SEQ ID NO:229, an LCDR2 comprising the amino acid sequence of SEQ ID NO:183, and an LCDR3 comprising the amino acid sequence of SEQ ID NO:200 (AB-65); an HCDR1 comprising the amino acid sequence of SEQ ID NO:118, an HCDR2 comprising the amino acid sequence of SEQ ID NO:148, an HCDR3 comprising the amino acid sequence of SEQ ID NO:228, an LCDR 1 comprising the amino acid sequence of SEQ ID NO:177, an LCDR2 comprising the amino acid sequence of SEQ ID NO:183, and an LCDR3 comprising the amino acid sequence of SEQ ID NO:200 (AB-75); an HCDR1 comprising the amino acid sequence of SEQ ID NO:118, an HCDR2 comprising the amino acid sequence of SEQ ID NO:139, an HCDR3 comprising the amino acid sequence of SEQ ID NO:170, an LCDR 1 comprising the amino acid sequence of SEQ ID NO:178, an LCDR2 comprising the amino acid sequence of SEQ ID NO:183, and an LCDR3 comprising the amino acid sequence of SEQ ID NO:194 (AB-74); an HCDR1 comprising the amino acid sequence of SEQ ID NO:107, an HCDR2 comprising the amino acid sequence of SEQ ID NO:127, an HCDR3 comprising the amino acid sequence of SEQ ID NO:151, an LCDR 1 comprising the amino acid sequence of SEQ ID NO:172, an LCDR2 comprising the amino acid sequence of SEQ ID NO:179, and an LCDR3 comprising the amino acid sequence of SEQ ID NO:184 (AB-1); an HCDR1 comprising the amino acid sequence of SEQ ID NO:107, an HCDR2 comprising the amino acid sequence of SEQ ID NO:127, an HCDR3 comprising the amino acid sequence of SEQ ID NO:152, an LCDR 1 comprising the amino acid sequence of SEQ ID NO:172, an LCDR2 comprising the amino acid sequence of SEQ ID NO:179, and an LCDR3 comprising the amino acid sequence of SEQ ID NO:185 (AB-2); an HCDR1 comprising the amino acid sequence of SEQ ID NO:108, an HCDR2 comprising the amino acid sequence of SEQ ID NO:128, an HCDR3 comprising the amino acid sequence of SEQ ID NO:153, an LCDR 1 comprising the amino acid sequence of SEQ ID NO:172, an LCDR2 comprising the amino acid sequence of SEQ ID NO:179, and an LCDR3 comprising the amino acid sequence of SEQ ID NO:186 (AB-3); an HCDR1 comprising the amino acid sequence of SEQ ID NO:107, an HCDR2 comprising the amino acid sequence of SEQ ID NO:127, an HCDR3 comprising the amino acid sequence of SEQ ID NO:151, an LCDR 1 comprising the amino acid sequence of SEQ - 49 - 3820371.v1 5708.1067001 ID NO:172, an LCDR2 comprising the amino acid sequence of SEQ ID NO:179, and an LCDR3 comprising the amino acid sequence of SEQ ID NO:187 (AB-4); an HCDR1 comprising the amino acid sequence of SEQ ID NO:109, an HCDR2 comprising the amino acid sequence of SEQ ID NO:129, an HCDR3 comprising the amino acid sequence of SEQ ID NO:151, an LCDR 1 comprising the amino acid sequence of SEQ ID NO:172, an LCDR2 comprising the amino acid sequence of SEQ ID NO:179, and an LCDR3 comprising the amino acid sequence of SEQ ID NO:188 (AB-5); an HCDR1 comprising the amino acid sequence of SEQ ID NO:110, an HCDR2 comprising the amino acid sequence of SEQ ID NO:130, an HCDR3 comprising the amino acid sequence of SEQ ID NO:154, an LCDR 1 comprising the amino acid sequence of SEQ ID NO:172, an LCDR2 comprising the amino acid sequence of SEQ ID NO:179, and an LCDR3 comprising the amino acid sequence of SEQ ID NO:189 (AB-6); an HCDR1 comprising the amino acid sequence of SEQ ID NO:109, an HCDR2 comprising the amino acid sequence of SEQ ID NO:131, an HCDR3 comprising the amino acid sequence of SEQ ID NO:151, an LCDR 1 comprising the amino acid sequence of SEQ ID NO:172, an LCDR2 comprising the amino acid sequence of SEQ ID NO:179, and an LCDR3 comprising the amino acid sequence of SEQ ID NO:190 (AB-7); an HCDR1 comprising the amino acid sequence of SEQ ID NO:111, an HCDR2 comprising the amino acid sequence of SEQ ID NO:132, an HCDR3 comprising the amino acid sequence of SEQ ID NO:155, an LCDR 1 comprising the amino acid sequence of SEQ ID NO:172, an LCDR2 comprising the amino acid sequence of SEQ ID NO:179, and an LCDR3 comprising the amino acid sequence of SEQ ID NO:184 (AB-8); an HCDR1 comprising the amino acid sequence of SEQ ID NO:111, an HCDR2 comprising the amino acid sequence of SEQ ID NO:133, an HCDR3 comprising the amino acid sequence of SEQ ID NO:154, an LCDR 1 comprising the amino acid sequence of SEQ ID NO:172, an LCDR2 comprising the amino acid sequence of SEQ ID NO:179, and an LCDR3 comprising the amino acid sequence of SEQ ID NO:191 (AB-9); an HCDR1 comprising the amino acid sequence of SEQ ID NO:112, an HCDR2 comprising the amino acid sequence of SEQ ID NO:127, an HCDR3 comprising the amino acid sequence of SEQ ID NO:151, an LCDR 1 comprising the amino acid sequence of SEQ ID NO:172, an LCDR2 comprising the amino acid sequence of SEQ ID NO:179, and an LCDR3 comprising the amino acid sequence of SEQ ID NO:188 (AB-10); - 50 - 3820371.v1 5708.1067001 an HCDR1 comprising the amino acid sequence of SEQ ID NO:107, an HCDR2 comprising the amino acid sequence of SEQ ID NO:127, an HCDR3 comprising the amino acid sequence of SEQ ID NO:151, an LCDR 1 comprising the amino acid sequence of SEQ ID NO:172, an LCDR2 comprising the amino acid sequence of SEQ ID NO:179, and an LCDR3 comprising the amino acid sequence of SEQ ID NO:192 (AB-11); an HCDR1 comprising the amino acid sequence of SEQ ID NO:113, an HCDR2 comprising the amino acid sequence of SEQ ID NO:134, an HCDR3 comprising the amino acid sequence of SEQ ID NO:151, an LCDR 1 comprising the amino acid sequence of SEQ ID NO:172, an LCDR2 comprising the amino acid sequence of SEQ ID NO:179, and an LCDR3 comprising the amino acid sequence of SEQ ID NO:184 (AB-12); an HCDR1 comprising the amino acid sequence of SEQ ID NO:114, an HCDR2 comprising the amino acid sequence of SEQ ID NO:135, an HCDR3 comprising the amino acid sequence of SEQ ID NO:156, an LCDR 1 comprising the amino acid sequence of SEQ ID NO:172, an LCDR2 comprising the amino acid sequence of SEQ ID NO:179, and an LCDR3 comprising the amino acid sequence of SEQ ID NO:192 (AB-13); an HCDR1 comprising the amino acid sequence of SEQ ID NO:115, an HCDR2 comprising the amino acid sequence of SEQ ID NO:136, an HCDR3 comprising the amino acid sequence of SEQ ID NO:151, an LCDR 1 comprising the amino acid sequence of SEQ ID NO:172, an LCDR2 comprising the amino acid sequence of SEQ ID NO:179, and an LCDR3 comprising the amino acid sequence of SEQ ID NO:193 (AB-14); an HCDR1 comprising the amino acid sequence of SEQ ID NO:116, an HCDR2 comprising the amino acid sequence of SEQ ID NO:137, an HCDR3 comprising the amino acid sequence of SEQ ID NO:153, an LCDR 1 comprising the amino acid sequence of SEQ ID NO:172, an LCDR2 comprising the amino acid sequence of SEQ ID NO:179, and an LCDR3 comprising the amino acid sequence of SEQ ID NO:188 (AB-15); an HCDR1 comprising the amino acid sequence of SEQ ID NO:114, an HCDR2 comprising the amino acid sequence of SEQ ID NO:138, an HCDR3 comprising the amino acid sequence of SEQ ID NO:157, an LCDR 1 comprising the amino acid sequence of SEQ ID NO:172, an LCDR2 comprising the amino acid sequence of SEQ ID NO:179, and an LCDR3 comprising the amino acid sequence of SEQ ID NO:184 (AB-16); an HCDR1 comprising the amino acid sequence of SEQ ID NO:117, an HCDR2 comprising the amino acid sequence of SEQ ID NO:131, an HCDR3 comprising the amino acid sequence of SEQ ID NO:151, an LCDR 1 comprising the amino acid sequence of SEQ - 51 - 3820371.v1 5708.1067001 ID NO:172, an LCDR2 comprising the amino acid sequence of SEQ ID NO:179, and an LCDR3 comprising the amino acid sequence of SEQ ID NO:189 (AB-17); an HCDR1 comprising the amino acid sequence of SEQ ID NO:118, an HCDR2 comprising the amino acid sequence of SEQ ID NO:139, an HCDR3 comprising the amino acid sequence of SEQ ID NO:158, an LCDR 1 comprising the amino acid sequence of SEQ ID NO:173, an LCDR2 comprising the amino acid sequence of SEQ ID NO:180, and an LCDR3 comprising the amino acid sequence of SEQ ID NO:194 (AB-18); an HCDR1 comprising the amino acid sequence of SEQ ID NO:119, an HCDR2 comprising the amino acid sequence of SEQ ID NO:140, an HCDR3 comprising the amino acid sequence of SEQ ID NO:159, an LCDR 1 comprising the amino acid sequence of SEQ ID NO:174, an LCDR2 comprising the amino acid sequence of SEQ ID NO:181, and an LCDR3 comprising the amino acid sequence of SEQ ID NO:195 (AB-19); an HCDR1 comprising the amino acid sequence of SEQ ID NO:120, an HCDR2 comprising the amino acid sequence of SEQ ID NO:139, an HCDR3 comprising the amino acid sequence of SEQ ID NO:160, an LCDR 1 comprising the amino acid sequence of SEQ ID NO:173, an LCDR2 comprising the amino acid sequence of SEQ ID NO:180, and an LCDR3 comprising the amino acid sequence of SEQ ID NO:194 (AB-20); an HCDR1 comprising the amino acid sequence of SEQ ID NO:120, an HCDR2 comprising the amino acid sequence of SEQ ID NO:139, an HCDR3 comprising the amino acid sequence of SEQ ID NO:160, an LCDR 1 comprising the amino acid sequence of SEQ ID NO:173, an LCDR2 comprising the amino acid sequence of SEQ ID NO:182, and an LCDR3 comprising the amino acid sequence of SEQ ID NO:194 (AB-21); an HCDR1 comprising the amino acid sequence of SEQ ID NO:121, an HCDR2 comprising the amino acid sequence of SEQ ID NO:139, an HCDR3 comprising the amino acid sequence of SEQ ID NO:151, an LCDR 1 comprising the amino acid sequence of SEQ ID NO:173, an LCDR2 comprising the amino acid sequence of SEQ ID NO:180, and an LCDR3 comprising the amino acid sequence of SEQ ID NO:194 (AB-22); an HCDR1 comprising the amino acid sequence of SEQ ID NO:120, an HCDR2 comprising the amino acid sequence of SEQ ID NO:139, an HCDR3 comprising the amino acid sequence of SEQ ID NO:160, an LCDR 1 comprising the amino acid sequence of SEQ ID NO:173, an LCDR2 comprising the amino acid sequence of SEQ ID NO:180, and an LCDR3 comprising the amino acid sequence of SEQ ID NO:194 (AB-23); - 52 - 3820371.v1 5708.1067001 an HCDR1 comprising the amino acid sequence of SEQ ID NO:120, an HCDR2 comprising the amino acid sequence of SEQ ID NO:139, an HCDR3 comprising the amino acid sequence of SEQ ID NO:160, an LCDR 1 comprising the amino acid sequence of SEQ ID NO:173, an LCDR2 comprising the amino acid sequence of SEQ ID NO:180, and an LCDR3 comprising the amino acid sequence of SEQ ID NO:194 (AB-24); an HCDR1 comprising the amino acid sequence of SEQ ID NO:120, an HCDR2 comprising the amino acid sequence of SEQ ID NO:139, an HCDR3 comprising the amino acid sequence of SEQ ID NO:160, an LCDR 1 comprising the amino acid sequence of SEQ ID NO:173, an LCDR2 comprising the amino acid sequence of SEQ ID NO:180, and an LCDR3 comprising the amino acid sequence of SEQ ID NO:194 (AB-25); an HCDR1 comprising the amino acid sequence of SEQ ID NO:120, an HCDR2 comprising the amino acid sequence of SEQ ID NO:139, an HCDR3 comprising the amino acid sequence of SEQ ID NO:160, an LCDR 1 comprising the amino acid sequence of SEQ ID NO:173, an LCDR2 comprising the amino acid sequence of SEQ ID NO:180, and an LCDR3 comprising the amino acid sequence of SEQ ID NO:194 (AB-26); an HCDR1 comprising the amino acid sequence of SEQ ID NO:120, an HCDR2 comprising the amino acid sequence of SEQ ID NO:139, an HCDR3 comprising the amino acid sequence of SEQ ID NO:160, an LCDR 1 comprising the amino acid sequence of SEQ ID NO:173, an LCDR2 comprising the amino acid sequence of SEQ ID NO:180, and an LCDR3 comprising the amino acid sequence of SEQ ID NO:194 (AB-27); an HCDR1 comprising the amino acid sequence of SEQ ID NO:118, an HCDR2 comprising the amino acid sequence of SEQ ID NO:139, an HCDR3 comprising the amino acid sequence of SEQ ID NO:151, an LCDR 1 comprising the amino acid sequence of SEQ ID NO:173, an LCDR2 comprising the amino acid sequence of SEQ ID NO:180, and an LCDR3 comprising the amino acid sequence of SEQ ID NO:194 (AB-28); an HCDR1 comprising the amino acid sequence of SEQ ID NO:120, an HCDR2 comprising the amino acid sequence of SEQ ID NO:139, an HCDR3 comprising the amino acid sequence of SEQ ID NO:161, an LCDR 1 comprising the amino acid sequence of SEQ ID NO:173, an LCDR2 comprising the amino acid sequence of SEQ ID NO:180, and an LCDR3 comprising the amino acid sequence of SEQ ID NO:194 (AB-29); an HCDR1 comprising the amino acid sequence of SEQ ID NO:121, an HCDR2 comprising the amino acid sequence of SEQ ID NO:139, an HCDR3 comprising the amino acid sequence of SEQ ID NO:162, an LCDR 1 comprising the amino acid sequence of SEQ - 53 - 3820371.v1 5708.1067001 ID NO:173, an LCDR2 comprising the amino acid sequence of SEQ ID NO:183, and an LCDR3 comprising the amino acid sequence of SEQ ID NO:194 (AB-30); an HCDR1 comprising the amino acid sequence of SEQ ID NO:121, an HCDR2 comprising the amino acid sequence of SEQ ID NO:141, an HCDR3 comprising the amino acid sequence of SEQ ID NO:163, an LCDR 1 comprising the amino acid sequence of SEQ ID NO:173, an LCDR2 comprising the amino acid sequence of SEQ ID NO:180, and an LCDR3 comprising the amino acid sequence of SEQ ID NO:196 (AB-31); an HCDR1 comprising the amino acid sequence of SEQ ID NO:121, an HCDR2 comprising the amino acid sequence of SEQ ID NO:139, an HCDR3 comprising the amino acid sequence of SEQ ID NO:151, an LCDR 1 comprising the amino acid sequence of SEQ ID NO:173, an LCDR2 comprising the amino acid sequence of SEQ ID NO:180, and an LCDR3 comprising the amino acid sequence of SEQ ID NO:194 (AB-32); an HCDR1 comprising the amino acid sequence of SEQ ID NO:121, an HCDR2 comprising the amino acid sequence of SEQ ID NO:139, an HCDR3 comprising the amino acid sequence of SEQ ID NO:164, an LCDR 1 comprising the amino acid sequence of SEQ ID NO:172, an LCDR2 comprising the amino acid sequence of SEQ ID NO:180, and an LCDR3 comprising the amino acid sequence of SEQ ID NO:194 (AB-33); an HCDR1 comprising the amino acid sequence of SEQ ID NO:121, an HCDR2 comprising the amino acid sequence of SEQ ID NO:139, an HCDR3 comprising the amino acid sequence of SEQ ID NO:162, an LCDR 1 comprising the amino acid sequence of SEQ ID NO:173, an LCDR2 comprising the amino acid sequence of SEQ ID NO:183, and an LCDR3 comprising the amino acid sequence of SEQ ID NO:194 (AB-34); an HCDR1 comprising the amino acid sequence of SEQ ID NO:121, an HCDR2 comprising the amino acid sequence of SEQ ID NO:139, an HCDR3 comprising the amino acid sequence of SEQ ID NO:151, an LCDR 1 comprising the amino acid sequence of SEQ ID NO:173, an LCDR2 comprising the amino acid sequence of SEQ ID NO:180, and an LCDR3 comprising the amino acid sequence of SEQ ID NO:194 (AB-35); an HCDR1 comprising the amino acid sequence of SEQ ID NO:122, an HCDR2 comprising the amino acid sequence of SEQ ID NO:139, an HCDR3 comprising the amino acid sequence of SEQ ID NO:151, an LCDR 1 comprising the amino acid sequence of SEQ ID NO:173, an LCDR2 comprising the amino acid sequence of SEQ ID NO:180, and an LCDR3 comprising the amino acid sequence of SEQ ID NO:194 (AB-36); - 54 - 3820371.v1 5708.1067001 an HCDR1 comprising the amino acid sequence of SEQ ID NO:114, an HCDR2 comprising the amino acid sequence of SEQ ID NO:139, an HCDR3 comprising the amino acid sequence of SEQ ID NO:151, an LCDR 1 comprising the amino acid sequence of SEQ ID NO:172, an LCDR2 comprising the amino acid sequence of SEQ ID NO:183, and an LCDR3 comprising the amino acid sequence of SEQ ID NO:194 (AB-37); an HCDR1 comprising the amino acid sequence of SEQ ID NO:121, an HCDR2 comprising the amino acid sequence of SEQ ID NO:139, an HCDR3 comprising the amino acid sequence of SEQ ID NO:151, an LCDR 1 comprising the amino acid sequence of SEQ ID NO:173, an LCDR2 comprising the amino acid sequence of SEQ ID NO:183, and an LCDR3 comprising the amino acid sequence of SEQ ID NO:194 (AB-38); an HCDR1 comprising the amino acid sequence of SEQ ID NO:118, an HCDR2 comprising the amino acid sequence of SEQ ID NO:139, an HCDR3 comprising the amino acid sequence of SEQ ID NO:165, an LCDR 1 comprising the amino acid sequence of SEQ ID NO:172, an LCDR2 comprising the amino acid sequence of SEQ ID NO:183, and an LCDR3 comprising the amino acid sequence of SEQ ID NO:194 (AB-39); an HCDR1 comprising the amino acid sequence of SEQ ID NO:121, an HCDR2 comprising the amino acid sequence of SEQ ID NO:139, an HCDR3 comprising the amino acid sequence of SEQ ID NO:151, an LCDR 1 comprising the amino acid sequence of SEQ ID NO:173, an LCDR2 comprising the amino acid sequence of SEQ ID NO:180, and an LCDR3 comprising the amino acid sequence of SEQ ID NO:194 (AB-40); an HCDR1 comprising the amino acid sequence of SEQ ID NO:121, an HCDR2 comprising the amino acid sequence of SEQ ID NO:139, an HCDR3 comprising the amino acid sequence of SEQ ID NO:166, an LCDR 1 comprising the amino acid sequence of SEQ ID NO:172, an LCDR2 comprising the amino acid sequence of SEQ ID NO:180, and an LCDR3 comprising the amino acid sequence of SEQ ID NO:194 (AB-41); an HCDR1 comprising the amino acid sequence of SEQ ID NO:123, an HCDR2 comprising the amino acid sequence of SEQ ID NO:142, an HCDR3 comprising the amino acid sequence of SEQ ID NO:151, an LCDR 1 comprising the amino acid sequence of SEQ ID NO:173, an LCDR2 comprising the amino acid sequence of SEQ ID NO:180, and an LCDR3 comprising the amino acid sequence of SEQ ID NO:194 (AB-42); an HCDR1 comprising the amino acid sequence of SEQ ID NO:121, an HCDR2 comprising the amino acid sequence of SEQ ID NO:143, an HCDR3 comprising the amino acid sequence of SEQ ID NO:167, an LCDR 1 comprising the amino acid sequence of SEQ - 55 - 3820371.v1 5708.1067001 ID NO:173, an LCDR2 comprising the amino acid sequence of SEQ ID NO:183, and an LCDR3 comprising the amino acid sequence of SEQ ID NO:194 (AB-43); an HCDR1 comprising the amino acid sequence of SEQ ID NO:124, an HCDR2 comprising the amino acid sequence of SEQ ID NO:144, an HCDR3 comprising the amino acid sequence of SEQ ID NO:151, an LCDR 1 comprising the amino acid sequence of SEQ ID NO:173, an LCDR2 comprising the amino acid sequence of SEQ ID NO:180, and an LCDR3 comprising the amino acid sequence of SEQ ID NO:194 (AB-44); an HCDR1 comprising the amino acid sequence of SEQ ID NO:124, an HCDR2 comprising the amino acid sequence of SEQ ID NO:139, an HCDR3 comprising the amino acid sequence of SEQ ID NO:162, an LCDR 1 comprising the amino acid sequence of SEQ ID NO:173, an LCDR2 comprising the amino acid sequence of SEQ ID NO:183, and an LCDR3 comprising the amino acid sequence of SEQ ID NO:197 (AB-45); an HCDR1 comprising the amino acid sequence of SEQ ID NO:121, an HCDR2 comprising the amino acid sequence of SEQ ID NO:139, an HCDR3 comprising the amino acid sequence of SEQ ID NO:151, an LCDR 1 comprising the amino acid sequence of SEQ ID NO:173, an LCDR2 comprising the amino acid sequence of SEQ ID NO:180, and an LCDR3 comprising the amino acid sequence of SEQ ID NO:194 (AB-46); an HCDR1 comprising the amino acid sequence of SEQ ID NO:121, an HCDR2 comprising the amino acid sequence of SEQ ID NO:139, an HCDR3 comprising the amino acid sequence of SEQ ID NO:162, an LCDR 1 comprising the amino acid sequence of SEQ ID NO:173, an LCDR2 comprising the amino acid sequence of SEQ ID NO:183, and an LCDR3 comprising the amino acid sequence of SEQ ID NO:198 (AB-47); an HCDR1 comprising the amino acid sequence of SEQ ID NO:114, an HCDR2 comprising the amino acid sequence of SEQ ID NO:139, an HCDR3 comprising the amino acid sequence of SEQ ID NO:165, an LCDR 1 comprising the amino acid sequence of SEQ ID NO:172, an LCDR2 comprising the amino acid sequence of SEQ ID NO:183, and an LCDR3 comprising the amino acid sequence of SEQ ID NO:199 (AB-48); an HCDR1 comprising the amino acid sequence of SEQ ID NO:114, an HCDR2 comprising the amino acid sequence of SEQ ID NO:139, an HCDR3 comprising the amino acid sequence of SEQ ID NO:151, an LCDR 1 comprising the amino acid sequence of SEQ ID NO:172, an LCDR2 comprising the amino acid sequence of SEQ ID NO:179, and an LCDR3 comprising the amino acid sequence of SEQ ID NO:194 (AB-49); - 56 - 3820371.v1 5708.1067001 an HCDR1 comprising the amino acid sequence of SEQ ID NO:121, an HCDR2 comprising the amino acid sequence of SEQ ID NO:145, an HCDR3 comprising the amino acid sequence of SEQ ID NO:168, an LCDR 1 comprising the amino acid sequence of SEQ ID NO:173, an LCDR2 comprising the amino acid sequence of SEQ ID NO:180, and an LCDR3 comprising the amino acid sequence of SEQ ID NO:194 (AB-50); an HCDR1 comprising the amino acid sequence of SEQ ID NO:121, an HCDR2 comprising the amino acid sequence of SEQ ID NO:146, an HCDR3 comprising the amino acid sequence of SEQ ID NO:151, an LCDR 1 comprising the amino acid sequence of SEQ ID NO:173, an LCDR2 comprising the amino acid sequence of SEQ ID NO:183, and an LCDR3 comprising the amino acid sequence of SEQ ID NO:194 (AB-51); an HCDR1 comprising the amino acid sequence of SEQ ID NO:124, an HCDR2 comprising the amino acid sequence of SEQ ID NO:139, an HCDR3 comprising the amino acid sequence of SEQ ID NO:151, an LCDR 1 comprising the amino acid sequence of SEQ ID NO:175, an LCDR2 comprising the amino acid sequence of SEQ ID NO:180, and an LCDR3 comprising the amino acid sequence of SEQ ID NO:194 (AB-52); an HCDR1 comprising the amino acid sequence of SEQ ID NO:121, an HCDR2 comprising the amino acid sequence of SEQ ID NO:139, an HCDR3 comprising the amino acid sequence of SEQ ID NO:162, an LCDR 1 comprising the amino acid sequence of SEQ ID NO:176, an LCDR2 comprising the amino acid sequence of SEQ ID NO:183, and an LCDR3 comprising the amino acid sequence of SEQ ID NO:194 (AB-53); an HCDR1 comprising the amino acid sequence of SEQ ID NO:118, an HCDR2 comprising the amino acid sequence of SEQ ID NO:147, an HCDR3 comprising the amino acid sequence of SEQ ID NO:165, an LCDR 1 comprising the amino acid sequence of SEQ ID NO:177, an LCDR2 comprising the amino acid sequence of SEQ ID NO:183, and an LCDR3 comprising the amino acid sequence of SEQ ID NO:200 (AB-54); an HCDR1 comprising the amino acid sequence of SEQ ID NO:121, an HCDR2 comprising the amino acid sequence of SEQ ID NO:139, an HCDR3 comprising the amino acid sequence of SEQ ID NO:151, an LCDR 1 comprising the amino acid sequence of SEQ ID NO:173, an LCDR2 comprising the amino acid sequence of SEQ ID NO:183, and an LCDR3 comprising the amino acid sequence of SEQ ID NO:194 (AB-55); an HCDR1 comprising the amino acid sequence of SEQ ID NO:121, an HCDR2 comprising the amino acid sequence of SEQ ID NO:146, an HCDR3 comprising the amino acid sequence of SEQ ID NO:151, an LCDR 1 comprising the amino acid sequence of SEQ - 57 - 3820371.v1 5708.1067001 ID NO:173, an LCDR2 comprising the amino acid sequence of SEQ ID NO:180, and an LCDR3 comprising the amino acid sequence of SEQ ID NO:201 (AB-56); an HCDR1 comprising the amino acid sequence of SEQ ID NO:118, an HCDR2 comprising the amino acid sequence of SEQ ID NO:139, an HCDR3 comprising the amino acid sequence of SEQ ID NO:165, an LCDR 1 comprising the amino acid sequence of SEQ ID NO:172, an LCDR2 comprising the amino acid sequence of SEQ ID NO:183, and an LCDR3 comprising the amino acid sequence of SEQ ID NO:194 (AB-57); an HCDR1 comprising the amino acid sequence of SEQ ID NO:121, an HCDR2 comprising the amino acid sequence of SEQ ID NO:139, an HCDR3 comprising the amino acid sequence of SEQ ID NO:169, an LCDR 1 comprising the amino acid sequence of SEQ ID NO:173, an LCDR2 comprising the amino acid sequence of SEQ ID NO:183, and an LCDR3 comprising the amino acid sequence of SEQ ID NO:194 (AB-58); an HCDR1 comprising the amino acid sequence of SEQ ID NO:118, an HCDR2 comprising the amino acid sequence of SEQ ID NO:139, an HCDR3 comprising the amino acid sequence of SEQ ID NO:170, an LCDR 1 comprising the amino acid sequence of SEQ ID NO:178, an LCDR2 comprising the amino acid sequence of SEQ ID NO:183, and an LCDR3 comprising the amino acid sequence of SEQ ID NO:194 (AB-59); an HCDR1 comprising the amino acid sequence of SEQ ID NO:118, an HCDR2 comprising the amino acid sequence of SEQ ID NO:147, an HCDR3 comprising the amino acid sequence of SEQ ID NO:170, an LCDR 1 comprising the amino acid sequence of SEQ ID NO:178, an LCDR2 comprising the amino acid sequence of SEQ ID NO:183, and an LCDR3 comprising the amino acid sequence of SEQ ID NO:200 (AB-60); an HCDR1 comprising the amino acid sequence of SEQ ID NO:121, an HCDR2 comprising the amino acid sequence of SEQ ID NO:146, an HCDR3 comprising the amino acid sequence of SEQ ID NO:162, an LCDR 1 comprising the amino acid sequence of SEQ ID NO:176, an LCDR2 comprising the amino acid sequence of SEQ ID NO:183, and an LCDR3 comprising the amino acid sequence of SEQ ID NO:201 (AB-61); an HCDR1 comprising the amino acid sequence of SEQ ID NO:118, an HCDR2 comprising the amino acid sequence of SEQ ID NO:148, an HCDR3 comprising the amino acid sequence of SEQ ID NO:165, an LCDR 1 comprising the amino acid sequence of SEQ ID NO:177, an LCDR2 comprising the amino acid sequence of SEQ ID NO:183, and an LCDR3 comprising the amino acid sequence of SEQ ID NO:200 (AB-62); - 58 - 3820371.v1 5708.1067001 an HCDR1 comprising the amino acid sequence of SEQ ID NO:125, an HCDR2 comprising the amino acid sequence of SEQ ID NO:149, an HCDR3 comprising the amino acid sequence of SEQ ID NO:171, an LCDR 1 comprising the amino acid sequence of SEQ ID NO:172, an LCDR2 comprising the amino acid sequence of SEQ ID NO:183, and an LCDR3 comprising the amino acid sequence of SEQ ID NO:194 (AB-63); an HCDR1 comprising the amino acid sequence of SEQ ID NO:126, an HCDR2 comprising the amino acid sequence of SEQ ID NO:150, an HCDR3 comprising the amino acid sequence of SEQ ID NO:165, an LCDR 1 comprising the amino acid sequence of SEQ ID NO:177, an LCDR2 comprising the amino acid sequence of SEQ ID NO:183, and an LCDR3 comprising the amino acid sequence of SEQ ID NO:200 (AB-64); an HCDR1 comprising the amino acid sequence of SEQ ID NO:118, an HCDR2 comprising the amino acid sequence of SEQ ID NO:139, an HCDR3 comprising the amino acid sequence of SEQ ID NO:227, an LCDR 1 comprising the amino acid sequence of SEQ ID NO:178, an LCDR2 comprising the amino acid sequence of SEQ ID NO:183, and an LCDR3 comprising the amino acid sequence of SEQ ID NO:194 (AB-66); an HCDR1 comprising the amino acid sequence of SEQ ID NO:118, an HCDR2 comprising the amino acid sequence of SEQ ID NO:147, an HCDR3 comprising the amino acid sequence of SEQ ID NO:227, an LCDR 1 comprising the amino acid sequence of SEQ ID NO:229, an LCDR2 comprising the amino acid sequence of SEQ ID NO:183, and an LCDR3 comprising the amino acid sequence of SEQ ID NO:194 (AB-67); an HCDR1 comprising the amino acid sequence of SEQ ID NO:126, an HCDR2 comprising the amino acid sequence of SEQ ID NO:150, an HCDR3 comprising the amino acid sequence of SEQ ID NO:171, an LCDR 1 comprising the amino acid sequence of SEQ ID NO:178, an LCDR2 comprising the amino acid sequence of SEQ ID NO:183, and an LCDR3 comprising the amino acid sequence of SEQ ID NO:200 (AB-68); an HCDR1 comprising the amino acid sequence of SEQ ID NO:118, an HCDR2 comprising the amino acid sequence of SEQ ID NO:139, an HCDR3 comprising the amino acid sequence of SEQ ID NO:170, an LCDR 1 comprising the amino acid sequence of SEQ ID NO:178, an LCDR2 comprising the amino acid sequence of SEQ ID NO:183, and an LCDR3 comprising the amino acid sequence of SEQ ID NO:194 (AB-69); an HCDR1 comprising the amino acid sequence of SEQ ID NO:118, an HCDR2 comprising the amino acid sequence of SEQ ID NO:148, an HCDR3 comprising the amino acid sequence of SEQ ID NO:165, an LCDR 1 comprising the amino acid sequence of SEQ - 59 - 3820371.v1 5708.1067001 ID NO:177, an LCDR2 comprising the amino acid sequence of SEQ ID NO:183, and an LCDR3 comprising the amino acid sequence of SEQ ID NO:200 (AB-70); an HCDR1 comprising the amino acid sequence of SEQ ID NO:118, an HCDR2 comprising the amino acid sequence of SEQ ID NO:142, an HCDR3 comprising the amino acid sequence of SEQ ID NO:227, an LCDR 1 comprising the amino acid sequence of SEQ ID NO:229, an LCDR2 comprising the amino acid sequence of SEQ ID NO:183, and an LCDR3 comprising the amino acid sequence of SEQ ID NO:194 (AB-71); an HCDR1 comprising the amino acid sequence of SEQ ID NO:118, an HCDR2 comprising the amino acid sequence of SEQ ID NO:147, an HCDR3 comprising the amino acid sequence of SEQ ID NO:170, an LCDR 1 comprising the amino acid sequence of SEQ ID NO:178, an LCDR2 comprising the amino acid sequence of SEQ ID NO:183, and an LCDR3 comprising the amino acid sequence of SEQ ID NO:200 (AB-72); an HCDR1 comprising the amino acid sequence of SEQ ID NO:118, an HCDR2 comprising the amino acid sequence of SEQ ID NO:147, an HCDR3 comprising the amino acid sequence of SEQ ID NO:170, an LCDR 1 comprising the amino acid sequence of SEQ ID NO:178, an LCDR2 comprising the amino acid sequence of SEQ ID NO:183, and an LCDR3 comprising the amino acid sequence of SEQ ID NO:200 (AB-73); or an HCDR1 comprising the amino acid sequence of SEQ ID NO:126, an HCDR2 comprising the amino acid sequence of SEQ ID NO:150, an HCDR3 comprising the amino acid sequence of SEQ ID NO:165, an LCDR 1 comprising the amino acid sequence of SEQ ID NO:177, an LCDR2 comprising the amino acid sequence of SEQ ID NO:183, and an LCDR3 comprising the amino acid sequence of SEQ ID NO:200 (AB-76). [0073] In some embodiments, a polypeptide comprises: an HCDR1 comprising the amino acid sequence of SEQ ID NO:118, an HCDR2 comprising the amino acid sequence of SEQ ID NO:147, an HCDR3 comprising the amino acid sequence of SEQ ID NO:227, an LCDR 1 comprising the amino acid sequence of SEQ ID NO:229, an LCDR2 comprising the amino acid sequence of SEQ ID NO:183, and an LCDR3 comprising the amino acid sequence of SEQ ID NO:200 (AB-65); an HCDR1 comprising the amino acid sequence of SEQ ID NO:118, an HCDR2 comprising the amino acid sequence of SEQ ID NO:148, an HCDR3 comprising the amino acid sequence of SEQ ID NO:228, an LCDR 1 comprising the amino acid sequence of SEQ ID NO:177, an LCDR2 comprising the amino acid sequence of SEQ ID NO:183, and an LCDR3 comprising the amino acid sequence of SEQ ID NO:200 (AB-75); or - 60 - 3820371.v1 5708.1067001 an HCDR1 comprising the amino acid sequence of SEQ ID NO:118, an HCDR2 comprising the amino acid sequence of SEQ ID NO:139, an HCDR3 comprising the amino acid sequence of SEQ ID NO:170, an LCDR 1 comprising the amino acid sequence of SEQ ID NO:178, an LCDR2 comprising the amino acid sequence of SEQ ID NO:183, and an LCDR3 comprising the amino acid sequence of SEQ ID NO:194 (AB-74). [0074] In some embodiments, a polypeptide comprises: a) an HCDR1 comprising the amino acid sequence of SEQ ID NO:118, an HCDR2 comprising the amino acid sequence of SEQ ID NO:147, and an HCDR3 comprising the amino acid sequence of SEQ ID NO:227; and b) an LCDR 1 comprising the amino acid sequence of SEQ ID NO:229, an LCDR2 comprising the amino acid sequence of SEQ ID NO:183, and an LCDR3 comprising the amino acid sequence of SEQ ID NO:200 (AB-65). [0075] In some embodiments, a polypeptide comprises: a) an HCDR1 comprising the amino acid sequence of SEQ ID NO:118, an HCDR2 comprising the amino acid sequence of SEQ ID NO:148, and an HCDR3 comprising the amino acid sequence of SEQ ID NO:228; and b) an LCDR 1 comprising the amino acid sequence of SEQ ID NO:177, an LCDR2 comprising the amino acid sequence of SEQ ID NO:183, and an LCDR3 comprising the amino acid sequence of SEQ ID NO:200 (AB-75). [0076] In some embodiments, a polypeptide comprises: a) an HCDR1 comprising the amino acid sequence of SEQ ID NO:118, an HCDR2 comprising the amino acid sequence of SEQ ID NO:139, and an HCDR3 comprising the amino acid sequence of SEQ ID NO:170, and b) an LCDR 1 comprising the amino acid sequence of SEQ ID NO:178, an LCDR2 comprising the amino acid sequence of SEQ ID NO:183, and an LCDR3 comprising the amino acid sequence of SEQ ID NO:194 (AB-74). [0077] In some embodiments, the disclosure provides a polypeptide that specifically binds PD-1, comprising a VH comprising: a) the amino acid sequence of SEQ ID NO:2, wherein: X 1 is L or F; X2 is G, A, S, T or P; X 3 is V, F or absent; X 4 is S or absent; - 61 - 3820371.v1 5708.1067001 X5 is S, G, N or absent; X6 is F, D, I, T, S or V; X 7 is A, S, R, N or K; X8 is A, H or T; X9 is M or I; X 10 is S or G; X 11 is S or G; X12 is S or G; X 13 is G, D, A, R, E or T; X 14 is H, D, A, S or N; X15 is A or I; X16 is H, A, I, Y or V; X 17 is S or D; X18 is Y, T or H; or X19 is A, Y or T, or any combination of the foregoing; or b) the amino acid sequence of SEQ ID NO:18, wherein: X1 is V or E; X 2 is L or I; X 3 is V or A; X4 is G or S; X 5 is H, Q or L; X 6 is P or L; X7 is T or A; X8 is F, G or S; X 9 is G, D or S; X10 is Y, S or A; X11 is T, Y or A; X 12 is L or I; X 13 is K, R or E; X14 is V or M; X 15 is V, T or I; X 16 is K, R, T or S; - 62 - 3820371.v1 5708.1067001 X17 is C, G, Q or S; X18 is K, G or S; X 19 is G or S; X20 is C or Y; X21 is V or F; X 22 is V or G; X 23 is R or T; X24 is R, T or A; X 25 is K, R or N; X 26 is D or N; X27 is C or Y; X28 is H, Q or E; X 29 is P or L; X30 is V, E or A; X31 is S or E; X 32 is Y or T; X 33 is N, S, Q, T or absent; X34 is S or absent; X 35 is S or absent; X 36 is D, S or absent; X37 is V, T, I or absent; X 38 is Y or absent X 39 is Y, T or N; X40 is D or A; X41 is Y, S or A; X 42 is K or Q; X43 is V or I; X44 is V or I; or X 45 is S or absent, or any combination of the foregoing. [0078] The sequences identified as SEQ ID NO:2 and SEQ ID NO:18 are shown in Table 4. SEQ ID NO:2 is a consensus V H sequence for SEQ ID Nos:3-17 disclosed herein, and SEQ ID NO:18 is a consensus V H sequence for SEQ ID Nos:19-58 disclosed herein. - 63 - 3820371.v1 5708.1067001 [0079] In some embodiments, polypeptides disclosed herein further comprise a VL. In some embodiments, the polypeptide comprises a VL comprising: a) the amino acid sequence of SEQ ID NO:59, wherein: X20 is H, Q, A, S, Y, R or K; or X21 is A, S, T or G, or any combination of the foregoing; or b) the amino acid sequence of SEQ ID NO:70, wherein: X46 is V, I or F; X 47 is V, K, T, M, R or L; X 48 is P or T; X49 is P or Q; X50 is P, F or S; X 51 is P or S; X52 is V or L; X53 is H or Q; X 54 is D, G or Y; X 55 is D, T or N; X56 is C, Y or A; X 57 is K or E; X 58 is M, T, I or S; X59 is Y or S; X 60 is R, G, S or D; X 61 is R or S; X62 is Y, I or F; X63 is Y or S; X 64 is V, R or T; X65 is T or S; X66 is T or I; X 67 is H or Q; X 68 is H, F or Y; X69 is C or Y; X 70 is T or S; X 71 is Y, T or W; - 64 - 3820371.v1 5708.1067001 X72 is P or A; or X73 is L or Y, or any combination of the foregoing. [0080] The sequences identified as SEQ ID NO:59 and SEQ ID NO:70 are shown in Table 5, SEQ ID NO:59 is a consensus VL sequence for SEQ ID Nos:60-69 herein, and SEQ ID NO:70 is a consensus V L sequence for SEQ ID Nos:71-106 herein. [0081] In some embodiments, the disclosure provides a polypeptide that specifically binds PD-1, comprising a VH comprising the amino acid sequence of SEQ ID NO:2, wherein: X 1 is L or F; X 2 is G, A, S, T or P; X3 is V, F or absent; X4 is S or absent; X 5 is S, G, N or absent; X6 is F, D, I, T, S or V; X7 is A, S, R, N or K; X 8 is A, H or T; X 9 is M or I; X10 is S or G; X 11 is S or G; X 12 is S or G; X13 is G, D, A, R, E or T; X 14 is H, D, A, S or N; X 15 is A or I; X16 is H, A, I, Y or V; X17 is S or D; X 18 is Y, T or H; or X19 is A, Y or T, or any combination of the foregoing. [0082] In some embodiments, polypeptides disclosed herein further a V L comprising the amino acid sequence of SEQ ID NO:59, wherein: X20 is H, Q, A, S, Y, R or K; or X 21 is A, S, T or G, or any combination of the foregoing. - 65 - 3820371.v1 5708.1067001 [0083] In some embodiments, the disclosure provides a polypeptide that specifically binds PD-1, comprising a VH comprising the amino acid sequence of SEQ ID NO:18, wherein: X1 is V or E; X2 is L or I; X 3 is V or A; X 4 is G or S; X5 is H, Q or L; X 6 is P or L; X 7 is T or A; X8 is F, G or S; X9 is G, D or S; X 10 is Y, S or A; X11 is T, Y or A; X12 is L or I; X 13 is K, R or E; X 14 is V or M; X15 is V, T or I; X 16 is K, R, T or S; X 17 is C, G, Q or S; X18 is K, G or S; X 19 is G or S; X 20 is C or Y; X21 is V or F; X22 is V or G; X 23 is R or T; X24 is R, T or A; X25 is K, R or N; X 26 is D or N; X 27 is C or Y; X28 is H, Q or E; X 29 is P or L; X 30 is V, E or A; - 66 - 3820371.v1 5708.1067001 X31 is S or E; X32 is Y or T; X 33 is N, S, Q, T or absent; X34 is S or absent; X35 is S or absent; X 36 is D, S or absent; X 37 is V, T, I or absent; X38 is Y or absent X 39 is Y, T or N; X 40 is D or A; X41 is Y, S or A; X42 is K or Q; X 43 is V or I; X44 is V or I; or X45 is S or absent, or any combination of the foregoing. [0084] In some embodiments, polypeptides disclosed herein comprises a V L comprising the amino acid sequence of SEQ ID NO:70, wherein: X 46 is V, I or F; X 47 is V, K, T, M, R or L; X48 is P or T; X 49 is P or Q; X 50 is P, F or S; X51 is P or S; X52 is V or L; X 53 is H or Q; X54 is D, G or Y; X55 is D, T or N; X 56 is C, Y or A; X 57 is K or E; X58 is M, T, I or S; X 59 is Y or S; X 60 is R, G, S or D; - 67 - 3820371.v1 5708.1067001 X61 is R or S; X62 is Y, I or F; X 63 is Y or S; X64 is V, R or T; X65 is T or S; X 66 is T or I; X 67 is H or Q; X68 is H, F or Y; X 69 is C or Y; X 70 is T or S; X71 is Y, T or W; X72 is P or A; or X 73 is L or Y, or any combination of the foregoing. [0085] In some embodiments, a polypeptide disclosed herein comprises a VH that comprises an HCDR1, an HCDR2 and an HCDR3 that are substantially similar in amino acid sequence to an HCDR1, an HCDR2 and an HCDR3, respectively, of a V H amino acid sequence set forth in any of SEQ ID NOs:3-17, SEQ ID NOs:19-58, and SEQ ID NOs:206- 216 (see Table 4 for SEQ ID NOs:3-17, SEQ ID NOs:19-58, and SEQ ID NOs:206-216, and Table 6 for non-limiting examples of corresponding HCDR1, HCDR2 and HCDR3 sequences). [0086] In some embodiments, a polypeptide comprises a V H that comprises an HCDR1, an HCDR2 and an HCDR3 that are substantially similar in amino acid sequence to an HCDR1, an HCDR2 and an HCDR3, respectively, of a VH amino acid sequence set forth in any one of SEQ ID NO:206, SEQ ID NO:215 and SEQ ID NO:214. In some embodiments, a polypeptide comprises a V H that comprises an HCDR1, an HCDR2 and an HCDR3 that are substantially similar in amino acid sequence to an HCDR1, an HCDR2 and an HCDR3, respectively, of a VH amino acid sequence set forth in SEQ ID NO:206. In some embodiments, a polypeptide comprises a V H that comprises an HCDR1, an HCDR2 and an HCDR3 that are substantially similar in amino acid sequence to an HCDR1, an HCDR2 and an HCDR3, respectively, of a VH amino acid sequence set forth in SEQ ID NO:215. In some embodiments, a polypeptide comprises a V H that comprises an HCDR1, an HCDR2 and an - 68 - 3820371.v1 5708.1067001 HCDR3 that are substantially similar in amino acid sequence to an HCDR1, an HCDR2 and an HCDR3, respectively, of a VH amino acid sequence set forth in SEQ ID NO:214. [0087] In some embodiments, a polypeptide disclosed herein comprises a V L that comprises an LCDR1, an LCDR2 and an LCDR3 that are substantially similar in amino acid sequence to an LCDR1, an LCDR2 and an LCDR3, respectively, of a VL amino acid sequence set forth in any of SEQ ID NOs:60-69, SEQ ID NOs:71-106, and SEQ ID NOs:217-226 (see Table 5 for SEQ ID NOs:60-69, SEQ ID NOs:71-106, and SEQ ID NOs:217-226, and Table 6 for non-limiting examples of corresponding LCDR1, LCDR2 and LCDR3 sequences). [0088] In some embodiments, a polypeptide comprises a V L that comprises an LCDR1, an LCDR2 and an LCDR3 that are substantially similar in amino acid sequence to an LCDR1, an LCDR2 and an LCDR3, respectively, of a VL amino acid sequence set forth in any one of SEQ ID NO:217, SEQ ID NO:104 and SEQ ID NO:226. In some embodiments, a polypeptide comprises a VL that comprises an LCDR1, an LCDR2 and an LCDR3 that are substantially similar in amino acid sequence to an LCDR1, an LCDR2 and an LCDR3, respectively, of a V L amino acid sequence set forth in SEQ ID NO:217. In some embodiments, a polypeptide comprises a V L that comprises an LCDR1, an LCDR2 and an LCDR3 that are substantially similar in amino acid sequence to an LCDR1, an LCDR2 and an LCDR3, respectively, of a V L amino acid sequence set forth in SEQ ID NO:104. In some embodiments, a polypeptide comprises a V L that comprises an LCDR1, an LCDR2 and an LCDR3 that are substantially similar in amino acid sequence to an LCDR1, an LCDR2 and an LCDR3, respectively, of a V L amino acid sequence set forth in SEQ ID NO:226. [0089] In some embodiments, a polypeptide disclosed herein comprises a V H that comprises an HCDR1, an HCDR2 and an HCDR3 that are identical in amino acid sequence to an HCDR1, an HCDR2 and an HCDR3, respectively, of a VH amino acid sequence set forth in any of SEQ ID NOs:3-17, SEQ ID NOs:19-58, and SEQ ID NOs:206-216 (see Table 4 for SEQ ID NOs:3-17, SEQ ID NOs:19-58, and SEQ ID NOs:206-216, and Table 6 for non-limiting examples of corresponding HCDR1, HCDR2 and HCDR3 sequences). [0090] In some embodiments, a polypeptide comprises a V H that comprises an HCDR1, an HCDR2 and an HCDR3 that are identical in amino acid sequence to an HCDR1, an HCDR2 and an HCDR3, respectively, of a VH amino acid sequence set forth in any one of SEQ ID NO:206, SEQ ID NO:215 and SEQ ID NO:214. In some embodiments, a polypeptide comprises a V H that comprises an HCDR1, an HCDR2 and an HCDR3 that are - 69 - 3820371.v1 5708.1067001 identical in amino acid sequence to an HCDR1, an HCDR2 and an HCDR3, respectively, of a VH amino acid sequence set forth in SEQ ID NO:206. In some embodiments, a polypeptide comprises a V H that comprises an HCDR1, an HCDR2 and an HCDR3 that are identical in amino acid sequence to an HCDR1, an HCDR2 and an HCDR3, respectively, of a VH amino acid sequence set forth in SEQ ID NO:215. In some embodiments, a polypeptide comprises a V H that comprises an HCDR1, an HCDR2 and an HCDR3 that are identical in amino acid sequence to an HCDR1, an HCDR2 and an HCDR3, respectively, of a V H amino acid sequence set forth in SEQ ID NO:214. [0091] In some embodiments, a polypeptide disclosed herein comprises a V L that comprises an LCDR1, an LCDR2 and an LCDR3 that are identical in amino acid sequence to an LCDR1, an LCDR2 and an LCDR3, respectively, of a VL amino acid sequence set forth in any of SEQ ID NOs:60-69, SEQ ID NOs:71-106, and SEQ ID NOs:217-226 (see Table 5 for SEQ ID NOs:60-69, SEQ ID NOs:71-106, and SEQ ID NOs:217-226, and Table 6 for non- limiting examples of corresponding LCDR1, LCDR2 and LCDR3 sequences). [0092] In some embodiments, a polypeptide comprises a VL that comprises an LCDR1, an LCDR2 and an LCDR3 that are identical in amino acid sequence to an LCDR1, an LCDR2 and an LCDR3, respectively, of a V L amino acid sequence set forth in any one of SEQ ID NO:217, SEQ ID NO:104 and SEQ ID NO:226. In some embodiments, a polypeptide comprises a V L that comprises an LCDR1, an LCDR2 and an LCDR3 that are identical in amino acid sequence to an LCDR1, an LCDR2 and an LCDR3, respectively, of a VL amino acid sequence set forth in SEQ ID NO:217. In some embodiments, a polypeptide comprises a V L that comprises an LCDR1, an LCDR2 and an LCDR3 that are identical in amino acid sequence to an LCDR1, an LCDR2 and an LCDR3, respectively, of a V L amino acid sequence set forth in SEQ ID NO:104. In some embodiments, a polypeptide comprises a VL that comprises an LCDR1, an LCDR2 and an LCDR3 that are identical in amino acid sequence to an LCDR1, an LCDR2 and an LCDR3, respectively, of a V L amino acid sequence set forth in SEQ ID NO:226. [0093] In some embodiments, a polypeptide disclosed herein comprises a paratope that is substantially similar to a paratope of a V H/ V L combination selected from: a) SEQ ID NO:206/SEQ ID NO:217 (AB-65), SEQ ID NO:215/SEQ ID NO:104 (AB-75), SEQ ID NO:214/SEQ ID NO:226 (AB-74), SEQ ID NO:207/SEQ ID NO:218 (AB-66), SEQ ID NO:208/SEQ ID NO:219 (AB-67), SEQ ID NO:209/SEQ ID NO:220 (AB-68), SEQ ID NO:53/SEQ ID NO:221 (AB-69), - 70 - 3820371.v1 5708.1067001 SEQ ID NO:210/SEQ ID NO:222 (AB-70), SEQ ID NO:211/SEQ ID NO:223 (AB-71), SEQ ID NO:212/SEQ ID NO:224 (AB-72), SEQ ID NO:213/SEQ ID NO:225 (AB-73), or SEQ ID NO:216/SEQ ID NO:106 (AB-76); b) SEQ ID NO:3/SEQ ID NO:60 (AB-1), SEQ ID NO:4/SEQ ID NO:61 (AB-2), SEQ ID NO:5/SEQ ID NO:62 (AB-3), SEQ ID NO:3/SEQ ID NO:63 (AB-4), SEQ ID NO:6/SEQ ID NO:64 (AB-5), SEQ ID NO:7/SEQ ID NO:65 (AB-6); SEQ ID NO:8/SEQ ID NO:66 (AB-7), SEQ ID NO:9/SEQ ID NO:60 (AB-8); SEQ ID NO:10/SEQ ID NO:67 (AB-9), SEQ ID NO:11/SEQ ID NO:64 (AB- 10), SEQ ID NO:3/SEQ ID NO:68 (AB-11); SEQ ID NO:12/SEQ ID NO:60 (AB-12); SEQ ID NO:13/SEQ ID NO:68 (AB-13); SEQ ID NO:14/SEQ ID NO:69 (AB-14), SEQ ID NO:15/SEQ ID NO:64 (AB-15), SEQ ID NO:16/SEQ ID NO:60 (AB-16), or SEQ ID NO:17/SEQ ID NO:65 (AB-17); or c) SEQ ID NO:19/SEQ ID NO:71 (AB-18), SEQ ID NO:20/SEQ ID NO:72 (AB-19), SEQ ID NO:21/SEQ ID NO:71 (AB-20), SEQ ID NO:22/SEQ ID NO:73 (AB-21), SEQ ID NO:23/SEQ ID NO:71 (AB-22), SEQ ID NO:24/SEQ ID NO:74 (AB-23), SEQ ID NO:21/SEQ ID NO:75 (AB-24), SEQ ID NO:21/SEQ ID NO:76 (AB-25), SEQ ID NO:21/SEQ ID NO:71 (AB-26), SEQ ID NO:25/SEQ ID NO:71 (AB-27), SEQ ID NO:26/SEQ ID NO:71 (AB-28), SEQ ID NO:27/SEQ ID NO:77 (AB-29), SEQ ID NO:28/SEQ ID NO:78 (AB-30), SEQ ID NO:29/SEQ ID NO:79 (AB-31), SEQ ID NO:30/SEQ ID NO:80 (AB-32), SEQ ID NO:31/SEQ ID NO:81 (AB-33), SEQ ID NO:28/SEQ ID NO:82 (AB-34), SEQ ID NO:23/SEQ ID NO:80 (AB-35), SEQ ID NO:32/SEQ ID NO:80 (AB-36), SEQ ID NO:33/SEQ ID NO:83 (AB-37), SEQ ID NO:34/SEQ ID NO:84 (AB-38), SEQ ID NO:35/SEQ ID NO:85 (AB-39), SEQ ID NO:23/SEQ ID NO:86 (AB-40), SEQ ID NO:36/SEQ ID NO:87 (AB-41), SEQ ID NO:37/SEQ ID NO:88 (AB-42), SEQ ID NO:38/SEQ ID NO:89 (AB-43); SEQ ID NO:39/SEQ ID NO:80 (AB-44), SEQ ID NO:40/SEQ ID NO:90 (AB-45); SEQ ID NO:41/SEQ ID NO:91 (AB-46), SEQ ID NO:42/SEQ ID NO:92 (AB-47), SEQ ID NO:43/SEQ ID NO:93 (AB-48), SEQ ID NO:44/SEQ ID NO:94 (AB-49); SEQ ID NO:45/SEQ ID NO:80 (AB-50), SEQ ID NO:46/SEQ ID NO:95 (AB-51); SEQ ID NO:47/SEQ ID NO:96 (AB-52), - 71 - 3820371.v1 5708.1067001 SEQ ID NO:48/SEQ ID NO:97 (AB-53); SEQ ID NO:49/SEQ ID NO:98 (AB-54), SEQ ID NO:50/SEQ ID NO:84 (AB-55); SEQ ID NO:51/SEQ ID NO:99 (AB-56), SEQ ID NO:35/SEQ ID NO:83 (AB-57), SEQ ID NO:52/SEQ ID NO:100 (AB-58), SEQ ID NO:53/SEQ ID NO:101 (AB-59); SEQ ID NO:54/SEQ ID NO:102 (AB-60), SEQ ID NO:55/SEQ ID NO:103 (AB-61); SEQ ID NO:56/SEQ ID NO:104 (AB-62); SEQ ID NO:57/SEQ ID NO:105 (AB-63), or SEQ ID NO:58/SEQ ID NO:106 (AB-64). [0094] In some embodiments, a polypeptide disclosed herein comprises a paratope that is identical to a paratope of a V H/ V L combination selected from: a) SEQ ID NO:206/SEQ ID NO:217 (AB-65), SEQ ID NO:215/SEQ ID NO:104 (AB-75), SEQ ID NO:214/SEQ ID NO:226 (AB-74), SEQ ID NO:207/SEQ ID NO:218 (AB-66), SEQ ID NO:208/SEQ ID NO:219 (AB-67), SEQ ID NO:209/SEQ ID NO:220 (AB-68), SEQ ID NO:53/SEQ ID NO:221 (AB-69), SEQ ID NO:210/SEQ ID NO:222 (AB-70), SEQ ID NO:211/SEQ ID NO:223 (AB-71), SEQ ID NO:212/SEQ ID NO:224 (AB-72), SEQ ID NO:213/SEQ ID NO:225 (AB-73), or SEQ ID NO:216/SEQ ID NO:106 (AB-76); b) SEQ ID NO:3/SEQ ID NO:60 (AB-1), SEQ ID NO:4/SEQ ID NO:61 (AB-2), SEQ ID NO:5/SEQ ID NO:62 (AB-3), SEQ ID NO:3/SEQ ID NO:63 (AB-4), SEQ ID NO:6/SEQ ID NO:64 (AB-5), SEQ ID NO:7/SEQ ID NO:65 (AB-6); SEQ ID NO:8/SEQ ID NO:66 (AB-7), SEQ ID NO:9/SEQ ID NO:60 (AB-8); SEQ ID NO:10/SEQ ID NO:67 (AB-9), SEQ ID NO:11/SEQ ID NO:64 (AB- 10), SEQ ID NO:3/SEQ ID NO:68 (AB-11); SEQ ID NO:12/SEQ ID NO:60 (AB-12); SEQ ID NO:13/SEQ ID NO:68 (AB-13); SEQ ID NO:14/SEQ ID NO:69 (AB-14), SEQ ID NO:15/SEQ ID NO:64 (AB-15), SEQ ID NO:16/SEQ ID NO:60 (AB-16), or SEQ ID NO:17/SEQ ID NO:65 (AB-17); or c) SEQ ID NO:19/SEQ ID NO:71 (AB-18), SEQ ID NO:20/SEQ ID NO:72 (AB-19), SEQ ID NO:21/SEQ ID NO:71 (AB-20), SEQ ID NO:22/SEQ ID NO:73 (AB-21), SEQ ID NO:23/SEQ ID NO:71 (AB-22), SEQ ID NO:24/SEQ ID NO:74 (AB-23), SEQ ID NO:21/SEQ ID NO:75 (AB-24), SEQ ID NO:21/SEQ ID NO:76 (AB-25), SEQ ID NO:21/SEQ ID NO:71 (AB-26), SEQ ID NO:25/SEQ ID NO:71 (AB-27), SEQ ID NO:26/SEQ ID NO:71 (AB-28), SEQ ID NO:27/SEQ ID NO:77 (AB-29), SEQ ID - 72 - 3820371.v1 5708.1067001 NO:28/SEQ ID NO:78 (AB-30), SEQ ID NO:29/SEQ ID NO:79 (AB-31), SEQ ID NO:30/SEQ ID NO:80 (AB-32), SEQ ID NO:31/SEQ ID NO:81 (AB-33), SEQ ID NO:28/SEQ ID NO:82 (AB-34), SEQ ID NO:23/SEQ ID NO:80 (AB-35), SEQ ID NO:32/SEQ ID NO:80 (AB-36), SEQ ID NO:33/SEQ ID NO:83 (AB-37), SEQ ID NO:34/SEQ ID NO:84 (AB-38), SEQ ID NO:35/SEQ ID NO:85 (AB-39), SEQ ID NO:23/SEQ ID NO:86 (AB-40), SEQ ID NO:36/SEQ ID NO:87 (AB-41), SEQ ID NO:37/SEQ ID NO:88 (AB-42), SEQ ID NO:38/SEQ ID NO:89 (AB-43); SEQ ID NO:39/SEQ ID NO:80 (AB-44), SEQ ID NO:40/SEQ ID NO:90 (AB-45); SEQ ID NO:41/SEQ ID NO:91 (AB-46), SEQ ID NO:42/SEQ ID NO:92 (AB-47), SEQ ID NO:43/SEQ ID NO:93 (AB-48), SEQ ID NO:44/SEQ ID NO:94 (AB-49); SEQ ID NO:45/SEQ ID NO:80 (AB-50), SEQ ID NO:46/SEQ ID NO:95 (AB-51); SEQ ID NO:47/SEQ ID NO:96 (AB-52), SEQ ID NO:48/SEQ ID NO:97 (AB-53); SEQ ID NO:49/SEQ ID NO:98 (AB-54), SEQ ID NO:50/SEQ ID NO:84 (AB-55); SEQ ID NO:51/SEQ ID NO:99 (AB-56), SEQ ID NO:35/SEQ ID NO:83 (AB-57), SEQ ID NO:52/SEQ ID NO:100 (AB-58), SEQ ID NO:53/SEQ ID NO:101 (AB-59); SEQ ID NO:54/SEQ ID NO:102 (AB-60), SEQ ID NO:55/SEQ ID NO:103 (AB-61); SEQ ID NO:56/SEQ ID NO:104 (AB-62); SEQ ID NO:57/SEQ ID NO:105 (AB-63), or SEQ ID NO:58/SEQ ID NO:106 (AB-64). [0095] In some embodiments, a polypeptide disclosed herein comprises a paratope that differs from a paratope of a V H/ V L combination selected from: a) SEQ ID NO:206/SEQ ID NO:217 (AB-65), SEQ ID NO:215/SEQ ID NO:104 (AB-75), SEQ ID NO:214/SEQ ID NO:226 (AB-74), SEQ ID NO:207/SEQ ID NO:218 (AB-66), SEQ ID NO:208/SEQ ID NO:219 (AB-67), SEQ ID NO:209/SEQ ID NO:220 (AB-68), SEQ ID NO:53/SEQ ID NO:221 (AB-69), SEQ ID NO:210/SEQ ID NO:222 (AB-70), SEQ ID NO:211/SEQ ID NO:223 (AB-71), SEQ ID NO:212/SEQ ID NO:224 (AB-72), SEQ ID NO:213/SEQ ID NO:225 (AB-73), or SEQ ID NO:216/SEQ ID NO:106 (AB-76), b) SEQ ID NO:3/SEQ ID NO:60 (AB-1), SEQ ID NO:4/SEQ ID NO:61 (AB-2), SEQ ID NO:5/SEQ ID NO:62 (AB-3), SEQ ID NO:3/SEQ ID NO:63 (AB-4), SEQ ID NO:6/SEQ ID NO:64 (AB-5), SEQ ID NO:7/SEQ ID NO:65 (AB-6); SEQ ID NO:8/SEQ ID NO:66 (AB-7), SEQ ID NO:9/SEQ ID NO:60 (AB-8); - 73 - 3820371.v1 5708.1067001 SEQ ID NO:10/SEQ ID NO:67 (AB-9), SEQ ID NO:11/SEQ ID NO:64 (AB- 10), SEQ ID NO:3/SEQ ID NO:68 (AB-11); SEQ ID NO:12/SEQ ID NO:60 (AB-12); SEQ ID NO:13/SEQ ID NO:68 (AB-13); SEQ ID NO:14/SEQ ID NO:69 (AB-14), SEQ ID NO:15/SEQ ID NO:64 (AB-15), SEQ ID NO:16/SEQ ID NO:60 (AB-16), or SEQ ID NO:17/SEQ ID NO:65 (AB-17); or c) SEQ ID NO:19/SEQ ID NO:71 (AB-18), SEQ ID NO:20/SEQ ID NO:72 (AB-19), SEQ ID NO:21/SEQ ID NO:71 (AB-20), SEQ ID NO:22/SEQ ID NO:73 (AB-21), SEQ ID NO:23/SEQ ID NO:71 (AB-22), SEQ ID NO:24/SEQ ID NO:74 (AB-23), SEQ ID NO:21/SEQ ID NO:75 (AB-24), SEQ ID NO:21/SEQ ID NO:76 (AB-25), SEQ ID NO:21/SEQ ID NO:71 (AB-26), SEQ ID NO:25/SEQ ID NO:71 (AB-27), SEQ ID NO:26/SEQ ID NO:71 (AB-28), SEQ ID NO:27/SEQ ID NO:77 (AB-29), SEQ ID NO:28/SEQ ID NO:78 (AB-30), SEQ ID NO:29/SEQ ID NO:79 (AB-31), SEQ ID NO:30/SEQ ID NO:80 (AB-32), SEQ ID NO:31/SEQ ID NO:81 (AB-33), SEQ ID NO:28/SEQ ID NO:82 (AB-34), SEQ ID NO:23/SEQ ID NO:80 (AB-35), SEQ ID NO:32/SEQ ID NO:80 (AB-36), SEQ ID NO:33/SEQ ID NO:83 (AB-37), SEQ ID NO:34/SEQ ID NO:84 (AB-38), SEQ ID NO:35/SEQ ID NO:85 (AB-39), SEQ ID NO:23/SEQ ID NO:86 (AB-40), SEQ ID NO:36/SEQ ID NO:87 (AB-41), SEQ ID NO:37/SEQ ID NO:88 (AB-42), SEQ ID NO:38/SEQ ID NO:89 (AB-43); SEQ ID NO:39/SEQ ID NO:80 (AB-44), SEQ ID NO:40/SEQ ID NO:90 (AB-45); SEQ ID NO:41/SEQ ID NO:91 (AB-46), SEQ ID NO:42/SEQ ID NO:92 (AB-47), SEQ ID NO:43/SEQ ID NO:93 (AB-48), SEQ ID NO:44/SEQ ID NO:94 (AB-49); SEQ ID NO:45/SEQ ID NO:80 (AB-50), SEQ ID NO:46/SEQ ID NO:95 (AB-51); SEQ ID NO:47/SEQ ID NO:96 (AB-52), SEQ ID NO:48/SEQ ID NO:97 (AB-53); SEQ ID NO:49/SEQ ID NO:98 (AB-54), SEQ ID NO:50/SEQ ID NO:84 (AB-55); SEQ ID NO:51/SEQ ID NO:99 (AB-56), SEQ ID NO:35/SEQ ID NO:83 (AB-57), SEQ ID NO:52/SEQ ID NO:100 (AB-58), SEQ ID NO:53/SEQ ID NO:101 (AB-59); SEQ ID NO:54/SEQ ID NO:102 (AB-60), SEQ ID NO:55/SEQ ID NO:103 (AB-61); SEQ ID NO:56/SEQ ID NO:104 (AB-62); SEQ ID NO:57/SEQ ID NO:105 (AB-63), or SEQ ID NO:58/SEQ ID NO:106 (AB-64), - 74 - 3820371.v1 5708.1067001 by substitution (e.g., conservative such as highly conservative substitution) of from 1 to 3 (e.g., 1, 2 or 3) residues. [0096] In some embodiments, a polypeptide disclosed herein comprises a V H that has at least about 70% sequence identity to the amino acid sequence of a VH amino acid sequence set forth in any of SEQ ID NOs:3-17, SEQ ID NOs:19-58, and SEQ ID NOs:206-216. For example, the V H can have at least about: 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% sequence identity to the amino acid sequence of a VH amino acid sequence set forth in any of SEQ ID NOs:3-17, SEQ ID NOs:19-58, and SEQ ID NOs:206- 216. In some embodiments, the V H has at least about 85% or at least about 90% sequence identity to the amino acid sequence of a VH amino acid sequence set forth in any of SEQ ID NOs:3-17, SEQ ID NOs:19-58, and SEQ ID NOs:206-216. [0097] In some embodiments, a polypeptide comprises a V H that has at least about 70% sequence identity to the amino acid sequence of a VH amino acid sequence set forth in any one of SEQ ID NO:206, SEQ ID NO:215, and SEQ ID NO:214. For example, the VH can have at least about: 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% sequence identity to the amino acid sequence of a VH amino acid sequence set forth in any one of SEQ ID NO:206, SEQ ID NO:215, and SEQ ID NO:214. In some embodiments, the V H has at least about 85% or at least about 90% sequence identity to the amino acid sequence of a VH amino acid sequence set forth in any one of SEQ ID NO:206, SEQ ID NO:215, and SEQ ID NO:214. [0098] In some embodiments, a polypeptide disclosed herein comprises a V H that has at least about 70% sequence identity to the amino acid sequence of a VH amino acid sequence set forth in SEQ ID NO:206. For example, the VH can have at least about: 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% sequence identity to the amino acid sequence of a VH amino acid sequence set forth in SEQ ID NO:206. In some embodiments, the V H has at least about 85% or at least about 90% sequence identity to the amino acid sequence of a V H amino acid sequence set forth in SEQ ID NO:206. [0099] In some embodiments, a polypeptide disclosed herein comprises a VH that has at least about 70% sequence identity to the amino acid sequence of a V H amino acid sequence set forth in SEQ ID NO:215. For example, the V H can have at least about: 71%, 72%, 73%, - 75 - 3820371.v1 5708.1067001 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% sequence identity to the amino acid sequence of a V H amino acid sequence set forth in SEQ ID NO:215. In some embodiments, the VH has at least about 85% or at least about 90% sequence identity to the amino acid sequence of a VH amino acid sequence set forth in SEQ ID NO:215. [00100] In some embodiments, a polypeptide disclosed herein comprises a V H that has at least about 70% sequence identity to the amino acid sequence of a V H amino acid sequence set forth in SEQ ID NO:214. For example, the VH can have at least about: 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% sequence identity to the amino acid sequence of a VH amino acid sequence set forth in SEQ ID NO:214. In some embodiments, the VH has at least about 85% or at least about 90% sequence identity to the amino acid sequence of a V H amino acid sequence set forth in SEQ ID NO:214. [00101] In some embodiments, a polypeptide disclosed herein comprises a VL that has at least about 70% sequence identity to the amino acid sequence of a VL amino acid sequence set forth in any of SEQ ID NOs:60-69, SEQ ID NOs:71-106, and SEQ ID NOs:217-226. For example, the V L can be at least about: 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% sequence identity to the amino acid sequence of a V L amino acid sequence set forth in any of SEQ ID NOs:60-69, SEQ ID NOs:71-106, and SEQ ID NOs:217-226. In some embodiments, the VL has at least about 85% or at least about 90% sequence identity to the amino acid sequence of a V L amino acid sequence set forth in any of SEQ ID NOs:60-69, SEQ ID NOs:71-106, and SEQ ID NOs:217-226. [00102] In some embodiments, a polypeptide comprises a VL that has at least about 70% sequence identity to the amino acid sequence of a VL amino acid sequence set forth in any one of SEQ ID NO:217, SEQ ID NO:104, and SEQ ID NO:226. For example, the V L can be at least about: 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% sequence identity to the amino acid sequence of a V L amino acid sequence set forth in any one of SEQ ID NO:217, SEQ ID NO:104, and SEQ ID NO:226. In some embodiments, the VL has at least about 85% or at least about 90% sequence identity to the amino acid sequence of a V L amino acid sequence set forth in any one of SEQ ID NO:217, SEQ ID NO:104, and SEQ ID NO:226. - 76 - 3820371.v1 5708.1067001 [00103] In some embodiments, a polypeptide comprises a VL that has at least about 70% sequence identity to the amino acid sequence of a VL amino acid sequence set forth in SEQ ID NO:217. For example, the V L can be at least about: 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% sequence identity to the amino acid sequence of a V L amino acid sequence set forth in SEQ ID NO:217. In some embodiments, the V L has at least about 85% or at least about 90% sequence identity to the amino acid sequence of a V L amino acid sequence set forth in SEQ ID NO:217. [00104] In some embodiments, a polypeptide comprises a V L that has at least about 70% sequence identity to the amino acid sequence of a V L amino acid sequence set forth in SEQ ID NO:104. For example, the VL can be at least about: 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% sequence identity to the amino acid sequence of a VL amino acid sequence set forth in SEQ ID NO:104. In some embodiments, the VL has at least about 85% or at least about 90% sequence identity to the amino acid sequence of a VL amino acid sequence set forth in SEQ ID NO:104. [00105] In some embodiments, a polypeptide comprises a V L that has at least about 70% sequence identity to the amino acid sequence of a VL amino acid sequence set forth in SEQ ID NO:226. For example, the V L can be at least about: 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% sequence identity to the amino acid sequence of a V L amino acid sequence set forth in SEQ ID NO:226. In some embodiments, the V L has at least about 85% or at least about 90% sequence identity to the amino acid sequence of a V L amino acid sequence set forth in SEQ ID NO:226. [00106] In some embodiments, a polypeptide disclosed herein comprises a VH that comprises at least 1 amino acid substitution relative to the amino acid sequence of a V H amino acid sequence set forth in any of SEQ ID NOs:3-17, SEQ ID NOs:19-58, and SEQ ID NOs:206-216. For example, the number of amino acid substitutions can be at least about: 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19 or 20, or about: 1-20, 1-19, 2-19, 2-18, 2-17, 3-17, 3-16, 4-16, 4-15, 5-15, 5-14, 6-14, 6-13, 7-13, 7-12, 8-12, 8-11 or 9-11. In some embodiments, the VH comprises about 1-10 amino acid substitutions, relative to the amino acid sequence of a V H amino acid sequence set forth in any of SEQ ID NOs:3-17, SEQ ID NOs:19-58, and SEQ ID NOs:206-216. In some embodiments, the at least 1 amino acid - 77 - 3820371.v1 5708.1067001 substitution replaces only an HCDR1, an HCDR2 and/or an HCDR3 residue, of a VH amino acid sequence set forth in any of SEQ ID NOs:3-17, SEQ ID NOs:19-58, and SEQ ID NOs:206-216. In some embodiments, the at least 1 amino acid substitution replaces only a non-CDR residue (e.g., within a framework region), of a VH amino acid sequence set forth in any of SEQ ID NOs:3-17, SEQ ID NOs:19-58, and SEQ ID NOs:206-216. [00107] In some embodiments, a polypeptide comprises a V H that comprises at least 1 amino acid substitution relative to the amino acid sequence of a V H amino acid sequence set forth in any one of SEQ ID NO:206, SEQ ID NO:215, and SEQ ID NO:214. For example, the number of amino acid substitutions can be at least about: 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19 or 20, or about: 1-20, 1-19, 2-19, 2-18, 2-17, 3-17, 3-16, 4-16, 4-15, 5-15, 5-14, 6-14, 6-13, 7-13, 7-12, 8-12, 8-11 or 9-11. In some embodiments, the VH comprises about 1-10 amino acid substitutions, relative to the amino acid sequence of a VH amino acid sequence set forth in any one of SEQ ID NO:206, SEQ ID NO:215, and SEQ ID NO:214. In some embodiments, the at least 1 amino acid substitution replaces only an HCDR1, an HCDR2 and/or an HCDR3 residue, of a VH amino acid sequence set forth in any one of SEQ ID NO:206, SEQ ID NO:215, and SEQ ID NO:214. In some embodiments, the at least 1 amino acid substitution replaces only a non-CDR residue (e.g., within a framework region), of a VH amino acid sequence set forth in any one of SEQ ID NO:206, SEQ ID NO:215, and SEQ ID NO:214. [00108] In some embodiments, a polypeptide comprises a V H that comprises at least 1 amino acid substitution relative to the amino acid sequence of a VH amino acid sequence set forth in SEQ ID NO:206. For example, the number of amino acid substitutions can be at least about: 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19 or 20, or about: 1-20, 1-19, 2- 19, 2-18, 2-17, 3-17, 3-16, 4-16, 4-15, 5-15, 5-14, 6-14, 6-13, 7-13, 7-12, 8-12, 8-11 or 9-11. In some embodiments, the VH comprises about 1-10 amino acid substitutions, relative to the amino acid sequence of a V H amino acid sequence set forth in SEQ ID NO:206. In some embodiments, the at least 1 amino acid substitution replaces only an HCDR1, an HCDR2 and/or an HCDR3 residue, of a VH amino acid sequence set forth in SEQ ID NO:206. In some embodiments, the at least 1 amino acid substitution replaces only a non-CDR residue (e.g., within a framework region), of a V H amino acid sequence set forth in SEQ ID NO:206. [00109] In some embodiments, a polypeptide comprises a VH that comprises at least 1 amino acid substitution relative to the amino acid sequence of a V H amino acid sequence set forth in SEQ ID NO:215. For example, the number of amino acid substitutions can be at least - 78 - 3820371.v1 5708.1067001 about: 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19 or 20, or about: 1-20, 1-19, 2- 19, 2-18, 2-17, 3-17, 3-16, 4-16, 4-15, 5-15, 5-14, 6-14, 6-13, 7-13, 7-12, 8-12, 8-11 or 9-11. In some embodiments, the V H comprises about 1-10 amino acid substitutions, relative to the amino acid sequence of a VH amino acid sequence set forth in SEQ ID NO:215. In some embodiments, the at least 1 amino acid substitution replaces only an HCDR1, an HCDR2 and/or an HCDR3 residue, of a V H amino acid sequence set forth in SEQ ID NO:215. In some embodiments, the at least 1 amino acid substitution replaces only a non-CDR residue (e.g., within a framework region), of a VH amino acid sequence set forth in SEQ ID NO:215. [00110] In some embodiments, a polypeptide comprises a V H that comprises at least 1 amino acid substitution relative to the amino acid sequence of a V H amino acid sequence set forth in SEQ ID NO:214. For example, the number of amino acid substitutions can be at least about: 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19 or 20, or about: 1-20, 1-19, 2- 19, 2-18, 2-17, 3-17, 3-16, 4-16, 4-15, 5-15, 5-14, 6-14, 6-13, 7-13, 7-12, 8-12, 8-11 or 9-11. In some embodiments, the VH comprises about 1-10 amino acid substitutions, relative to the amino acid sequence of a VH amino acid sequence set forth in SEQ ID NO:214. In some embodiments, the at least 1 amino acid substitution replaces only an HCDR1, an HCDR2 and/or an HCDR3 residue, of a V H amino acid sequence set forth in SEQ ID NO:214. In some embodiments, the at least 1 amino acid substitution replaces only a non-CDR residue (e.g., within a framework region), of a V H amino acid sequence set forth in SEQ ID NO:214. [00111] In some embodiments, the amino acid substitutions are conservative substitutions. The term “conservative amino acid substitution(s)” or “conservative substitution(s)” refers to an amino acid substitution having a value of 0 or greater in BLOSUM62. [00112] In some embodiments, the amino acid substitutions are highly conservative substitutions. The term “highly conservative amino acid substitution(s)” or “highly conservative substitution(s)” refers to an amino acid substitution having a value of at least 1 (e.g., at least 2) in BLOSUM62. [00113] In some embodiments, a polypeptide disclosed herein comprises a VL that comprises at least 1 amino acid substitution relative to the amino acid sequence of a VL amino acid sequence set forth in any of SEQ ID NOs:60-69, SEQ ID NOs:71-106, and SEQ ID NOs:217-226. For example, the number of amino acid substitutions can be at least about: 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19 or 20, or about: 1-20, 1-19, 2-19, 2- 18, 2-17, 3-17, 3-16, 4-16, 4-15, 5-15, 5-14, 6-14, 6-13, 7-13, 7-12, 8-12, 8-11 or 9-11. In some embodiments, the V L comprises about 1-10 amino acid substitutions, relative to the - 79 - 3820371.v1 5708.1067001 amino acid sequence of a VL amino acid sequence set forth in any of SEQ ID NOs:60-69, SEQ ID NOs:71-106, and SEQ ID NOs:217-226. In some embodiments, the at least 1 amino acid substitution replaces only an LCDR1, an LCDR2 and/or an LCDR3 residue, of a V L amino acid sequence set forth in any of SEQ ID NOs:60-69, SEQ ID NOs:71-106, and SEQ ID NOs:217-226. In some embodiments, the at least 1 amino acid substitution replaces only a non-CDR residue (e.g., within a framework region), of a V L amino acid sequence set forth in any of SEQ ID NOs:60-69, SEQ ID NOs:71-106, and SEQ ID NOs:217-226. [00114] In some embodiments, a polypeptide comprises a VL that comprises at least 1 amino acid substitution relative to the amino acid sequence of a V L amino acid sequence set forth in any one of SEQ ID NO:217, SEQ ID NO:104, and SEQ ID NO:226. For example, the number of amino acid substitutions can be at least about: 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19 or 20, or about: 1-20, 1-19, 2-19, 2-18, 2-17, 3-17, 3-16, 4-16, 4-15, 5-15, 5-14, 6-14, 6-13, 7-13, 7-12, 8-12, 8-11 or 9-11. In some embodiments, the V L comprises about 1-10 amino acid substitutions, relative to the amino acid sequence of a VL amino acid sequence set forth in any one of SEQ ID NO:217, SEQ ID NO:104, and SEQ ID NO:226. In some embodiments, the at least 1 amino acid substitution replaces only an LCDR1, an LCDR2 and/or an LCDR3 residue, of a V L amino acid sequence set forth in any one of SEQ ID NO:217, SEQ ID NO:104, and SEQ ID NO:226. In some embodiments, the at least 1 amino acid substitution replaces only a non-CDR residue (e.g., within a framework region), of a V L amino acid sequence set forth in any one of SEQ ID NO:217, SEQ ID NO:104, and SEQ ID NO:226. [00115] In some embodiments, a polypeptide comprises a V L that comprises at least 1 amino acid substitution relative to the amino acid sequence of a V L amino acid sequence set forth in SEQ ID NO:217. For example, the number of amino acid substitutions can be at least about: 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19 or 20, or about: 1-20, 1-19, 2- 19, 2-18, 2-17, 3-17, 3-16, 4-16, 4-15, 5-15, 5-14, 6-14, 6-13, 7-13, 7-12, 8-12, 8-11 or 9-11. In some embodiments, the VL comprises about 1-10 amino acid substitutions, relative to the amino acid sequence of a VL amino acid sequence set forth in SEQ ID NO:217. In some embodiments, the at least 1 amino acid substitution replaces only an LCDR1, an LCDR2 and/or an LCDR3 residue, of a V L amino acid sequence set forth in SEQ ID NO:217. In some embodiments, the at least 1 amino acid substitution replaces only a non-CDR residue (e.g., within a framework region), of a V L amino acid sequence set forth in SEQ ID NO:217. - 80 - 3820371.v1 5708.1067001 [00116] In some embodiments, a polypeptide comprises a VL that comprises at least 1 amino acid substitution relative to the amino acid sequence of a VL amino acid sequence set forth in SEQ ID NO:104. For example, the number of amino acid substitutions can be at least about: 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19 or 20, or about: 1-20, 1-19, 2- 19, 2-18, 2-17, 3-17, 3-16, 4-16, 4-15, 5-15, 5-14, 6-14, 6-13, 7-13, 7-12, 8-12, 8-11 or 9-11. In some embodiments, the V L comprises about 1-10 amino acid substitutions, relative to the amino acid sequence of a V L amino acid sequence set forth in SEQ ID NO:104. In some embodiments, the at least 1 amino acid substitution replaces only an LCDR1, an LCDR2 and/or an LCDR3 residue, of a V L amino acid sequence set forth in SEQ ID NO:104. In some embodiments, the at least 1 amino acid substitution replaces only a non-CDR residue (e.g., within a framework region), of a VL amino acid sequence set forth in SEQ ID NO:104. [00117] In some embodiments, a polypeptide comprises a VL that comprises at least 1 amino acid substitution relative to the amino acid sequence of a V L amino acid sequence set forth in SEQ ID NO:226. For example, the number of amino acid substitutions can be at least about: 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19 or 20, or about: 1-20, 1-19, 2- 19, 2-18, 2-17, 3-17, 3-16, 4-16, 4-15, 5-15, 5-14, 6-14, 6-13, 7-13, 7-12, 8-12, 8-11 or 9-11. In some embodiments, the V L comprises about 1-10 amino acid substitutions, relative to the amino acid sequence of a VL amino acid sequence set forth in SEQ ID NO:226. In some embodiments, the at least 1 amino acid substitution replaces only an LCDR1, an LCDR2 and/or an LCDR3 residue, of a V L amino acid sequence set forth in SEQ ID NO:226. In some embodiments, the at least 1 amino acid substitution replaces only a non-CDR residue (e.g., within a framework region), of a V L amino acid sequence set forth in SEQ ID NO:226. [00118] In some embodiments, a polypeptide comprises: a) an HCDR1 comprising at least 1 amino acid substitution relative to at least one amino acid sequence set forth in any one of SEQ ID NOs:107-126; b) an HCDR2 comprising at least 1 amino acid substitution relative to at least one amino acid sequence set forth in any one of SEQ ID NOs:127-150; c) an HCDR3 comprising at least 1 amino acid substitution relative to at least one amino acid sequence set forth in any one of SEQ ID NOs:151-171, SEQ ID NO:227, and SEQ ID NO:228; d) an LCDR1 comprising at least 1 amino acid substitution relative to at least one amino acid sequence set forth in any one of SEQ ID NOs:172-178 and SEQ ID NO:229; - 81 - 3820371.v1 5708.1067001 e) an LCDR2 comprising at least 1 amino acid substitution relative to at least one amino acid sequence set forth in any one of SEQ ID NOs:179-183; f) an LCDR3 comprising at least 1 amino acid substitution relative to at least one amino acid sequence set forth in any one of SEQ ID NOs:184-201; or any combination of the foregoing. [00119] In some embodiments, a polypeptide disclosed herein comprises a V H that comprises an amino acid sequence set forth in any of SEQ ID NOs:3-17, SEQ ID NOs:19-58, and SEQ ID NOs:206-216. [00120] In some embodiments, a polypeptide comprises a V H that comprises an amino acid sequence set forth in any one of SEQ ID NO:206, SEQ ID NO:215, and SEQ ID NO:214. In some embodiments, a polypeptide comprises a VH that comprises an amino acid sequence set forth in SEQ ID NO:206. In some embodiments, a polypeptide comprises a VH that comprises an amino acid sequence set forth in SEQ ID NO:215. In some embodiments, a polypeptide comprises a VH that comprises an amino acid sequence set forth in SEQ ID NO:214. [00121] In some embodiments, a polypeptide disclosed herein comprises a V L that comprises an amino acid sequence set forth in any of SEQ ID NOs:59-69, SEQ ID NOs:71- 106, and SEQ ID NOs:217-226. [00122] In some embodiments, a polypeptide comprises a V L that comprises an amino acid sequence set forth in any one of SEQ ID NO:217, SEQ ID NO:104, and SEQ ID NO:226. In some embodiments, a polypeptide comprises a VL that comprises an amino acid sequence set forth in SEQ ID NO:217. In some embodiments, a polypeptide comprises a V L that comprises an amino acid sequence set forth in SEQ ID NO:104. In some embodiments, a polypeptide comprises a VL that comprises an amino acid sequence set forth in SEQ ID NO:226. [00123] In some embodiments, a polypeptide disclosed herein comprises: a V H comprising an amino acid sequence set forth in any of SEQ ID NOs:3-17, SEQ ID NOs:19-58, and SEQ ID NOs:206-216; and a VL comprising an amino acid sequence set forth in any of SEQ ID NOs:60-69, SEQ ID NOs:71-106, and SEQ ID NOs:217-226. [00124] In some embodiments, a polypeptide comprises: a VH comprising an amino acid sequence set forth in any one of SEQ ID NO:53 and SEQ ID NOs:206-216; and - 82 - 3820371.v1 5708.1067001 a VL comprising an amino acid sequence set forth in any one of SEQ ID NO:104, SEQ ID NO:106, and SEQ ID NOs:217-226. [00125] In some embodiments, a polypeptide comprises: a VH comprising an amino acid sequence set forth in any one of SEQ ID NO:206, SEQ ID NO:215, and SEQ ID NO:214; and a V L comprising an amino acid sequence set forth in any one of SEQ ID NO:217, SEQ ID NO:104, and SEQ ID NO:226. [00126] In some embodiments, a polypeptide comprises: a V H comprising an amino acid sequence set forth in SEQ ID NO:206; and a V L comprising an amino acid sequence set forth in SEQ ID NO:217. [00127] In some embodiments, a polypeptide comprises: a VH comprising an amino acid sequence set forth in SEQ ID NO:215; and a V L comprising an amino acid sequence set forth in SEQ ID NO:104. [00128] In some embodiments, a polypeptide comprises: a VH comprising an amino acid sequence set forth in SEQ ID NO:214; and a V L comprising an amino acid sequence set forth in SEQ ID NO:226. [00129] In some embodiments, a polypeptide disclosed herein comprises: a VH comprising an amino acid sequence set forth in any of SEQ ID NOs:3-17; and a V L comprising an amino acid sequence set forth in any of SEQ ID NOs:59-69. [00130] In some embodiments, a polypeptide disclosed herein comprises: a VH comprising an amino acid sequence set forth in any of SEQ ID NOs:19-58; and a V L comprising an amino acid sequence set forth in any of SEQ ID NOs:71-106. [00131] In some embodiments, a polypeptide disclosed herein comprises a V H and V L that are human. In some embodiments, a polypeptide disclosed herein comprises a VH and VL that are humanized, contain human framework regions, or a combination thereof. [00132] In some embodiments, a polypeptide disclosed herein is an immunoglobulin molecule, such as an antibody (e.g., a whole antibody, an intact antibody) or an antigen- binding fragment of an antibody. [00133] In some embodiments, a polypeptide disclosed herein is an antibody. As used herein, the term “antibody” refers to an immunoglobulin molecule capable of specific binding to a target, such as a carbohydrate, polynucleotide, lipid, polypeptide, etc., through at least one antigen recognition site, located in the variable domain of the immunoglobulin molecule. As used herein, the term “antibody” refers to a full-length antibody. - 83 - 3820371.v1 5708.1067001 [00134] In some embodiments, a polypeptide disclosed herein is a single-domain antibody or an antigen-binding fragment thereof. As used herein, the term “single-domain antibody (sdAb)” or “nanobody” refers to an immunoglobulin molecule consisting of a single monomeric variable antibody domain and capable of specific binding to a target. The single- domain antibody can be of any species, such as a murine antibody, a human antibody or a humanized single-domain antibody. [00135] In some embodiments, a polypeptide disclosed herein is a heavy-chain antibody comprising two or more heavy chains, but lacking light chains, or an antigen-binding fragment thereof. Non-limiting examples of heavy chain antibodies include camelid Vhh (also referred to as VHH or V H H) antibodies. Camelid antibodies are antibodies from the Camelidae family of mammals that include llamas, camels, and alpacas. [00136] In some embodiments, a polypeptide disclosed herein is an antibody comprising two heavy (H) chains and two light (L) chains inter-connected by disulfide bonds or multimers thereof (for example, IgM). Each heavy chain comprises a heavy chain variable domain (VH) and a heavy chain constant domain (comprising domains CH1, hinge CH2 and CH3). Each light chain comprises a light chain variable domain (V L ) and a light chain constant domain (CL). The V H and the V L regions may be further subdivided into regions of hypervariability, termed complementarity determining regions (CDR), interspersed within framework regions (FR). V H and V L each comprises three CDRs and four FR segments, arranged from the amino-terminus to the carboxy-terminus in the following order: FR1, CDR1, FR2, CDR2, FR3, CDR3, and FR4. The antibody can be of any species, such as a murine antibody, a human antibody or a humanized antibody. [00137] The extent of the framework region and the CDRs of an antibody can be identified using one of several suitable methodologies that are well known in the art, for example, by the Kabat definition, the Chothia definition, the AbM definition, and/or the contact definition. Publicly and/or commercially available tools for identifying framework and/or CDR regions include, IgBlast (accessible at www.ncbi.nlm.nih.gov/igblast/), Scaligner (available from drugdesigntech at www.scaligner.com/), IMGT rules and/or tools (see, for example, www.imgt.org/IMGTScientificChart/Nomenclature/IMGT-FRCDRdefi
nition.html, also accessible at www.imgt.org/), Chothia Canonical Assignment (accessible at www.bioinf.org.uk/abs/chothia.html), Antigen receptor Numbering And Receptor CalssificatiIon (ANARCI, accessible at opig.stats.ox.ac.uk/webapps/newsabdab/sabpred/anarci/), or the Paratome web server - 84 - 3820371.v1 5708.1067001 (accessible at www.ofranlab.org/paratome/, see Vered Kunik, et al, Nucleic Acids Research, Volume 40, Issue W1, 1 July 2012, Pages W521–W524). [00138] As used herein, a “CDR” encompasses any CDR defined by an art-recognized method for identifying the CDR residues on an antibody. See, e.g., Kabat, E.A., et al., (1991) Sequences of Proteins of Immunological Interest, Fifth Edition, U.S. Department of Health and Human Services, NIH Publication No.91-3242, Chothia et al., (1989) Nature 342:877; Chothia, C. et al., (1987) J. Mol. Biol.196:901-917; Al-lazikani et al., (1997) J. Molec. Biol. 273:927-948; and Almagro, J. Mol. Recognit.17:132-143 (2004). See also hgmp.mrc.ac.uk and bioinf.org.uk/abs. Two antibodies are determined to have the same CDR as one another with respect to an HCDR1, HCDR2, HCDR3, LCDR1, LCDR2 and/or LCDR3, when the identity of that CDR is determined for both antibodies using the same method. [00139] In some embodiments, a polypeptide disclosed herein is an antigen-binding fragment of an antibody. The term “antigen-binding fragment” refers to a portion of an immunoglobulin molecule (e.g., antibody) that retains the antigen binding properties of the full-length antibody. Non-limiting examples of antigen-binding fragments include a VH region, a V L region, an Fab fragment, an F(ab’) 2 fragment, an Fd fragment, an Fv fragment, and a domain antibody (dAb) consisting of one V H domain or one V L domain, etc. V H and V L domains may be linked together via a synthetic linker to form various types of single-chain antibody designs in which the V H /V L domains pair intramolecularly, or intermolecularly in those cases when the V H and V L domains are expressed by separate chains, to form a monovalent antigen binding site, such as single chain Fv (scFv) or diabody. In some embodiments, a polypeptide disclosed herein is an antigen binding fragment selected from Fab, F(ab’) 2 , Fab’, scFv, or Fv. In some embodiments, a polypeptide is a scFv. [00140] In some embodiments, a polypeptide disclosed herein is a modified or engineered antibody. Examples of modified or engineered antibodies include chimeric antibodies, multiparatopic antibodies (e.g., biparatopic antibodies), and multispecific antibodies (e.g., bispecific antibodies). For example, multispecific antibodies (e.g., bispecific antibodies) or related molecules can be produced featuring a polypeptide that binds PD-1 disclosed herein with a moiety targeting one or more of the following targets or, where relevant, their receptors: IL-1beta, IL-1RA, IL-2, IL4, IL-5, IL-13, IL-18, IL-23, IL-36, CLTA-4, OX40, GITR, BTLA, VISTA, TNF-alpha and other TNF family or TNF receptor family members, interferon-beta or interferon-gamma. - 85 - 3820371.v1 5708.1067001 [00141] As used herein, “multiparatopic antibody” means an antibody that comprises at least two single domain antibodies, in which at least one single domain antibody is directed against a first antigenic determinant on an antigen and at least one other single domain antibody is directed against a second antigenic determinant on the same antigen. Thus, for example, a “biparatopic” antibody comprises at least one single domain antibody directed against a first antigenic determinant on an antigen and at least one further single domain antibody directed against a second antigenic determinant on the same antigen. [00142] As used herein, “multispecific antibody” means an antibody that comprises at least two single domain antibodies, in which at least one single domain antibody is directed against a first antigen and at least one other single domain antibody is directed against a second antigen (different from the first antigen). Thus, for example, a “bispecific” antibody is one that comprises at least one single domain antibody directed against a first antigen and at least one further single domain antibody directed against a second antigen, e.g., different from the first antigen. [00143] In some embodiments, a polypeptide is an antibody mimetic. The term “antibody mimetic” refers to polypeptides capable of mimicking an antibody’s ability to bind an antigen, but structurally differ from native antibody structures. Non-limiting examples of antibody mimetics include Adnectins, Affibodies, Affilins, Affimers, Affitins, Alphabodies, Anticalins, Avimers, DARPins, Fynomers, Kunitz domain peptides, monobodies, nanobodies, nanoCLAMPs, and Versabodies. [00144] In some embodiments, a polypeptide disclosed herein competes with a reference antibody for binding to a full-length PD-1 (e.g., SEQ ID NO:1). The term “specifically binding” or “specifically binds” refers to preferential interaction, i.e., significantly higher binding affinity, between an antibody, or an antigen-binding fragment thereof, and its epitope relative to other antigens or amino acid sequences. [00145] In some embodiments, a polypeptide disclosed herein comprises: a) an antibody heavy chain constant domain sequence; b) an antibody light chain constant domain sequence; or c) both an antibody heavy chain constant domain sequence and an antibody light chain constant domain sequence. [00146] In some embodiments, a polypeptide disclosed herein comprises an antibody heavy chain constant domain sequence. In some embodiments, the antibody heavy chain constant domain is selected from the group consisting of an IgA constant domain, an IgD - 86 - 3820371.v1 5708.1067001 constant domain, an IgE constant domain, an IgG constant domain and an IgM constant domain. In some embodiments, the IgG constant domain is an IgG1 constant domain, an IgG2 constant domain, an IgG3 constant domain or an IgG4 constant domain. In some embodiments, the IgG2 constant domain is an IgG2a, an IgG2b constant domain or an IgG2c constant domain. In some embodiments, the IgA constant domain is an IgA1 constant domain or an IgA2 constant domain. In some embodiments, the antibody heavy chain constant domain is an IgG2 constant domain. [00147] In some embodiments, a polypeptide disclosed herein comprises an immunoglobulin light chain variable domain (V L ). The V H and V L domains may be linked together via a linker (e.g., a synthetic linker) to form various types of single-chain antibody designs in which the VH/VL domains pair intramolecularly, or intermolecularly in those cases when the VH and VL domains are expressed by separate chains, to form a monovalent antigen binding site. [00148] In some embodiments, a polypeptide disclosed herein comprises an antibody light chain constant domain sequence. In some embodiments, the antibody light chain constant domain is selected from the group consisting of a κ constant domain and a λ constant domain. In some embodiments, the antibody heavy chain constant domain is an IgG2 constant domain, and the antibody light chain constant domain is a λ constant domain. [00149] In some embodiments, the antibody heavy chain constant domain sequence has at least about 60% sequence identity to the amino acid sequence of SEQ ID NO:202. For example, the antibody heavy chain constant domain sequence can have at least about: 61%, 62%, 63%, 64%, 65%, 66%, 67%, 68%, 69%, 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% sequence identity to the amino acid sequence of SEQ ID NO:202. In some embodiments, the antibody heavy chain constant domain sequence has at least about 70% or at least about 80% sequence identity to the amino acid sequence of SEQ ID NO:202. The sequence identified as SEQ ID NO:202 is shown below: [00150] ASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGALTSGVH TFPAVLQSSGLYSLSSVVTVPSSNFGTQTYTCNVDHKPSNTKVDKTVERKCCVECPP CPAPPVAGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVQFNWYVDGVEVHN AKTKPREEQFNSTFRVVSVLTVVHQDWLNGKEYKCKVSNKGLPAPIEKTISKTKGQP REPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTFPPMLDS - 87 - 3820371.v1 5708.1067001 DGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK (SEQ ID NO:202). [00151] In some embodiments, the antibody light chain constant domain sequence has at least about 60% sequence identity to the amino acid sequence of SEQ ID NO:203 or SEQ ID NO:204. For example, the antibody light chain constant domain sequence can have at least about: 61%, 62%, 63%, 64%, 65%, 66%, 67%, 68%, 69%, 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% sequence identity to the amino acid sequence of SEQ ID NO:203 or SEQ ID NO:204. In some embodiments, the antibody light chain constant domain sequence has at least about 70% or at least about 80% sequence identity to SEQ ID NO:203 or SEQ ID NO:204. The sequences identified as SEQ ID NO:203 or SEQ ID NO:204 are shown below: [00152] RTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSG NSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC (SEQ ID NO:203). [00153] GQPKAAPSVTLFPPSSEELQANKATLVCLISDFYPGAVTVAWKADSSPVK AGVETTTPSKQSNNKYAASSYLSLTPEQWKSHRSYSCQVTHEGSTVEKTVAPTECS (SEQ ID NO:204). [00154] In some embodiments, an antibody heavy chain constant domain sequence comprises at least 1 amino acid substitution relative to the amino acid sequence of SEQ ID NO:202. For example, the number of amino acid substitutions can be at least about: 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19 or 20, or about: 1-20, 1-19, 2-19, 2-18, 2-17, 3-17, 3-16, 4-16, 4-15, 5-15, 5-14, 6-14, 6-13, 7-13, 7-12, 8-12, 8-11 or 9-11. In some embodiments, an antibody heavy chain constant domain sequence comprises about 1-10 amino acid substitutions, relative to the amino acid sequence of SEQ ID NO:202. [00155] In some embodiments, an antibody light chain constant domain sequence comprises at least 1 amino acid substitution relative to the amino acid sequence of SEQ ID NO:203 or SEQ ID NO:204. For example, the number of amino acid substitutions can be at least about: 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19 or 20, or about: 1-20, 1- 19, 2-19, 2-18, 2-17, 3-17, 3-16, 4-16, 4-15, 5-15, 5-14, 6-14, 6-13, 7-13, 7-12, 8-12, 8-11 or 9-11. In some embodiments, an antibody light chain constant domain sequence comprises about 1-10 amino acid substitutions, relative to the amino acid sequence of SEQ ID NO:203 or SEQ ID NO:204. - 88 - 3820371.v1 5708.1067001 [00156] In some embodiments, an antibody light chain constant domain sequence comprises at least 1 amino acid substitution relative to the amino acid sequence of SEQ ID NO:203. For example, the number of amino acid substitutions can be at least about: 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19 or 20, or about: 1-20, 1-19, 2-19, 2-18, 2-17, 3-17, 3-16, 4-16, 4-15, 5-15, 5-14, 6-14, 6-13, 7-13, 7-12, 8-12, 8-11 or 9-11. In some embodiments, the antibody light chain constant domain sequence comprises about 1-10 amino acid substitutions, relative to the amino acid sequence of SEQ ID NO:203. [00157] In some embodiments, one or more amino acid substitutions are conservative substitutions. In some embodiments, one or more amino acid substitutions are highly conservative substitutions. In some embodiments, a polypeptide disclosed herein is an isolated polypeptide. In some embodiments, the isolated polypeptide is recombinantly produced. In some embodiments, the isolated polypeptide is synthetically produced. [00158] In some embodiments, a polypeptide disclosed herein is linked to a second polypeptide. The term “linked” means attached, via a covalent or noncovalent interaction. Conjugation can employ a suitable linking agent. Non-limiting examples include peptide linkers, compound linkers, and chemical cross-linking agents. In some embodiments, the linker is a disulfide bond. [00159] In some embodiments, a polypeptide disclosed herein is conjugated to a heterologous moiety. The term “conjugated” refers to attached, via a covalent or noncovalent interaction. Conjugation can employ any of suitable linking agents. Non-limiting examples include peptide linkers, compound linkers, and chemical cross-linking agents. [00160] In some embodiments, the heterologous moiety is a therapeutic agent, a diagnostic agent or a combination thereof. In some embodiments, the heterologous moiety is polyethylene glycol (PEG), hexadecanoic acid, hydrogels, nanoparticles, multimerization domains and carrier peptides. [00161] In some embodiments, the nanoparticle is a lipid nanoparticle. In some embodiments, the nanoparticle is a polymer nanoparticle. In some embodiments, the polymer is an amphiphilic polymer. In some embodiments, the polymer is a hydrophobic or hydrophilic polymer. Non-limiting examples of polymers include poly(lactic acid)- poly(ethylene glycol), poly(lactic-co-glycolic acid)-poly(ethylene glycol), poly(lactic-co- glycolic) acid (PLGA), poly(lactic-co-glycolic acid)-d-α-tocopheryl polyethylene glycol succinate, poly(lactic-co-glycolic acid)-ethylene oxide fumarate, poly(glycolic acid)- - 89 - 3820371.v1 5708.1067001 poly(ethylene glycol), polycaprolactone-poly(ethylene glycol), or any salts thereof. In some embodiments, the polymer nanoparticle comprises poly(lactic-co-glycolic) acid (PLGA). [00162] In some embodiments, the carrier polypeptide is albumin or an Fc polypeptide. [00163] In some embodiments, a polypeptide described herein comprises an Fc polypeptide, or Fc domain (e.g., an IgG1 domain, an IgG2 domain or an IgG4 domain). In some embodiments, the Fc domain comprises a mutation that for example, decreases (e.g., inhibits, ablates) an effector function of the Fc domain, increases half-life of an antibody or antibody fragment that comprises the Fc domain, or a combination thereof. See, e.g., Dumet et al., Insights into the IgG heavy chain engineering patent landscape as applied to IgG4 antibody development, MAbs.11(8):1341-50 (2019) (particularly Tables 1 and 2 therein) and WO02060919, the contents of which are incorporated by reference herein in their entirety. In some embodiments, an Fc domain comprises an LS modification (M428L/N434S substitutions with numbering determined by Kabat) or a YTE modification (i.e., M252Y/S254T/T256E substitutions as determined by Kabat numbering). In some embodiments, an Fc domain comprises a YTE modification. [00164] In some embodiments, a polypeptide binds PD-1 with a binding constant (K D ) of about 100 pM or less. As used herein the term “K D ,” also referred to as “binding constant,” “equilibrium dissociation constant” or “affinity constant,” is a measure of the extent of a reversible association between two molecular species (e.g., antibody and target protein) and includes both the actual binding affinity as well as the apparent binding affinity. Binding affinity can be determined using methods known in the art including, for example, by measurement of surface plasmon resonance, e.g., using a Biolayer interferometry (Octet, ForteBio) or a surface plasmon resonance (Biacore) system and assay. A reference that compares various surface technologies for measuring binding affinity and kinetics is Yang, D., Singh, A., Wu, H., & Kroe-Barrett, R., Comparison of biosensor platforms in the evaluation of high affinity antibody-antigen binding kinetics, Analytical Biochemistry 508: 78-96 (2016), the contents of which are incorporated by reference herein in their entirety. [00165] In some embodiments, a polypeptide disclosed herein competes with one or more other antibodies disclosed herein for binding to a PD-1 protein (e.g., SEQ ID NO:1). Techniques and assays for assessing competition between antibodies are known in the art. - 90 - 3820371.v1 5708.1067001 Fusion Proteins [00166] In some embodiments, the disclosure provides a fusion protein comprising one or more of polypeptides described herein. [00167] The term “fusion protein” refers to a synthetic, semi-synthetic or recombinant single protein molecule. A fusion protein can comprise all or a portion of two or more different proteins and/or polypeptides that are attached by covalent bonds (e.g., peptide bonds). For example, a fusion protein can comprise a full-length polypeptide disclosed herein (e.g., a whole antibody), or a fragment thereof (e.g., an antigen-binding fragment of an antibody). The heterologous partner can be a full-length protein or a fragment thereof (e.g., a truncated protein). [00168] Fusion proteins can be produced recombinantly or synthetically, using routine methods and reagents that are well known in the art. For example, a fusion protein can be produced recombinantly in a suitable host cell (e.g., bacteria) according to methods known in the art. See, e.g., Current Protocols in Molecular Biology, Second Edition, Ausubel et al. eds., John Wiley & Sons, 1992; and Molecular Cloning: a Laboratory Manual, 2nd edition, Sambrook et al., 1989, Cold Spring Harbor Laboratory Press. For example, a nucleic acid molecule comprising a nucleotide sequence encoding a fusion protein described herein can be introduced and expressed in suitable host cell (e.g., E. coli), and the expressed fusion protein can be isolated/purified from the host cell (e.g., in inclusion bodies) using routine methods and readily available reagents. For example, DNA fragments coding for different protein sequences (e.g., a light-responsive domain, a heterologous peptide component) can be ligated together in-frame in accordance with conventional techniques. In some embodiments, the fusion gene can be synthesized by conventional techniques including automated DNA synthesizers. Alternatively, PCR amplification of nucleic acid fragments can be carried out using anchor primers that give rise to complementary overhangs between two consecutive nucleic acid fragments that can subsequently be annealed and re-amplified to generate a chimeric nucleic acid sequence (see Ausubel et al., Current Protocols in Molecular Biology, 1992). Nucleic Acids, Vectors, Host Cells [00169] In some embodiments, the disclosure provides one or more polynucleotides (e.g., DNA, RNA, or analogs of either, e.g., optionally including one or more modified nucleotides; the polynucleotide may be linear or circular, e.g., linear or circular RNA) encoding any one - 91 - 3820371.v1 5708.1067001 of the polypeptides or fusion proteins described herein. In some embodiments, polypeptides or fusion proteins disclosed herein is encoded by a single polynucleotide. In some embodiments, polypeptides or fusion proteins disclosed herein is encoded by multiple polynucleotides. [00170] In some embodiments, the polynucleotide comprises a nucleotide sequence that is codon-optimized for a chosen host cell. [00171] In some embodiments, the disclosure provides a vector (e.g., an expression vector, including a viral-delivery vector) comprising any one or more of the polynucleotides described herein. [00172] The term “expression vector” refers to a replicable nucleic acid from which one or more proteins can be expressed when the expression vector is transformed into a suitable expression host cell. [00173] In some embodiments, the vector (e.g., expression vector) comprises an expression control polynucleotide sequence operably linked to the polynucleotide, a polynucleotide sequence encoding a selectable marker, or both. In some embodiments, the expression control polynucleotide sequence comprises a promoter sequence, an enhancer sequence, or both. In some embodiments, the expression control polynucleotide sequence comprises an inducible promoter sequence. The term “promoter” refers to a region of DNA to which RNA polymerase binds and initiates the transcription of a gene. The term “operably linked” means that the nucleic acid is positioned in the recombinant polynucleotide, e.g., vector, in such a way that enables expression of the nucleic acid under control of the element (e.g., promoter) to which it is linked. The term “selectable marker element” is an element that confers a trait suitable for artificial selection. Selectable marker elements can be negative or positive selection markers. [00174] In some embodiments, the disclosure provides an expression host cell comprising any one or more of the polynucleotides or expression vectors described herein. [00175] The term “expression host cell” refers to a cell useful for receiving, maintaining, reproducing and/or amplifying a vector. [00176] Non-limiting examples of expression host cells include mammalian cells such as hybridoma cells, Chinese hamster ovary (CHO) cells, COS cells, human embryonic kidney (HEK), yeast cells such as Pichia pastoris cells, or bacterial cells such as E. coli, including DH5α, etc. - 92 - 3820371.v1 5708.1067001 Compositions [00177] In some embodiments, the disclosure provides a composition comprising any one of the polypeptides or fusion proteins described herein. In some embodiments, the composition is a pharmaceutical composition. [00178] In some embodiments, the composition (e.g., pharmaceutical composition) comprises pharmaceutically acceptable carriers, excipients, stabilizers, diluents or tonifiers (Remington's Pharmaceutical Sciences 16 th edition, Osol, A. Ed. (1980)). Suitable pharmaceutically acceptable carriers, excipients, or stabilizers are nontoxic to recipients at the dosages and concentrations employed. Non-limiting examples of pharmaceutically acceptable carriers, excipients, stabilizers, diluents or tonifiers include buffers (e.g., phosphate, citrate, histidine), antioxidants (e.g., ascorbic acid or methionine), preservatives, proteins (e.g., serum albumin, gelatin or immunoglobulins); hydrophilic polymers, amino acids, carbohydrates (e.g., monosaccharides, disaccharides, glucose, mannose or dextrins); chelating agents (e.g., EDTA), sugars (e.g., sucrose, mannitol, trehalose or sorbitol), salt- forming counter-ions (e.g., sodium), metal complexes (e.g., Zn-protein complexes); non-ionic surfactants (e.g., Tween), PLURONICS™ and polyethylene glycol (PEG). [00179] In some embodiments, the composition (e.g., pharmaceutical composition) disclosed herein is formulated for a suitable administration schedule and route. Non-limiting examples of administration routes include oral, rectal, mucosal, intravenous, intramuscular, subcutaneous and topical, etc. In some embodiments, the composition (e.g., pharmaceutical composition) disclosed herein is stored in the form of an aqueous solution or a dried formulation (e.g., lyophilized). [00180] In some embodiments, the composition is formulated to be administered by infusion (e.g., intravenous infusion). In some embodiments, the composition is formulated to be administered with a second therapeutic agent as a combination therapy. In some embodiments, the second therapeutic agent reduces (e.g., decreases, inhibits) an immune response, such as an inflammatory response. In some embodiments, the second therapeutic agent promotes immune tolerance. [00181] In some embodiments, a polypeptide or composition disclosed herein is used in conjunction with other immune modulators, such as immune modulators that target aberrant T- or B-cell responses with complementary or orthogonal mechanisms, in a multispecific (e.g., bispecific) molecule (e.g., antibody) or co-administered format. Such agents include, for example, molecules modulating the following targets or, where relevant, their receptors: - 93 - 3820371.v1 5708.1067001 IL-1beta, IL-1RA, IL-2, IL4, IL-5, IL-13, IL-18, IL-23, IL-36, CLTA-4, OX40, GITR, BTLA, VISTA, TNF-alpha and other TNF family or TNF receptor family members, interferon-beta or interferon-gamma. [00182] Non-limiting examples of second therapeutic agents that are useful in combination with polypeptides and compositions described herein include disease-modifying anti- rheumatic drugs (DMARs), anti-TNF agents, TNF-Fcs, non-steroidal anti-inflammatory drugs (NSAIDs), Immune Selective Anti-Inflammatory Derivatives (ImSAIDs), corticosteroids (e.g., glucocorticoids), therapeutic Treg cells, autophagy-related (ATG) proteins, α-l-guluronic acid (ALG), interferons, anti-inflammatory interleukins (e.g., IL-2, IL- 10), macrolides and biologics (e.g., dupilumab). Particular examples of second therapeutic agents that are useful in combination with polypeptides and compositions described herein include an insulin preparation (e.g., human insulin, insulin glargine, insulin lispro, insulin detemir, or insulin aspart), a sulfonylurea agent (e.g., glibenclamide, gliclazide, or glimepiride), a quick-acting insulin secretion promoter (e.g., nateglinide), a biguanide preparation (e.g., metformin), an insulin sensitizer (e.g., pioglitazone), an alpha-glucosidase inhibitor (e.g., acarbose or voglibose), a diabetic neuropathy therapeutic agent (e.g., epalrestat, mexiletine, or imidapril), a GLP-1 analog preparation (e.g., liraglutide, exenatide, or lixisenatide), a DPP-4 inhibitor (e.g., sitagliptin, vildagliptin, or alogliptin), a steroid agent (e.g., cortisone acetate, hydrocortisone, hydrocortisone sodium phosphate, hydrocortisone sodium succinate, fludrocortisone acetate, prednisolone, prednisolone acetate, prednisolone sodium succinate, prednisolone butylacetate, prednisolone sodium phosphate, halopredone acetate, methylprednisolone, methylprednisolone acetate, methylprednisolone sodium succinate, triamsinolone, triamsinolone acetate, triamsinolone acetonide, dexamethasone, dexamethasone acetate, dexamethasone sodium phosphate, dexamethasone palmitate, paramethasone acetate, or betamethasone), interferon beta-1a, interferon beta-1b, glatiramer acetate, mitoxantrone, azathioprine, cyclophosphamide, cyclosporin, methotrexate, cladribine, adrenocorticotropic hormone (ACTH), corticotropin, mizoribine, tacrolimus, fingolimod, or alemtuzumab. Methods of Use [00183] In some embodiments, the disclosure provides a method of modulating (e.g., inhibiting) PD-1 signaling in a subject, comprising administering to the subject an effective amount of a pharmaceutical composition comprising a pharmaceutically acceptable carrier - 94 - 3820371.v1 5708.1067001 and, wherein as an active ingredient, any one of the polypeptides or fusion proteins described herein. [00184] The terms “subject” and “patient” are used herein interchangeably to refer to an animal (e.g., a mammal, such as a human) who is to be treated according to a method disclosed herein. A subject to be treated according to methods described herein may be one who has been diagnosed with inflammation, such as inflammation associated with an inflammatory bowel disease (IBD) and/or autoimmune disease. Diagnosis may be performed by any method or technique known in the art. One skilled in the art will understand that a subject to be treated according to the present disclosure may have been subjected to standard tests or may have been identified, without examination, as one at risk due to the presence of one or more risk factors associated with the disease or condition. [00185] In some embodiments, the subject is a mammal. In some embodiments, the subject is a mammal selected from the group consisting of a dog, a cat, a mouse, a rat, a hamster, a guinea pig, a horse, a pig, a sheep, a cow, a chimpanzee, a macaque, a cynomolgus, and a human. In some embodiments, the subject is a primate. In some embodiments, the subject is a human. [00186] In some embodiments, the subject is 18 years of age or older, for example, about: 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75 or 80 years of age or older. In some embodiments, the subject is 65 years of age or older. In some embodiments, the subject is about: 18-80, 20-80, 20-75, 25-75, 25-70, 30-70, 30-65, 35-65, 35-60, 40-60, 40-55, 45-55 years of age. In some embodiments, the subject is about 18-65 years of age. [00187] In some embodiments, the subject is about 18 years of age or younger. In some embodiments, the subject is about: 16, 14, 12, 10, 8, 6, 4 or 2 years of age or older. In some embodiments, the subject is two years of age or older, for example, about: 2-18, 3-18, 3-16, 4-16, 4-14, 5-14, 5-12, 6-12, 6-10 or 8-10 years of age. [00188] In some embodiments, methods disclosed herein are useful for treating inflammation. In some embodiments, methods disclosed herein are useful for treating an inflammatory disease, condition, or disorder. Non-limiting examples of inflammatory diseases, conditions, or disorders include inflammatory bowel diseases (IBD) (e.g., Crohn’s disease, ulcerative colitis, and other forms of colitis or inflammation along the digestive tract thought to be caused by aberrant T-or B-cell biology), asthma and airway inflammation, autoimmune diseases (e.g., idiopathic autoimmune conditions), graft-versus-host disease - 95 - 3820371.v1 5708.1067001 (GvHD), and other conditions with aberrant T- or B-cell biology manifest as anti-self clinical syndromes. [00189] In some embodiments, methods disclosed herein are used for treating autoimmune disease. Non-limiting examples of autoimmune diseases that can be treated using the compositions and methods described herein include achalasia, Addison’s disease, adult Still's disease, agammaglobulinemia, alopecia areata, amyloidosis, ankylosing spondylitis, anti- GBM/anti-TBM nephritis, antiphospholipid syndrome, atopic dermatitis and other autoimmune dermatologic or mixed dermatologic-rheumatologic syndromes, autoimmune angioedema, autoimmune dermatitis, autoimmune dysautonomia, autoimmune encephalomyelitis, autoimmune hepatitis, autoimmune inner ear disease (AIED), autoimmune myocarditis, autoimmune oophoritis, autoimmune orchitis, autoimmune pancreatitis, autoimmune retinopathy, autoimmune urticaria, axonal and neuronal neuropathy (AMAN), Baló disease, Behcet’s disease, benign mucosal pemphigoid, bullous pemphigoid, Castleman disease (CD), celiac disease, Chagas disease, chronic inflammatory demyelinating polyneuropathy (CIDP), chronic recurrent multifocal osteomyelitis (CRMO), Churg-Strauss Syndrome (CSS) or eosinophilic granulomatosis (EGPA), cicatricial pemphigoid, Cogan’s syndrome, cold agglutinin disease, congenital heart block, Coxsackie myocarditis, CREST syndrome, Crohn’s disease, dermatitis herpetiformis, dermatomyositis, Devic’s disease (neuromyelitis optica), discoid lupus, Dressler’s syndrome, endometriosis, eosinophilic esophagitis (EoE), eosinophilic fasciitis, erythema nodosum, essential mixed cryoglobulinemia, Evans syndrome, fibromyalgia, fibrosing alveolitis, giant cell arteritis (temporal arteritis), giant cell myocarditis, glomerulonephritis, Goodpasture’s syndrome, granulomatosis with polyangiitis, Graves’ disease, Guillain-Barre syndrome, Hashimoto’s thyroiditis, hemolytic anemia, Henoch-Schonlein purpura (HSP), herpes gestationis or pemphigoid gestationis (PG), hidradenitis suppurativa (HS) (acne inversa), hypogammalglobulinemia, IgA nephropathy, IgG4-related sclerosing disease, immune thrombocytopenic purpura (ITP), inclusion body myositis (IBM), interstitial cystitis (IC), juvenile arthritis, juvenile diabetes (Type 1 diabetes), juvenile myositis (JM), Kawasaki disease, Lambert-Eaton syndrome, leukocytoclastic vasculitis, lichen planus, lichen sclerosus, ligneous conjunctivitis, linear IgA disease (LAD), Lyme disease chronic, Meniere’s disease, microscopic polyangiitis (MPA), mixed connective tissue disease (MCTD), Mooren’s ulcer, Mucha-Habermann disease, multifocal motor neuropathy (MMN) or MMNCB, multiple sclerosis, myasthenia gravis, myositis, narcolepsy, neonatal lupus, neuromyelitis optica and - 96 - 3820371.v1 5708.1067001 other neurologic syndromes that do not formally meet the definition of MS, neutropenia, ocular cicatricial pemphigoid, optic neuritis, palindromic rheumatism (PR), PANDAS, paraneoplastic cerebellar degeneration (PCD), paroxysmal nocturnal hemoglobinuria (PNH), Parry Romberg syndrome, pars planitis (peripheral uveitis), Parsonage-Turner syndrome, pemphigus, peripheral neuropathy, perivenous encephalomyelitis, pernicious anemia (PA), POEMS syndrome, polyarteritis nodosa, polyglandular syndromes type I, II and III, polymyalgia rheumatica, polymyositis, postmyocardial infarction syndrome, postpericardiotomy syndrome, primary biliary cirrhosis, primary sclerosing cholangitis, progesterone dermatitis, psoriasis, psoriatic arthritis, pure red cell aplasia (PRCA), pyoderma gangrenosum, Raynaud’s phenomenon, reactive arthritis, reflex sympathetic dystrophy, relapsing polychondritis, restless legs syndrome (RLS), retroperitoneal fibrosis, rheumatic fever, rheumatoid arthritis and other autoimmune arthritis, sarcoidosis, Schmidt syndrome, scleritis, scleroderma, Sjögren’s syndrome, sperm and testicular autoimmunity, stiff person syndrome (SPS), subacute bacterial endocarditis (SBE), Susac’s syndrome, sympathetic ophthalmia (SO), systemic lupus erythematosus (SLE) and other lupus-like conditions that do not meet the formal definition of SLE, Takayasu’s arteritis, temporal arteritis/giant cell arteritis, thrombocytopenic purpura (TTP), thyroid eye disease (TED), Tolosa-Hunt syndrome (THS), transverse myelitis, Type 1 diabetes, ulcerative colitis (UC), undifferentiated connective tissue disease (UCTD), uveitis, vasculitis, vitiligo, and Vogt- Koyanagi-Harada Disease. [00190] The term “treating” or “treatment” refers to the medical management of a subject with the intent to improve, ameliorate, stabilize (i.e., not worsen), prevent or cure a disease, pathological condition, or disorder—such as the particular indications exemplified herein. This term includes active treatment (treatment directed to improve the disease, pathological condition, or disorder), causal treatment (treatment directed to the cause of the associated disease, pathological condition, or disorder), palliative treatment (treatment designed for the relief of symptoms), preventative treatment (treatment directed to minimizing or partially or completely inhibiting the development of the associated disease, pathological condition, or disorder); and supportive treatment (treatment employed to supplement another therapy). Treatment also includes diminishment of the extent of the disease or condition; preventing spread of the disease or condition; delay or slowing the progress of the disease or condition; amelioration or palliation of the disease or condition; and remission (whether partial or total), whether detectable or undetectable. “Ameliorating” or “palliating” a disease or condition - 97 - 3820371.v1 5708.1067001 means that the extent and/or undesirable clinical manifestations of the disease, disorder, or condition are lessened and/or time course of the progression is slowed or lengthened, as compared to the extent or time course in the absence of treatment. “Treatment” can also mean prolonging survival as compared to expected survival if not receiving treatment. Those in need of treatment include those already with the condition or disorder, as well as those prone to have the condition or disorder or those in which the condition or disorder is to be prevented. [00191] “A therapeutically effective amount,” “an effective amount” or “an effective dosage” is an amount effective, at dosages and for periods of time necessary, to achieve a desired therapeutic result (e.g., treatment, healing, inhibition or amelioration of physiological response or condition, etc.). The therapeutic effect does not necessarily occur by administration of one dose, and may occur only after administration of a series of doses. Thus, a therapeutically effective amount may be administered in one or more administrations. A therapeutically effective amount may vary according to factors such as disease state, age, sex, and weight of a mammal, mode of administration and the ability of a therapeutic, or combination of therapeutics, to elicit a desired response in an individual. [00192] Desired response or desired results include effects at the cellular level, tissue level, or clinical results. As such, “a therapeutically effective amount” or synonym thereto depends upon the context in which it is being applied. For example, in some embodiments it is an amount of the composition sufficient to achieve a treatment response as compared to the response obtained without administration of the composition. In some embodiments, it is an amount that results in a beneficial or desired result in a subject as compared to a control. As defined herein, a therapeutically effective amount of a composition disclosed herein may be readily determined by one of ordinary skill by routine methods known in the art. Dosage regimen and route of administration may be adjusted to provide the optimum therapeutic response. [00193] A therapeutic agent described herein can be administered via a variety of routes of administration, including, for example, topical, transdermal, parenteral (e.g., intra-arterial, intravenous, intramuscular, subcutaneous injection, intradermal injection), intravenous infusion and inhalation (e.g., intrabronchial, intranasal or oral inhalation, intranasal drops) routes of administration, depending on the compound and the particular disease to be treated. [00194] In some embodiments, a polypeptide, composition, or pharmaceutical composition disclosed herein is administered to a subject as a monotherapy. - 98 - 3820371.v1 5708.1067001 [00195] In some embodiments, a polypeptide, composition, or pharmaceutical composition disclosed herein is administered to a subject in combination with one or more additional therapeutic agents (e.g., concurrently or sequentially with one or more additional therapeutic agents). In some embodiments, a subject has been previously treated with one or more therapeutic agents prior to being administered a polypeptide, composition, or pharmaceutical composition disclosed herein. In some embodiments, the method comprises administering a therapeutically effective amount of one or more additional therapeutic agents to the subject at the same time as, or following administration of a polypeptide, composition, or pharmaceutical composition disclosed herein. In some embodiments, the subject previously received a therapeutic agent. [00196] Administration of the two or more therapeutic agents encompasses co- administration of the therapeutic agents in a substantially simultaneous manner, such as in a pharmaceutical combination. In some embodiments, such administration encompasses co- administration in multiple containers, or separate containers (e.g., capsules, powders, and liquids) for each therapeutic agent. Such administration also encompasses use of each type of therapeutic agent in a sequential manner, either at approximately the same time or at different times. The composition described herein and the second therapeutic agent can be administered via the same administration route or via different administration routes. [00197] Administration can be local or systemic as indicated. The preferred mode of administration can vary depending on the particular compound chosen. [00198] The disclosure provides, among other things, a method of increasing (e.g., enhancing, promoting) binding of PD-L1 and/or PD-L2 to PD-1 in a cell, comprising contacting the cell an effective amount of any one of the polypeptides or fusion proteins described herein. [00199] The disclosure provides, among other things, a method of inhibiting PD-1 signaling in a cell (e.g., a T cell), comprising contacting the cell an effective amount of any one of the polypeptides or fusion proteins described herein. [00200] Unless otherwise defined, all terms of art, notations and other scientific terms or terminology used herein are intended to have the meanings commonly understood by those of skill in the art to which this disclosure pertains. In some cases, terms with commonly understood meanings are defined herein for clarity and/or for ready reference, and the inclusion of such definitions herein should not necessarily be construed to represent a substantial difference over what is generally understood in the art. It will be further - 99 - 3820371.v1 5708.1067001 understood that terms, such as those defined in commonly-used dictionaries, should be interpreted as having a meaning that is consistent with their meaning in the context of the relevant art and/or as otherwise defined herein. [00201] The terminology used herein is for the purpose of describing some embodiments only and is not intended to be limiting. [00202] As used herein, the indefinite articles “a,” “an” and “the” should be understood to include plural reference unless the context clearly indicates otherwise. [00203] Throughout this specification and the claims which follow, unless the context requires otherwise, the word “comprise,” and variations such as “comprises” and “comprising”, will be understood to imply the inclusion of, e.g., a stated integer or step or group of integers or steps, but not the exclusion of any other integer or step or group of integer or step. When used herein, the term “comprising” can be substituted with the term “containing” or “including.” [00204] As used herein, “consisting of” excludes any element, step, or ingredient not specified in the claim element. When used herein, “consisting essentially of” does not exclude materials or steps that do not materially affect the basic and novel characteristics of the claim. Any of the terms “comprising,” “containing,” “including,” and “having,” whenever used herein in the context of an aspect or embodiment disclosed herein, can in some embodiments, be replaced with the term “consisting of,” or “consisting essentially of” to vary scopes of the disclosure. [00205] As used herein, the conjunctive term “and/or” between multiple recited elements is understood as encompassing both individual and combined options. For instance, where two elements are conjoined by “and/or,” a first option refers to the applicability of the first element without the second. A second option refers to the applicability of the second element without the first. A third option refers to the applicability of the first and second elements together. Any one of these options is understood to fall within the meaning, and, therefore, satisfy the requirement of the term “and/or” as used herein. Concurrent applicability of more than one of the options is also understood to fall within the meaning, and, therefore, satisfy the requirement of the term “and/or.” [00206] When a list is presented, unless stated otherwise, it is to be understood that each individual element of that list, and every combination of that list, is a separate embodiment. For example, a list of embodiments presented as “A, B, or C” is to be interpreted as including the embodiments, “A,” “B,” “C,” “A or B,” “A or C,” “B or C,” or “A, B, or C.” For all - 100 - 3820371.v1 5708.1067001 numerical bounds describing some parameter in this application, such as “about,” “at least,” “less than,” “fewer than,” and “more than,” the description also necessarily encompasses any range bounded by the recited values. Accordingly, for example, the description “at least 1, 2, 3, 4, or 5” also describes, inter alia, the ranges 1-2, 1-3, 1-4, 1-5, 2-3, 2-4, 2-5, 3-4, 3-5, and 4-5, et cetera. [00207] Headings used in this application are for convenience only and do not affect the interpretation of this application. [00208] Preferred features of each of the aspects or embodiments provided by the invention are applicable to all of the other aspects or embodiments of the invention mutatis mutandis and, without limitation, are exemplified by the dependent claims and also encompass combinations and permutations of individual features (e.g., elements, including numerical ranges and exemplary embodiments) of some embodiments and aspects of the invention, including the working examples. For example, particular experimental parameters exemplified in the working examples can be adapted for use in the claimed invention piecemeal without departing from the invention. For example, for materials that are disclosed, while specific reference of each of the various individual and collective combinations and permutations of these compounds may not be explicitly disclosed, each is specifically contemplated and described herein. Thus, if a class of elements A, B, and C are disclosed as well as a class of elements D, E, and F and an example of a combination of elements A-D is disclosed, then, even if each is not individually recited, each is individually and collectively contemplated. Thus, in this example, each of the combinations A-E, A-F, B- D, B-E, B-F, C-D, C-E, and C-F are specifically contemplated and should be considered disclosed from disclosure of A, B, and C; D, E, and F; and the example combination A-D. Likewise, any subset or combination of these is also specifically contemplated and disclosed. Thus, for example, the sub-groups of A-E, B-F, and C-E are specifically contemplated and should be considered disclosed from disclosure of A, B, and C; D, E, and F; and the example combination A-D. This concept applies to all aspects of this application, including elements of a composition of matter and steps of method of making or using the compositions. [00209] The forgoing aspects of the invention, as recognized by the person having ordinary skill in the art following the teachings of the specification, can be claimed in any combination or permutation to the extent that they are novel and non-obvious over the prior art—thus, to the extent an element is described in one or more references known to the - 101 - 3820371.v1 5708.1067001 person having ordinary skill in the art, they may be excluded from the claimed invention by, inter alia, a negative proviso or disclaimer of the feature or combination of features. Exemplification [00210] Programmed cell death protein 1 (PD-1) is an immune checkpoint inhibitory protein expressed mainly on activated and tolerized T cells. PD-1 plays a role in mediating immune homeostasis and T cell tolerance by inhibiting T cell receptor (TCR) signaling [1-3]. While antagonizing PD-1 has been a common approach in oncology, agonizing PD-1 is a relatively underexplored approach for ameliorating auto-immune disease. For example, mice deficient of PD-1 have been shown to spontaneously develop autoimmune disorders such as a lupus-like disease, suggesting an important role of PD-1 signaling in the regulation of autoimmunity [1, 4]. Activation of PD-1 leads to a downregulation of PD-1 expression, reduced cytokine release, and suppression of immune response, representing a promising treatment for autoimmune diseases. Agonistic activity of an antibody is driven by targeting specific epitopes on the target, which Applicant identified. Whereas PD-1 antagonist antibodies such as Pembrolizumab and Nivolumab disrupt PD-1 binding with its natural ligands PD-L1 and PD-L2, PD-1 agonist antibodies show no competition with PD-L1 or PD- L2, indicating that they bound a distinct epitope space on PD-1. Without wishing to be bound by theory, it is believed that binding agonist epitopes leads to crosslinking of PD-1 on the surface of T cells and elicits an immune inhibitory signaling pathway. Example 1. Generation and Experimental Characterization of Initial Antibody Designs [00211] Guided by structural studies, the region shown in magenta in FIG.6A was designated by Applicant as the target binding site. Using this as input, multiple antibodies that bind this region were designed de novo. These molecules were subsequently characterized experimentally. [00212] Antibodies were formatted as single-chain variable fragments (scFv) for screening by yeast display. To increase chances of recovering higher-affinity binders, error-prone PCR (Agilent GeneMorph II kit, Agilent, Santa Clara, CA) was performed to introduce random mutations to the antibody variants, creating a yeast library of 6.4 x 10^7 variants. One round of magnetic-activated cell sorting (MACS) was performed to isolate cells that bound to recombinant biotinylated PD-1, and one round fluorescence-activated cell sorting (FACS) was performed to isolate cells that bound to PD-1 Fc (Acro Biosystems). Yeast library outputs were sequenced by Sanger sequencing (Azenta, Burlington, MA). Molecules were - 102 - 3820371.v1 5708.1067001 further optimized computationally, followed by additional library creation and screening, to isolate clones that bound to biotinylated PD-1 (ACROBiosystems, Newark, Delaware). Yeast library outputs were sequenced by Sanger sequencing (Azenta, Burlington, MA). Example 2. Functional Characterization of Antibodies [00213] Antibodies were formatted into full-length human immunoglobulin 1 (IgG1) by subcloning the variable heavy (V H ) chain and variable light (V L ) chains into mammalian expression vectors containing corresponding constant regions (SEQ ID NO:202 and SEQ ID NO:203) using conventional methods. Each IgG protein was expressed in ExpiCHO cells following manufacturer’s methods (Thermo Fisher Scientific, Waltham, MA). Binding kinetics and affinity to PD-1 were measured with Bio-layer interferometry (BLI) using a ForteBio (Fremont, CA) Octet Red96e instrument or surface plasmon resonance (SPR) using a CARTERRA ® (Andover, MA) LSA™ instrument. The SPR data are shown in Tables 1-3. Binding to PD-1 expressed on Raji cells was assessed by flow cytometry using an Intellicyt (Albuquerque, NM) iQue3 instrument (Table 1). To assess PD-1 agonism in vitro, an engineered Jurkat cell line expressing both PD-1 and a luciferase reporter driven by an NFAT response element (Promega) was used. It was found that the antibodies required crosslinking for functional agonism of PD-1. Accordingly, Raji cells, which express Fc receptors, were used to crosslink the antibodies. Briefly, Jurkat PD-1 NFAT reporter cells were cocultured with Raji cells and activated with an anti-CD3 antibody to stimulate TCR activation and downstream NFAT driven luminescence in the presence of the PD-1 antibodies. A decrease in luminescent signal indicates a decrease in TCR activation mediated by PD-1 agonism. Table 1. Binding Kinetics & Functional Characterization of PD-1 Agonistic Antibodies [00214] a) Structural characterization of clone AB-49 [00215] The structure of AB-49 alone (without the antigen) was solved using X-ray crystallography, at 2.46 A resolution. The structure is shown in FIG.6B, with - 103 - 3820371.v1 5708.1067001 superimposition onto the corresponding computational model in FIG.6D. There is close agreement between the model and experimental structure (i.e., backbone RMSD over all CDR residues is 1.6 Å, despite the fact that the comparison is between a Fab-only crystal structure and a computational model of the antibody in the bound state). This strongly suggests that the de-novo generated antibody bound the target and epitope in the way intended during the generation process. [00216] b) Affinity maturation of antibodies [00217] AB-49 was subjected to another round of affinity maturation using two rounds of proprietary library construction and screening. The libraries were enriched by MACS and FACS for binding to biotinylated PD-1 (ACROBiosystems, Newark, Delaware). Library hits were reformatted as full-length IgG and expressed in Expi293 cells. Binding kinetics and affinity to PD-1 were measured by surface plasmon resonance (SPR) using a Carterra LSA instrument. [00218] Binding to PD-1 expressed on Jurkat cell cells was assessed by flow cytometry using an Intellicyt iQue3 instrument. PD-1 agonism was assessed in vitro using the same engineered Jurkat cell line expressing both PD-1 and a luciferase reporter driven by an NFAT response element (Promega, Madison, WI). Overall, the affinity maturation produced hits with over 100-fold improvements in binding affinity (KD) and over 10-fold improvements in on-cell binding affinity, with minor improvements to TCR inhibition (Table 2). - 104 - 3820371.v1 5708.1067001 Table 2. Binding Kinetics & Functional Characterization of PD-1 Agonistic Antibodies [00219] AB-58 to AB-64 were further optimized computationally and expressed as full- length IgG and expressed in Expi293 cells. The hits were functionally characterized for on- cell binding and TCR inhibition as described previously with one change: Jurkat cells expressing PD-1 were used to assess on-cell binding instead. Overall, computationally optimized hits showed 2-fold improvement in TCR inhibition (Table 3). - 105 - 3820371.v1 5708.1067001 Table 3. Functional Characterization of PD-1 Agonistic Antibodies Example 3. PBMC-Based Assay to Measure PD-1 Agonist Effects [00220] Peripheral blood mononuclear cells (PBMCs) are stimulated with anti-CD3 and anti-CD28 T cell activators prior to incubation with an anti-PD1 antibody disclosed herein. PD-1 agonist activity is measured by detecting a decrease in PD-1 surface expression, inhibition of T cell proliferation in a CD4 + T cell population, and/or reduction of secreted cytokines (e.g., TNFα and IFNγ) in the cell supernatant as a result of antibody treatment. References 1. Francisco et al., The PD-1 pathway in tolerance and autoimmunity, Immunol Rev. 236:219-42 (2010). 2. Qin et al., The Diverse Function of PD-1/PD-L Pathway Beyond Cancer, Front Immunol. 10:2298 (2019). 3. Grebinoski & Vignali, Inhibitory receptor agonists: the future of autoimmune disease therapeutics? Curr Opin Immunol.67:1-9 (2020). 4. Nishimura et al., Development of lupus-like autoimmune diseases by disruption of the PD-1 gene encoding an ITIM motif-carrying immunoreceptor, Immunity 11(2):141-51 (1999). [00221] The teachings of all patents, published applications and references cited herein are incorporated by reference in their entirety. - 106 - 3820371.v1 5708.1067001 [00222] While example embodiments have been particularly shown and described, it will be understood by those skilled in the art that various changes in form and details may be made therein without departing from the scope of the embodiments encompassed by the appended claims. - 107 - 3820371.v1 5708.1067001 Table 4. Example V H Amino Acid Sequences - 108 - 3820371.v1 5708.1067001 - 109 - 3820371.v1 5708.1067001 - 110 - 3820371.v1 5708.1067001 - 111 - 3820371.v1 5708.1067001 - 112 - 3820371.v1 5708.1067001 Table 5. Example V L Amino Acid Sequences - 113 - 3820371.v1 5708.1067001 - 114 - 3820371.v1 5708.1067001 - 115 - 3820371.v1 5708.1067001 - 116 - 3820371.v1 5708.1067001 Table 6. CDR Amino Acid Sequences - 117 - 3820371.v1 5708.1067001 - 118 - 3820371.v1 5708.1067001 - 119 - 3820371.v1 5708.1067001 - 120 - 3820371.v1
Previous Patent: RE-EVALUATING VALVE FIT AND FUNCTION ON A PROCESS LINE
Next Patent: COMPACT DEEP ULTRAVIOLET MICROSCOPE
Next Patent: COMPACT DEEP ULTRAVIOLET MICROSCOPE